

# CITATION REPORT

List of articles citing

## The Brief Psychiatric Rating Scale

DOI: 10.2466/pr0.1962.10.3.799

Psychological Reports, 1962, 10, 799-812.

**Source:** <https://exaly.com/paper-pdf/7950066/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2272	Intramuscular Neuroleptics in Schizophrenia: Clinical Efficacy and Side-Effect. <b>1981</b> , 131-146		
2271	16 Effect of L-Tryptophan in Agitated Psychiatric Patients. <b>1987</b> , 193-197		
2270	Dimensions of manifest depression. <b>1962</b> , 1, 239-245		36
2269	Powered vector method of factor analysis. <b>1963</b> , 28, 415-422		31
2268	PARGYLINE AND TRANLYCYPROMINE IN THE TREATMENT OF HOSPITALIZED DEPRESSED PATIENTS. <b>1963</b> , 3, 309-16		9
2267	Oxyptertine in newly admitted schizophrenics. <b>1963</b> , 3, 26-31		14
2266	DIFFERENTIAL INTER-DRUG ANALYSIS: A PRELIMINARY STUDY. <b>1964</b> , 110, 514-9		6
2265	Preliminary investigation of SK&F 10810: an early clinical trial using "basic clinical controls". <b>1964</b> , 6, 462-71		2
2264	THE CLINICAL EVALUATION OF A NEW BUTYROPHENONE (WY-3457). <b>1964</b> , 5, 306-12		6
2263	SOME LIMITATIONS OF PSYCHIATRIC RATING SCALES: THE CLINICIAN'S VIEWPOINT. <b>1964</b> , 5, 93-101		5
2262	Voice Quality Changes in Depression. <b>1964</b> , 7, 84-88		24
2261	MODALINE SULFATE IN THE TREATMENT OF CHRONIC SCHIZOPHRENICS. <b>1964</b> , 4, 86-92		4
2260	CHANGES IN SCHIZOPHRENIC PSYCHOPATHOLOGY AND WARD BEHAVIOUR AS A FUNCTION OF PHENOTHIAZINE TREATMENT. <b>1965</b> , 111, 120-33		123
2259	VOICE QUALITY IN DEPRESSION. <b>1965</b> , 70, 218-20		33
2258	The right drug for the right patient. <b>1965</b> , 29, 546-51		36
2257	Oxyptertine. A review of clinical experience. <b>1965</b> , 111, 1173-9		12
2256	A CONTROLLED STUDY OF 4-(1-PHENYL-4-PIPERAZINYL)-BUTYL 3,4,5-TRIMETHOXYBENZATE HYDROCHLORIDE (MA 568) AND MEPROBAMATE IN PSYCHIATRIC OUTPATIENTS. <b>1965</b> , 5, 51-6		3

2255	Trifluoperidol and trifluoperazine in acute schizophrenic patients. <b>1965</b> , 5, 318-26		6
2254	TRIPERIDOL IN SCHIZOPHRENIA: FURTHER EVIDENCE FOR SPECIFIC PATTERNS OF ACTION OF ANTIPSYCHOTIC DRUGS. <b>1965</b> , 5, 34-42		5
2253	The sleep of depressed patients. An EEG and eye movement study. <b>1965</b> , 13, 503-7		82
2252	Reflections on the specificity of action of anti-depressants. <b>1965</b> , 6, 361-5		39
2251	The nurse and the depressed patient. Problems of assessment on a research ward. <b>1966</b> , 11 Suppl, Suppl:105-15		
2250	A study of thioridazine and its side-chain derivative, mesoridazine, in chronic male hospitalized psychiatric patients. <b>1966</b> , 6, 345-8		12
2249	Subjective correlates of clinically manifested anxiety and depression. <i>Psychological Reports</i> , <b>1967</b> , 20, 535-42	1.6	3
2248	Comparison of psychiatric and nonpsychiatric patients in nursing homes. <b>1967</b> , 15, 355-63		7
2247	Factorial study of psychopathology in psychiatric patients successfully placed in nursing homes. <b>1967</b> , 15, 437-47		4
2246	A Review of Psychiatric Rating Scales. <b>1967</b> , 12, 563-574		2
2245	Myxedema psychosis: clinical and biochemical changes during recovery. <b>1967</b> , 5, 289-96		15
2244	Empathy and perspective on consensus and automation? Implications of the new deal in psychiatric diagnosis. <b>1967</b> , 8, 265-6		2
2243	Dimensions of manifest depression in newly hospitalized patients. <b>1967</b> , 113, 981-6		3
2242	Controlled evaluation of nicotinamide adenine dinucleotide in the treatment of chronic schizophrenic patients. <b>1967</b> , 113, 731-42		14
2241	Estimating the magnitude of anxiety from speech. <b>1967</b> , 12, 289-95		9
2240	Are state mental hospitals dumping aged patients on nursing homes?. <b>1968</b> , 4, 53-61		1
2239	The reliability of the present state examination <b>1968</b> , 3, 123-129		92
2238	The evaluation of chlorpromazine therapy in chronic schizophrenic women. A replicated experiment. <b>1968</b> , 21, 445-60		4

2237	Estimating Individual Rater Reliabilities from Analysis of Treatment Effects. <b>1968</b> , 28, 255-264		6
2236	Two pilot studies of BC-347 in chronic schizophrenic patients. <b>1968</b> , 8, 196-9		
2235	Fluphenazine in the long term treatment of psychoses. A preliminary communication. <b>1968</b> , 203, 225-30		1
2234	Comparative effects of intramuscular thiothixene and trifluoperazine in psychotic patients. <b>1968</b> , 8, 400-3		2
2233	[Utilization of thiothixene in the treatment of mania: Pilot study]. <b>1968</b> , 13, 175-9		
2232	[Neuroleptics and extrapyramidal effects: correlation between antipsychotic and extrapyramidal properties]. <b>1968</b> , 13, 507-12		2
2231	[Clinical study of mesoridazine (TPS-23) with psychotic patients]. <b>1968</b> , 13, 513-20		
2230	Quantity control in psychiatry. <b>1968</b> , 13, 471-3		
2229	A trial of transcranial polarization in chronic schizophrenics. <b>1968</b> , 114, 635-7		22
2228	Groupings of psychiatric nomenclature classifications: cluster analyses of psychiatric subjective ratio scales. <i>Psychological Reports</i> , <b>1969</b> , 25, 351-5	1.6	2
2227	Predicting response to psychoactive drugs. <i>Psychological Reports</i> , <b>1969</b> , 25, 698	1.6	
2226	Mental changes accompanying thyroid gland dysfunction. A reappraisal using objective psychological measurement. <b>1969</b> , 20, 48-63		277
2225	Concerning least squares analysis of experimental data.. <b>1969</b> , 72, 311-322		233
2224	Profession, experience, and prognostic judgments regarding functional psychotic disorders: extension and replication. <b>1969</b> , 14, 371-7		1
2223	Severity of behavioral symptoms in schizophrenia. <b>1969</b> , 25, 163-4		
2222	Fluphenazine enanthate and fluphenazine decanoate: a comparative study in chronic schizophrenic outpatients. <b>1969</b> , 10, 42-5		7
2221	A sequential comparison of amitriptyline, perphenazine and the amitriptyline-perphenazine combination in recently admitted anergic schizophrenics. <b>1969</b> , 10, 296-303		7
2220	Treatment of psychiatric inpatients with mesoridazine. <b>1969</b> , 10, 244-8		2

2219	A social dysfunction rating scale. <b>1969</b> , 6, 299-306	55
2218	A double-blind comparison of trifluoperidol and trifluoperazine in acute schizophrenic patients. <b>1969</b> , 10, 355-60	1
2217	A conditioning test battery for the study of psychopathological mechanisms and psychopharmacological effects. <b>1970</b> , 15, 301-8	2
2216	Molindone in chronic schizophrenia. <b>1970</b> , 11, 680-8	20
2215	The differential response to parenteral chlorpromazine and mesoridazine in psychotic patients. <b>1970</b> , 10, 126-31	3
2214	A controlled comparison of the treatment of schizophrenic patients when treated according to the neurologic threshold or by clinical judgment. <b>1970</b> , 212, 38-43	10
2213	The use of molindone in the treatment of acute psychotic states: comparison of two dosage schedules. <b>1970</b> , 10, 349-55	3
2212	Dimensions of outpatient neurotic pathology: comparison of a clinical vrsus an empirical assessment. <b>1970</b> , 34, 164-71	75
2211	Attempts to predict suicidal risk using psychological tests. <b>1970</b> , 74, 1-17	56
2210	Alpha activity during inhibitory brain processes. <b>1970</b> , 7, 442-50	10
2209	Chlorpromazine in chronic schizophrenia: behavioral dose-response relationships. <b>1970</b> , 18, 260-70	27
2208	Mandrax as a Hypnotic for Psychiatric In-patients: A Comparative Trial with Chloral Hydrate. <b>1970</b> , 117, 209-210	4
2207	Quantitative EEG Changes During High and Low Dosage Fluphenazine Hydrochloride Treatment. <b>1970</b> , 4, 43-52	4
2206	A rating scale for evaluation of the clinical course and symptomatology in amphetamine psychosis. <b>1970</b> , 117, 661-5	14
2205	Computer Documentation for the Evaluation of Clinical Psychotropic Drug Studies. <b>1970</b> , 4, 55-65	
2204	International Comparison of Diagnostic Patterns by Fr. Engelsmann, O. Vinar, P. Pichot, H. Hippus, F. Giberti, L. Rossi, and J. E. Overall. Typescript. 6 pp. 5 tables. <b>1970</b> , 7, 130-137	4
2203	A standardized psychiatric interview for use in community surveys. <b>1970</b> , 24, 18-23	157
2202	Emotions profile index (EPI) pattern for paranoid personality types: cross-validation and extension. <i>Psychological Reports</i> , <b>1970</b> , 26, 303-8	1.6 3

2201	Sociopsychiatric study of schizophrenia. <b>1970</b> , 4, 82-92	4
2200	Some Double Binds of Clinical Psychopharmacology: A Personal View. <b>1970</b> , 1, 38-39	
2199	Weight changes with schizophrenic psychosis and psychotropic drug therapy. <b>1970</b> , 11, 551-61	26
2198	Relationships of psychopathology to age, sex, ethnicity, education and marital status in state hospital patients. <b>1970</b> , 7, 143-52	36
2197	Prediction of changes in severity of the schizophrenic syndrome with discontinuation and administration of phenothiazines in chronic schizophrenic patients: language as a predictor and measure of change in schizophrenia. <b>1970</b> , 11, 123-40	18
2196	Validity features of a mental health questionnaire. <b>1970</b> , 4, 669-73	2
2195	Some uses of haloperidol in the treatment of psychiatric conditions. <b>1970</b> , 11, 188-93	3
2194	A brief rating scale for antidepressant drug trials. <b>1971</b> , 12, 122-35	5
2193	Psychiatric assessment from documentary evidence. <b>1971</b> , 12, 564-71	6
2192	Haloperidol versus thioridazine for hospitalized psychogeriatric patients: double-blind study. <b>1971</b> , 19, 593-600	40
2191	Some reflections on the meaning of psychodiagnosis. <b>1971</b> , 26, 160-7	28
2190	Associations between marital history and the nature of manifest psychopathology. <b>1971</b> , 78, 213-21	14
2189	Self-administered aversive stimulation with hallucinating hospitalized schizophrenics. <b>1971</b> , 36, 422-9	29
2188	Pharmacologic considerations in the treatment of anxiety and depression in medical practice. <b>1971</b> , 55, 485-94	3
2187	Clinical and quantitative EEG changes at different dosage levels of fluphenazine treatment. <b>1971</b> , 47, 440-51	27
2186	Are antidepressants better than placebo?. <b>1971</b> , 127, 1605-11	27
2185	Oxyperline and thiothixene in newly admitted schizophrenic patients. A further search for specific indications of antipsychotic drugs. <b>1971</b> , 12, 531-8	8
2184	Quantifizierung psychotischer Symptome unter transkulturellen Aspekten. <b>1971</b> , 6, 66-72	5

2183	Phenothiazine effects on auditory signal detection in paranoid and nonparanoid schizophrenics. <b>1971</b> , 174, 723-5		34
2182	The Use of Psychotropic Drug Combinations [Comments and Observations. <b>1971</b> , 4, 297-307		1
2181	Background variables and outpatient psychopathology. <i>Psychological Reports</i> , <b>1971</b> , 28, 303-9	1.6	4
2180	ANXIETY AND IMPULSIVENESS: TOWARD A NEUROPSYCHOLOGICAL MODEL. <b>1972</b> , 195-222		25
2179	Concordance between clinical assessments and patients' self-report in depression. <b>1972</b> , 26, 546-52		159
2178	Perfenazin Enantat och Perfenazintabletter: En dubbelblind-jñhfñelse vid schizofrena psykosser. <b>1972</b> , 26, 474-482		1
2177	Comparative therapeutic factors in schizophrenia. <b>1972</b> , 17, Suppl 2:SS145		2
2176	Chlorpromazine in Chronic Schizophrenia. <b>1972</b> , 27, 479		22
2175	Nicotinic acid, thioridazine, fluoxymesterone and their combinations in hospitalized geriatric patients: a systematic clinical study. <b>1972</b> , 17, 315-20		5
2174	Rating scales for psychotropic drug research with geriatric patients. I. Behavior ratings. <b>1972</b> , 20, 209-14		13
2173	Empirical correlates of frequently occurring two-point MMPI code types: a replicated study. <b>1972</b> , 39, 467-72		39
2172	Inducing assertive behavior in chronic schizophrenics: a comparison of socioenvironmental, desensitization, and relaxation therapies. <b>1972</b> , 39, 246-52		48
2171	Role of antidepressants and neuroleptics in the treatment of depression. <b>1972</b> , 27, 337-45		29
2170	Group vs individual psychotherapy with schizophrenics. A controlled outcome study. <b>1972</b> , 27, 474-8		51
2169	Sex and Age Differences in Psychiatric Symptoms of Alcoholics. <i>Psychological Reports</i> , <b>1972</b> , 30, 887-889	1.6	13
2168	A one-year trial of clopenthixol in chronic schizophrenia. <b>1972</b> , 17, 321-4		3
2167	Some methodological considerations in the evaluation of drug-induced extrapyramidal disorders: a study of Ex10-029, a new morphanthridine derivative. <b>1972</b> , 12, 142-52		1
2166	Placebo-controlled evaluation of phenaglycodol in anxious, depressed outpatients. <b>1972</b> , 12, 280-5		

2165	An investigation of the clinical effect of GPA-1714, a catechol-O-methyl transferase inhibitor. <b>1972</b> , 12, 417-21		4
2164	Two studies of the effects of mesoridazine. <b>1972</b> , 12, 349-55		1
2163	Chlorpromazine in geriatric psychiatry. <b>1972</b> , 20, 403-6		8
2162	2. Improvement criteria in drug trials with neurotic patients. <b>1972</b> , 2, 73-80		63
2161	Multiple monitored electroconvulsive treatment of schizophrenia. <b>1972</b> , 13, 9-17		14
2160	Chlordiazepoxide plasma levels and clinical responses. <b>1972</b> , 13, 519-27		21
2159	Work study in the assessment of the effects of phenothiazines in schizophrenia. <b>1972</b> , 13, 549-54		12
2158	Symptom syndromes of emergency cases in an urban community mental health center. <b>1972</b> , 13, 265-72		2
2157	Piperacetazine vs. thioridazine for the control of schizophrenia in outpatients. <b>1972</b> , 13, 373-6		9
2156	Personal adjustment and authoritarian attitudes toward the mentally ill. <i>Psychological Reports</i> , <b>1972</b> , 31, 483-6	1.6	3
2155	Decisions about drug therapy. I. Prescriptions for adult psychiatric outpatients. <b>1972</b> , 26, 140-5		18
2154	Depressive typologies and response to amitriptyline. <b>1972</b> , 120, 147-56		129
2153	Hand Movements. <b>1972</b> , 22, 353-374		302
2152	Amantadine in depression: Relationship between behavioural effects and plasma levels. <b>1973</b> , 5, 226-228		30
2151	Sleeplessness in acute and chronic schizophrenia--response to haloperidol and anti-parkinsonism agents. <b>1973</b> , 29, 21-32		19
2150	The effects of ward change on patients' psychopathology and behavior: a failure to replicate. <b>1973</b> , 29, 97		1
2149	"Noise" as a unifying concept in the theory of schizophrenia. <b>1973</b> , 41, 223-42		5
2148	Comparative evaluation of injectable chlorpromazine and piperacetazine. <b>1973</b> , 14, 220-1		1



2147	Haloperidol and the butyrophenones. <b>1973</b> , 14, 286-97	2
2146	Kinetics and dynamics of response to haloperidol in acute schizophrenia--A longitudinal study of the therapeutic process. <b>1973</b> , 14, 393-414	25
2145	Study of cognitive functioning in a medical population. <b>1973</b> , 14, 331-8	15
2144	Double-blind comparison of haloperidol and thioridazine in treatment resistant psychoneurotic outpatients. <b>1973</b> , 14, 235-40	0
2143	Rejection of motherhood. A psychosomatic appraisal of habitual abortion. <b>1973</b> , 14, 241-4	8
2142	The language barrier in evaluating Spanish-American patients. <b>1973</b> , 29, 655-9	87
2141	Inter- and intra-rater reliability of the Brief Psychiatric Rating Scale. <i>Psychological Reports</i> , <b>1973</b> , 32, 783- <del>88</del>	92
2140	Unilateral versus bilateral ECT in schizophrenia. <b>1973</b> , 123, 73-9	16
2139	Symptomatic volunteers: another patient dimension for clinical trials. <b>1973</b> , 13, 89-98	7
2138	Amitriptyline, weight gain and carbohydrate craving: a side effect. <b>1973</b> , 123, 501-7	200
2137	Potentiation of therapeutic effects of nicotinic acid by pyridoxine in chronic schizophrenics. <b>1973</b> , 18, 377-83	14
2136	Combined Administration of Thioridazine and Nicotinic Acid in the Treatment of Geriatric Patients. <b>1973</b> , 1, 188-191	
2135	A controlled one-year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Evaluation of results at 6 and 12 months' trial. <b>1973</b> , 241, 101-18	21
2134	A controlled comparison of metiapine and chlorpromazine in chronic schizophrenia. <b>1973</b> , 13, 408-15	1
2133	A double-blind comparison of haloperidol oral concentrate, haloperidol solutabs and placebo in the treatment of chronic schizophrenia. <b>1973</b> , 13, 99-110	2
2132	A comparison of fluspirilene and trifluoperazine in the treatment of acute schizophrenic psychosis. <b>1973</b> , 13, 44-7	8
2131	The relationship between blood levels of different forms of butaperazine and clinical response. <b>1973</b> , 13, 288-97	4
2130	Clinical and work performance variables in phenothiazine therapy of schizophrenia. <b>1973</b> , 49, 65-76	11

2129	A method of quantifying EEG for psychopharmacological research. <b>1973</b> , 8, 245-7		10
2128	Erfahrungen mit dem anhaltend wirkenden Neuroleptikum Fluspirilene bei arbeitstherapeutisch beschäftigten chronisch Schizophrenen. <b>1973</b> , 8, 37-59		1
2127	Psychopharmacological study of schizophrenia--some ways out of an impasse. A case study with haloperidol. <b>1973</b> , 8, 80-98		5
2126	Ipindole and imipramine in non-psychotic depressed out-patients. <b>1973</b> , 123, 329-39		28
2125	How antagonistic can doctor's bias be on drug effect? Oxazepam as an anti-anxiety agent. <b>1973</b> , 8, 27-36		1
2124	Video methodology for research in psychopathology and psychopharmacology: Rationale and application. <b>1974</b> , 31, 204-10		37
2123	Once versus thrice daily thiothixene in the treatment of schizophrenic in-patients. <b>1974</b> , 125, 73-8		5
2122	Evaluations of pharmacotherapy in cooperative studies. <b>1974</b> , 7, 23-32		
2121	Monthly intermittent chemotherapy of chronic schizophrenic outpatients with pipothiazine palmitate. <b>1974</b> , 19, 583-91		3
2120	Editorial: The renaissance of psychiatric diagnosis. <b>1974</b> , 19, 233-4		
2119	Validity of the felt figure techniques: a factor analytic approach. <b>1974</b> , 38, 255-62		5
2118	Relationship between the Brief Psychiatric Rating Scale and the Multiple Affect Adjective Check List for schizophrenic women. <i>Psychological Reports</i> , <b>1974</b> , 35, 79-82	1.6	2
2117	Further replication of factors of psychopathology in the interview, ward behavior and self-reported ratings of hospitalized depressed patients. <i>Psychological Reports</i> , <b>1974</b> , 34, 23-32	1.6	13
2116	An appraisal of the therapeutic value of the mental hospital milieu. <b>1974</b> , 2, 153-160		7
2115	Perphenazine concentrations in human whole blood. A pilot study during anti-psychotic therapy using different administration forms. <b>1974</b> , 37, 31-6		21
2114	Hypothalamic releasing hormones and catecholamines: A new interface. <b>1974</b> , 23, 962-968		1
2113	Psychological characteristics of long-term mental patients: some implications for treatment. <b>1974</b> , 15, 495-501		2
2112	Psychiatric diagnostic concepts among German-speaking psychiatrists. <b>1974</b> , 15, 103-17		10

2111	Creatine phosphokinase in functional psychosis. <b>1974</b> , 15, 435-8	2
2110	Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. <b>1974</b> , 50, 410-24	170
2109	Klinisk undersekelse av flupenthixol decanoat 10% (Lu 7105). <b>1974</b> , 28, 539-545	2
2108	Double-blind comparison of thiothixene, trifluoperazine, and placebo in chronic alcoholism. <b>1974</b> , 15, 85-7	4
2107	Haloperidol Versus Thioridazine For The Treatment Of Psychogeriatric Patients: A Double-Blind Clinical Trial. <b>1974</b> , 15, 134-138	47
2106	A double-blind controlled study of loxapine succinate in the treatment of anxiety neuroses. <b>1974</b> , 14, 464-9	5
2105	A study of flupenthixol decanoate and pipotiazine undecylenate in schizophrenics. <b>1974</b> , 50, 481-91	15
2104	Drug and sociotherapy in the aftercare of schizophrenic patients. III. Adjustment of nonrelapsed patients. <b>1974</b> , 31, 609-18	148
2103	Group therapy and maintenance treatment of schizophrenics. <b>1974</b> , 31, 361-5	33
2102	Diphenylhydantoin effectiveness in the treatment of chronic schizophrenics. A double-blind controlled study with a placebo. <b>1974</b> , 30, 106-11	8
2101	Treatment patterns in psychiatry: clinical and personality features of elderly hospitalized patients during milieu, single-drug and multiple-drug programs. <b>1974</b> , 22, 212-6	3
2100	Lithium carbonate and sleep in affective disorders. Further considerations. <b>1974</b> , 30, 79-84	41
2099	Diagnostic criteria of English, French, and German psychiatrists. <b>1974</b> , 4, 187-95	24
2098	Safety evaluation of penfluridol, a new long-acting oral antipsychotic agent. <b>1974</b> , 14, 202-9	9
2097	The treatment of mixed anxiety and depression with loxapine: a controlled comparative study. <b>1974</b> , 14, 455-63	8
2096	Behavioral correlates of single-scale MMPI code types. <b>1974</b> , 42, 398-402	21
2095	Differences between mental disorders of French Canadians and British Canadians. <b>1974</b> , 19, 247-57	13
2094	A double-blind study of amantadine hydrochloride versus benztropine mesylate in drug-induced parkinsonism. <b>1974</b> , 12, 65-73	18

2093	Controlled trial of depot fluphenazine in out-patient schizophrenics. <b>1974</b> , 124, 385-91	58
2092	The Brief Psychiatric Rating Scale in Psychopharmacology Research. <b>1974</b> , 7, 67-78	62
2091	Disorders in the Probability Organization of Speech Behavior in Schizophrenia. <b>1974</b> , 12, 54-66	2
2090	Effects of maintenance amitriptyline and psychotherapy on symptoms of depression. <b>1975</b> , 5, 67-77	138
2089	Correlation between plasma levels of prolactin and chlorpromazine in psychiatric patients. <b>1975</b> , 5, 214-6	43
2088	Factors associated with attempted suicide among hospitalized depressed patients. <b>1975</b> , 5, 381-8	26
2087	Loxapine in newly admitted chronic schizophrenic patients. <b>1975</b> , 15, 286-94	13
2086	A double-blind comparison of fluphenazine decanoate and flupenthixol decanoate in the treatment of acute schizophrenia. <b>1975</b> , 51, 257-67	39
2085	Metiapine: a double-blind comparison with chlorpromazine in acute schizophrenic patients. <b>1975</b> , 15, 700-4	2
2084	Effects of protriptyline and perphenazine in neurotic depressed outpatients. <b>1975</b> , 15, 627-30	2
2083	Penfluridol: a long-acting oral neuroleptic. A controlled study. <b>1975</b> , 15, 611-21	6
2082	Nicotinic acid in the treatment of schizophrenias. Canadian Mental Health Association collaborative study: progress report II. <b>1975</b> , 20, 103-12	10
2081	Anxiety in schizophrenia. The responses to chlordiazepoxide in an intensive design study. <b>1975</b> , 32, 1246-54	33
2080	Prognostic expectations and treatment outcome. <b>1975</b> , 43, 572-6	34
2079	The integration defect in paranoid and nonparanoid schizophrenia.. <b>1975</b> , 84, 629-636	12
2078	Effects of a procaine preparation (Gerovital H3) in hospitalized geriatric patients: a double-blind study. <b>1975</b> , 23, 355-9	7
2077	A psychogeriatric assessment program. I. Social functioning and ward behavior. <b>1975</b> , 23, 465-71	14
2076	A follow-up of patients found "unfit to stand trial" or "not guilty" because of insanity. <b>1975</b> , 20, 461-7	30

2075	Work role and depression in women: a comparison of workers and housewives in treatment. <b>1975</b> , 45, 538-548	33
2074	A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Theoretical implications for potency differences among neuroleptics. <b>1975</b> , 43, 103-13	113
2073	The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs: a double-blind cross-over trial with Madopar and placebo. <b>1975</b> , 44, 105-10	83
2072	Announcement. <b>1975</b> , 44, 110-110	
2071	[The logic of decision in symptom rating (author's transl)]. <b>1975</b> , 220, 225-35	0
2070	[Methodological problems of clinical trials of psychotropic drugs (author's transl)]. <b>1975</b> , 220, 255-68	5
2069	Epidemiology of marital problems in a psychiatric population. <b>1975</b> , 10, 139-144	2
2068	Supervision of the initial interview. A study of two methods. <b>1975</b> , 32, 265-8	24
2067	The clinical usefulness of narcotic antagonists: implications of behavioral research. <b>1975</b> , 2, 417-32	8
2066	Tranquilizers or anti-depressants for chronic schizophrenics: a long term study. <b>1975</b> , 9, 241-7	16
2065	Peroral and parenteral administration of long-acting neuroleptics: a double-blind study of penfluridol compared to flupenthixol decanoate in the treatment of schizophrenia. <b>1975</b> , 52, 132-44	17
2064	Validity of family informants' ratings of psychiatric patients: general validity. <i>Psychological Reports</i> , <b>1975</b> , 37, 619-30	1.6 7
2063	Fluphenazine enanthate induced decompensations. <b>1975</b> , 16, 37-40	9
2062	Thioridazine plasma levels and clinical response. <b>1975</b> , 16, 323-37	34
2061	Responses of chronic schizophrenic females to a combination of diphenylhydantoin and neuroleptics: a double-blind study. <b>1975</b> , 16, 529-36	3
2060	The effect of increased information upon community perception of ex-mental patients. <b>1975</b> , 91, 271-5	3
2059	Pimozide: a review of its pharmacological properties and therapeutic uses in psychiatry. <b>1976</b> , 12, 1-40	154
2058	Multivariate Methods in Clinical Assessment. <b>1976</b> , 139, 161	1

2057	Comparison of depot fluphenazines: duration of action and incidence of side effects. <b>1976</b> , 17, 369-76		8
2056	A study of the relationship of nonverbal to verbal behavior: effect of lip caressing on hope and oral references as expressed in the content of speech. <b>1976</b> , 17, 135-52		2
2055	Electroconvulsive therapy and EEG correlates in depressive disorders. <b>1976</b> , 17, 581-9		11
2054	The relationship between changes in 5-HT induced platelet aggregation and clinical state in patients treated with fluphenazine. <b>1976</b> , 3, 925-8		31
2053	Work performance versus clinical assessment in the evaluation of phenothiazine therapy. <b>1976</b> , 3, 50-5		7
2052	Assessment of drugs in schizophrenia. Discussion on assessment of psychiatric and social state. <b>1976</b> , 3, 391-3		
2051	Long-term follow-up studies of drugs in schizophrenia. <b>1976</b> , 3, 411-5		2
2050	Assessing inter-rater reliability for rating scales: resolving some basic issues. <b>1976</b> , 129, 452-6		256
2049	Literatur / Pharmakaverzeichnis. <b>1976</b> , 155, 200-251		
2048	Alpha-methyldopa-chlorpromazine combination in schizophrenic patients. <b>1976</b> , 2, 118-26		6
2047	Psychopharmacology Research Ward. Ten Years' Experience. <b>1976</b> , 11, 32-42		2
2046	Validity of Family Informants' Ratings of Psychiatric Patients: Differential Validity. <i>Psychological Reports</i> , <b>1976</b> , 38, 555-564	1.6	4
2045	Thiothixene in the treatment of geriatric patients with chronic organic brain syndrome. <b>1976</b> , 24, 105-7		50
2044	Ventilatory response to carbon dioxide inhalation in depression. <b>1976</b> , 38, 282-7		22
2043	Public perception of ex-mental patients. <b>1976</b> , 66, 74-6		3
2042	Clozapine in the treatment of newly admitted schizophrenic patients. A pilot study. <b>1976</b> , 16, 289-97		26
2041	Psychopathology, craving, and mood during heroin acquisition: an experimental study. <b>1976</b> , 11, 525-44		44
2040	Analysis and modification of opiate reinforcement. <b>1976</b> , 11, 467-84		10

2039	The endogenous--neurotic distinction as a predictor of response to antidepressant drugs. <b>1976</b> , 6, 59-70		89
2038	Clinical significance of plasma chlorpromazine levels. I. Plasma levels of the drug, some of its metabolites and prolactin during acute treatment. <b>1976</b> , 6, 407-15		72
2037	An evaluation of papaverine in tardive dyskinesia. <b>1976</b> , 16, 304-10		22
2036	Prediction of short-term outcome in newly admitted psychogeriatric patients. <b>1976</b> , 24, 72-8		5
2035	Post-hospital adjustment as related to therapists' in-therapy behavior.. <b>1976</b> , 13, 267-273		4
2034	Effect of sodium valproate on tardive dyskinesia. <b>1976</b> , 129, 114-9		100
2033	Bilateral and non-dominant unilateral ECT. Part I -- Therapeutic efficacy. <b>1976</b> , 21, 69-78		8
2032	[Critical remarks on the symptom of "thought insertion" (author's transl)]. <b>1976</b> , 221, 369-82		3
2031	Comparison of differential diagnostic discrimination for abbreviated and standard MMPI. <b>1976</b> , 32, 237-45		61
2030	Subjective objectivity: therapists' affection and successful psychotherapy. <i>Psychological Reports</i> , <b>1976</b> , 38, 1163-9	1.6	7
2029	Therapists' expectancies and treatment outcome: some overlooked factors. <i>Psychological Reports</i> , <b>1976</b> , 38, 1235-8	1.6	2
2028	The schizophrenic as soothsayer. <i>Psychological Reports</i> , <b>1976</b> , 39, 635-42	1.6	
2027	A double-blind comparative trial of loxapine and trifluoperazine in acute and chronic schizophrenic patients. <b>1976</b> , 4, 441-8		78
2026	Relaxing and encouraging suggestions given to hospitalized chronic schizophrenics. <b>1976</b> , 24, 228-37		5
2025	A double-blind trial of baclofen against placebo in the treatment of schizophrenia. <b>1976</b> , 54, 287-93		67
2024	A double-blind comparison study between penfluridol and perphenazine in acute schizophrenic patients. <b>1976</b> , 30, 384-391		3
2023	Computer Programs for Assessing Rater Agreement and Rater Bias for Qualitative Data. <b>1977</b> , 37, 195-201		68
2022	The Peak Experience Variable in DPT-Assisted Psychotherapy with Cancer Patients. <b>1977</b> , 9, 1-10		61

2021	Advances in the Methodology of Cross-Cultural Psychiatric Assessment. <b>1977</b> , 14, 125-143		10
2020	Necessary and sufficient conditions for schizophrenia research. <i>Psychological Reports</i> , <b>1977</b> , 41, 891-923	1.6	4
2019	Therapists' expectancies and patients' improvement in treatment: the shape of the link. <i>Psychological Reports</i> , <b>1977</b> , 40, 443-53	1.6	7
2018	Causative vs predictive models of therapists expectancies: a further evaluation. <i>Psychological Reports</i> , <b>1977</b> , 40, 835-9	1.6	3
2017	Adequacy of the Brief Psychiatric Rating Scale for distinguishing lesser forms of psychopathology. <i>Psychological Reports</i> , <b>1977</b> , 40, 167-73	1.6	9
2016	The Inpatient Behavioral Rating Scale: a 26-item scale for recording nursing observations of patients' mood and behavior. <i>Psychological Reports</i> , <b>1977</b> , 40, 543-9	1.6	17
2015	A review of psychological measures relevant to central nervous system toxicity, with specific reference to solvent inhalation. <b>1977</b> , 11, 317-24		6
2014	Fluspirilene in the treatment of non-hospitalized schizophrenic patients. <b>1977</b> , 4, 645-9		5
2013	The Felt Figure Replacement Technique as a personality assessment device: validity reconsidered. <b>1977</b> , 41, 392-5		4
2012	Psychedelic Drug (DPT)-Assisted Psychotherapy with Alcoholics: A Controlled Study. <b>1977</b> , 9, 287-300		14
2011	Intravenous naloxone administration in schizophrenia and affective illness. <b>1977</b> , 197, 74-7		156
2010	A standardized psychiatric assessment scale for rating chronic psychotic patients. <b>1977</b> , 55, 299-308		598
2009	Effect of fusaric acid on tardive dyskinesia and mental state in psychogeriatric patients. A pilot study. <b>1977</b> , 56, 57-61		19
2008	Antiparkinsonian agents and long-term neuroleptic treatment. Effect of G 31.406, orphenadrine, and placebo on parkinsonism, schizophrenic symptoms, depression and anxiety. <b>1977</b> , 55, 251-60		18
2007	Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit. <b>1977</b> , 17, 162-7		10
2006	EEG Studies of Schizophrenics Treated with Major Tranquilizers. <b>1977</b> , 8, 62-69		
2005	Choosing an approach for diagnosing schizophrenia. <b>1977</b> , 34, 1248-53		54
2004	Psychotherapy with terminally ill patients.. <b>1977</b> , 14, 403-410		9



2003	Therapists as prophets: Their expectancies and treatment outcome.. <b>1977</b> , 14, 188-195	2
2002	Relation of psychopathology and bilingualism to kinesic aspects of interview behavior in schizophrenia.. <b>1977</b> , 86, 492-500	14
2001	Reactions of chronic schizophrenics to symptomatic behavior in others.. <b>1977</b> , 86, 324-326	
2000	MMPI clinical scale correlates.. <b>1977</b> , 45, 739-750	23
1999	Differences in psychopathology of schizophrenic patients with normal and abnormal postimperative negative variation (PINV). <b>1977</b> , 18, 83-7	16
1998	Some methodological considerations for the clinical evaluation of neuroleptics--comparative effects of clozapine and haloperidol on schizophrenics. <b>1977</b> , 31, 17-24	6
1997	Some of the problems and difficulties associated with clinical studies of antidepressant agents. <b>1977</b> , 4Suppl 2, 199S-207S	16
1996	Psychological implications of adolescent pregnancy: patterns of family interaction in adolescent mothers-to-be. <b>1977</b> , 18, 13-6	5
1995	Propranolol as an adjunct to the treatment of schizophrenia. <b>1977</b> , 2, 575-8	80
1994	Behavioral comparison of a token economy and a standard psychiatric treatment ward. <b>1977</b> , 8, 381-385	5
1993	Clinical and social comparison of fluphenazine decanoate and flupenthixol decanoate in the community maintenance therapy of schizophrenia. <b>1977</b> , 12, 54-64	23
1992	EEG sleep diagnosis of medical disease in depression. <b>1977</b> , 3, 167-78	6
1991	A controlled study of a dopa decarboxylase inhibitor (benserazide) in the treatment of schizophrenic patients. <b>1977</b> , 12, 1-8	5
1990	Patients' expectancies and hospital outcome. <b>1977</b> , 33, 254-8	10
1989	Alpha wave biofeedback training therapy in alcoholics. <b>1977</b> , 33, 292-9	52
1988	Differences in word association commonality of schizophrenics: the self-editing-deficit model vs. the partial-collapse-of-response-hierarchy hypothesis. <b>1977</b> , 33, 32-9	4
1987	Therapists prophesy. <b>1977</b> , 33, 502-10	4
1986	Judgment of emotion among chronic schizophrenics. <b>1977</b> , 33, 662-6	84

1985	Patients' expectancies and improvement in treatment: the shape of the link. <b>1977</b> , 33, 827-33	8
1984	Patient characteristics and expectancy measures as factors that influence the expectancy-improvement relationship. <b>1977</b> , 33, 1125-7	4
1983	An application of actuarial methods in psychiatric diagnosis. <b>1977</b> , 33, 973-80	7
1982	Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment. <b>1977</b> , 53, 127-30	38
1981	Efficacy of loxapine in the treatment of paranoid schizophrenia. <b>1977</b> , 51, 107-15	11
1980	Controlled double-blind trial of camazepam, a new benzodiazepine derivative, versus chlordiazepoxide. <b>1978</b> , 13, 335-7	
1979	Clozapine in tardive dyskinesia. <b>1978</b> , 56, 75-80	105
1978	Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine. <b>1978</b> , 59, 105-12	79
1977	Effect of baclofen on tardive dyskinesia. <b>1978</b> , 56, 145-51	50
1976	Clinical and plasma level characteristics of intramuscular and oral loxapine. <b>1978</b> , 56, 225-32	22
1975	Opiates, catecholamines, behavior, and mood. <b>1978</b> , 56, 327-33	7
1974	The measurement of change in endogenous affective disorders. <b>1978</b> , 226, 95-112	36
1973	Nurse-rating of psychotic behaviour. <b>1978</b> , 3, 551-62	7
1972	Common factors in two methods for assessing psychiatric inpatients. <b>1978</b> , 34, 693-4	
1971	Brief treatment of hallucinatory behavior with behavioral techniques. <b>1978</b> , 9, 663-665	7
1970	Plasma concentrations of thioridazine metabolites and ECG abnormalities. <b>1978</b> , 67, 155-7	30
1969	Systems releasing action therapy with alcoholics: an experimental evaluation. <b>1978</b> , 34, 769-74	2
1968	Effects of ambiguous and unambiguous stimulus word differences on popular responses of schizophrenics. <b>1978</b> , 34, 838-43	39

1967	Roles of the gonadal steroid hormones in psychiatric depression in men and women. <b>1978</b> , 2, 487-503		70
1966	Recognition of psychiatric disorders from voice quality. <b>1978</b> , 21, 87-111		7
1965	Medical clinic patients with emotional disorders. <b>1978</b> , 19, 611-3, 617-9		10
1964	Social maladjustment and severity of depression. <b>1978</b> , 19, 121-8		48
1963	Treatment with mesoridazine and thioridazine in chronic schizophrenia: I. Assessment of clinical and electrophysiologic responses in refractory hallucinating schizophrenics. <b>1978</b> , 19, 517-25		9
1962	Psychological functioning of bipolar manic-depressives in remission. <b>1978</b> , 35, 1351-4		32
1961	Psychiatric symptoms of lobotomized and non-lobotomized chronic schizophrenics. <i>Psychological Reports</i> , <b>1978</b> , 42, 262	1.6	1
1960	Chemodectomas of the Carotid Body and Glomus Tympanicum. <b>1978</b> , 240, 1266		2
1959	A Comparison of Psychiatric and Psychological Assessments of Acute Schizophrenics. <b>1978</b> , 2, 175-187		1
1958	High- and Low-Potency Neuroleptics in Elderly Psychiatric Patients. <b>1978</b> , 239, 1860		28
1957	Procainamide-Induced Psychosis. <b>1978</b> , 240, 1265		16
1956	Baclofen in chronic schizophrenia: A controlled double-blind study. <b>1978</b> , 32, 412-415		
1955	A rating scale for mania: reliability, validity and sensitivity. <b>1978</b> , 133, 429-35		6023
1954	Loxapine succinate as a neuroleptic agent: evaluation in two populations of elderly psychiatric patients. <b>1978</b> , 26, 263-7		9
1953	Goal attainment, locus of control, and coping style in adolescent group counseling.. <b>1978</b> , 25, 310-319		6
1952	Effects of dopamine synthesis inhibition on WAIS Comprehension.. <b>1978</b> , 46, 385-388		2
1951	Comparing the empirical validity of the standard form with two abbreviated MMPIs.. <b>1978</b> , 46, 53-61		8
1950	Comparative effectiveness of day hospital and inpatient psychiatric treatment.. <b>1978</b> , 46, 94-101		28

1949	The prolactin response in clinical psychiatry. <b>1978</b> , 62, 409-24	13
1948	Three years' maintenance neuroleptic treatment in schizophrenia--before and beyond. <b>1978</b> , 57, 103-14	10
1947	Confrontation vs. belief modification in persistently deluded patients. <b>1978</b> , 51, 127-30	119
1946	A double-blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic outpatients. <b>1978</b> , 18, 148-54	13
1945	Maintenance treatment of chronic schizophrenic patients. A study with the long-acting thioxanthene derivative, cis(Z)-clopenthixol decanoate-sordinol depot. <b>1978</b> , 57, 299-304	12
1944	Double-blind therapeutic evaluation of fluspirilene compared with fluphenazine decanoate in chronic schizophrenics. <b>1978</b> , 57, 436-46	25
1943	The treatment of anxiety with a polyfluorinated benzodiazepine derivative. <b>1978</b> , 4, 283-7	2
1942	Fluphenazine decanoate and fluphenazine enanthate in the out-patient management of chronic schizophrenia. <b>1978</b> , 4, 360-5	2
1941	Trials of lithium, chlorpromazine and amitriptyline in schizoaffective patients. <b>1978</b> , 133, 162-8	73
1940	The neuroleptic hypothesis: study of the covariation of extrapyramidal and therapeutic drug effects. <b>1978</b> , 133, 169-75	29
1939	Somatic discomforts among depressed women. <b>1979</b> , 36, 465-71	43
1938	Neuroleptika-Absetzversuche bei chronisch schizophrenen Patienten. <b>1979</b> , 14, 278-293	9
1937	Untersuchung zur Validität der übergeordneten AMP-Skalen durch Vergleiche mit der Hamilton-Depressions-Skala, BPRS und IMPS. <b>1979</b> , 14, 338-349	5
1936	Platelet Monoamine Oxidase Activity in Schizophrenia: Relationship to Disease, Treatment, Institutionalization and Outcome. <b>1979</b> , 134, 366-371	29
1935	Depressive classification and prediction of response to phenelzine. <b>1979</b> , 134, 572-81	71
1934	Clinical significance of plasma drug and prolactin levels during acute chlorpromazine treatment: a replication study. <b>1979</b> , 135, 352-9	29
1933	High-dose propranolol in schizophrenia. <b>1979</b> , 134, 470-6	51
1932	Hyperactive Children in Young Adulthood: A Controlled, Prospective, Ten-Year Follow-Up. <b>1979</b> , 8, 52-66	11

1931	Discharge planning for hospitalized older veterans. <b>1979</b> , 2, 71-86		1
1930	Group Outcome: The Mediating Influence of Member Goals and Expectations. <b>1979</b> , 4, 453-460		2
1929	Long-term neuropsychological outcome of closed head injury. <b>1979</b> , 50, 412-22		243
1928	Electromyographic assessment of dimethylaminoethanol (deanol) in treatment of tardive dyskinesia. <i>Psychological Reports</i> , <b>1979</b> , 45, 415-9	1.6	4
1927	Sheltered-care needs of the mentally ill. <b>1979</b> , 4, 41-57		4
1926	The detection of doubtful data: the program DOUBT. <b>1979</b> , 9, 75-9		
1925	Neuropsychological impairment with schizophrenia vs. acute and chronic cerebral lesions. <b>1979</b> , 35, 46-53		16
1924	Correlates of alpha, beta and theta wave production. <b>1979</b> , 35, 364-369		2
1923	Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study. <b>1979</b> , 65, 219-23		10
1922	Audiovisual self-confrontation in schizophrenia. <b>1979</b> , 227, 341-51		9
1921	Hemodialysis in schizophrenia. Results in three chronic cases. <b>1979</b> , 227, 207-12		3
1920	Hemoperfusion in chronic schizophrenics: a critical report. <b>1979</b> , 57, 1329-30		3
1919	Plasma prolactin levels before and during propranolol treatment in chronic schizophrenia. <b>1979</b> , 7, 313-4		10
1918	Nomifensine: A review of its pharmacological properties and therapeutic efficacy in depressive illness. <b>1979</b> , 18, 1-24		107
1917	Depressive symptoms in acute schizophrenia. <b>1979</b> , 3, 429-33		39
1916	Assessment of client/patient satisfaction: development of a general scale. <b>1979</b> , 2, 197-207		1670
1915	Behavioral and endocrine responses of schizophrenic patients to TRH (protirelin). <b>1979</b> , 36, 1086-93		43
1914	Biological correlates of piracetam clinical effects in psychotic patients. <b>1979</b> , 7, 277-84		7

1913	Aspects of termination in a time-limited brief psychotherapy. <b>1979</b> , 42, 208-19	12
1912	Dichotic shadowing and selective attention to word meanings in schizophrenia.. <b>1979</b> , 88, 346-353	12
1911	Amantadine in senile dementia: electroencephalographic and clinical effects. <b>1979</b> , 27, 9-16	14
1910	Influence of D-or DL-propranolol and chlorpromazine on habituation of phasic electrodermal responses in schizophrenia. <b>1979</b> , 60, 241-8	12
1909	Fluphenazine enanthate in the outpatient treatment of late paraphrenia. <b>1979</b> , 27, 459-63	23
1908	A double-blind comparison of flupenthixol decanoate and fluphenazine decanoate in the treatment of chronic schizophrenia. <b>1979</b> , 60, 313-22	27
1907	Health-seeking behavior and social networks of the aged living in single-room occupancy hotels. <b>1979</b> , 27, 270-8	14
1906	Anxious symptomatic volunteers in the Twin Cities: sociodemographic description and MMPI psychodiagnosis. <b>1979</b> , 19, 467-75	1
1905	Combination of lithium carbonate and haloperidol in schizo-affective disorder: a controlled study. <b>1979</b> , 36, 327-33	105
1904	Altered platelet monoamine oxidase activity in affective disorders. <b>1979</b> , 9, 729-36	73
1903	Clinical trial of hemodialysis in chronic schizophrenia. <b>1980</b> , 61, 223-7	8
1902	Methodological issues in psychiatric case-identification. <b>1980</b> , 10, 5-10	23
1901	Auditory hallucinations and the Verbal Transformation Effect. <b>1980</b> , 10, 139-44	7
1900	Drug-related and illness-related factors in the outcome of chlorpromazine treatment: testing a model. <b>1980</b> , 10, 335-43	9
1899	Descriptive studies of H-reflex recovery curves in psychiatric patients. <b>1980</b> , 10, 541-8	18
1898	Failure of lithium treatment in established tardive dyskinesia. <b>1980</b> , 10, 583-7	30
1897	Psychosocial correlates of retention in methadone maintenance. <b>1980</b> , 15, 1003-9	22
1896	Antidepressant drugs in anergic schizophrenia. A double-blind cross-over study with maprotiline and placebo. <b>1980</b> , 61, 438-44	40

1895	Social and clinical correlates of the "new" long-stay. <b>1980</b> , 61, 365-75	21
1894	Active and passive avoidance learning in controls and schizophrenic patients on racemic propranolol and neuroleptics. <b>1980</b> , 137, 131-7	12
1893	Controlled trial of sulpiride in chronic schizophrenic patients. <b>1980</b> , 137, 522-9	61
1892	Phenomenological classification of depressive disorders. <b>1980</b> , 36, 372-7	13
1891	Comparison of two brief tests of organic brain impairment, the MSQ and the short portable MSQ. <b>1980</b> , 28, 381-4	84
1890	Coping styles and factors in male/female social integration. <b>1980</b> , 61, 8-20	9
1889	Effectiveness of alpha biofeedback therapy: negative results. <b>1980</b> , 36, 508-13	7
1888	Observational assessment of behavioral changes accompanying clinical improvement in hospitalized psychiatric patients. <b>1980</b> , 2, 207-223	20
1887	High dosage haloperidol therapy in chronic schizophrenic patients: a double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin. <b>1980</b> , 67, 17-23	76
1886	RMI-81,582, a novel antipsychotic drug. <b>1980</b> , 67, 101-6	22
1885	High dose diazepam in schizophrenia. <b>1980</b> , 71, 79-82	46
1884	EEG and behavioral profile of flutroline (CP-36,584), a novel antipsychotic drug. <b>1980</b> , 72, 67-71	9
1883	Neuroleptic blood levels and therapeutic effect. <b>1980</b> , 70, 191-3	38
1882	Modifications of biochemical parameters in blood platelets of schizophrenic and depressive patients. <b>1980</b> , 6, 290-6	10
1881	References / Glossary of Drugs. <b>1980</b> , 147-215	
1880	A double-blind comparison of three dosages of flutroline (CP-36,584) in the treatment of schizophrenia. <b>1980</b> , 15, 318-24	5
1879	Mobilization of refractory chronic schizophrenics with haloperidol. <b>1980</b> , 15, 180-5	1
1878	Some clinical and metabolic aspects of propranolol in chronic schizophrenia. <b>1980</b> , 137, 458-68	24

1877	Clinical state, plasma levels of haloperidol and prolactin: a correlation study in chronic schizophrenia. <b>1980</b> , 137, 518-21	50
1876	Free-thyroxine index in schizophrenic patients before and after neuroleptic treatment. <b>1980</b> , 6, 29-33	14
1875	[Hemodialysis in patients with chronic schizophrenia (author's transl)]. <b>1980</b> , 48, 393-400	3
1874	Anxiety reduction in hospitalized schizophrenics through thermal biofeedback and relaxation training. <b>1980</b> , 51, 475-82	18
1873	Effects of oral clonidine on plasma 3-methoxy-4-hydroxyphenethyleneglycol (MHPG) in man: preliminary report. <b>1980</b> , 26, 2179-85	57
1872	Comparative effects of phenelzine and amitriptyline: a placebo controlled trial. <b>1980</b> , 19, 1223-5	4
1871	A comparative uptake study of serotonin, dopamine, and norepinephrine by platelets of acute schizophrenic patients. <b>1980</b> , 3, 239-46	29
1870	Antipsychotic drugs in community-based sheltered-care homes. <b>1980</b> , 14, 589-596	1
1869	Depot fluphenazine and flupenthixol in the treatment of stabilized schizophrenics. A double-blind comparative trial. <b>1980</b> , 21, 135-9	7
1868	Thyrotropin releasing hormone (TRH): a useful tool for psychoneuroendocrine investigation. <b>1980</b> , 5, 63-80	82
1867	Immunoglobulins, cognitive status and duration of illness in alzheimer's disease. <b>1980</b> , 1, 165-8	4
1866	Immunoglobulin levels in psychotic patients. <b>1980</b> , 21, 751-6	9
1865	Prognosis in schizophrenia: individual differences in psychological response to a test dose of antipsychotic drug and their relationship to blood and saliva levels and treatment outcome. <b>1981</b> , 22, 147-52	4
1864	Schizophrenic symptomatology and cerebral dominance patterns: a comparison of EEG, AER, and BPRS measures. <b>1981</b> , 22, 218-25	13
1863	Artifact in client satisfaction assessment: experience in community mental health settings. <b>1981</b> , 4, 139-50	131
1862	A probable neuroleptic effect on platelet monoamine oxidase in chronic schizophrenic patients. <b>1981</b> , 4, 95-107	87
1861	Acute amphetamine response predicts antidepressant and antipsychotic responses to lithium carbonate in schizophrenic patients. <b>1981</b> , 4, 313-25	16
1860	Effect of carbamazepine on CSF opioid activity; relationship to antidepressant response. <b>1981</b> , 5, 59-66	9



1859	Fine motor performance before and after treatment in schizophrenic and schizoaffective patients. <b>1981</b> , 5, 247-55	14
1858	(Des-tyrosine <sup>1</sup> )-gamma-endorphin in schizophrenia: clinical, biochemical, and hormonal aspects. <b>1981</b> , 5, 293-309	20
1857	Fully automated psychiatric diagnosis: Some new possibilities. <b>1981</b> , 13, 413-416	4
1856	The prolactin response in patients receiving neuroleptic therapy. The effect of fluphenazine decanoate. <b>1981</b> , 5, 69-77	6
1855	Assessment of anti-psychotic drugs. <b>1981</b> , 11, 225-36	5
1854	The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients. <b>1981</b> , 11, 255-9	19
1853	The clinical assessment of depression. <b>1981</b> , 11, 5-14	13
1852	Orienting, habituation, sensitisation, and dishabituation in the electrodermal system of consecutive, drug free, admissions for schizophrenia. <b>1981</b> , 12, 187-209	39
1851	Dextro-propranolol in schizophrenia. <b>1980</b> , 4, 633-7	7
1850	Action of [Des-Tyr <sup>1</sup> ]-gamma-endorphin in schizophrenia. <b>1981</b> , 17, 279-86	7
1849	Des-tyrosine-gamma-endorphin administration in chronic schizophrenics. A preliminary report. <b>1981</b> , 38, 167-8	50
1848	A trial of propranolol in chronic schizophrenia. <b>1981</b> , 139, 118-21	26
1847	Motor neuron branching patterns in psychotic patients. <b>1981</b> , 38, 1097-103	10
1846	INTRODUCTION. <b>1981</b> , 63, 1-26	
1845	Effects of Language and Related Variables on the Expression of Psychopathology in Mexican American Psychiatric Patients. <b>1981</b> , 3, 145-160	41
1844	Motility, Parkinsonism, and prolactin with thiothixene and thioridazine. <b>1981</b> , 38, 668-75	12
1843	Personality changes in chronic schizophrenic patients during five years' treatment with intensive psychotherapy in combination with depot neuroleptics I. Analysis of changes as measured by the Holtzman Inkblot Technique. <b>1981</b> , 289, 27-55	1
1842	Does a plasma level of chlorpromazine help?. <b>1981</b> , 11, 729-34	34

1841	(Des-Tyr)-gamma-endorphin in the treatment of schizophrenia. <b>1981</b> , 11, 401-4	35
1840	Lack of effect of naloxone and schizophrenic auditory hallucinations. <b>1981</b> , 11, 405-7	7
1839	Compulsory admissions in a London borough: I. Social and clinical features and a follow-up. <b>1981</b> , 11, 617-36	75
1838	Effect of propranolol and phenothiazines on electrodermal orienting and habituation in schizophrenia. <b>1981</b> , 11, 93-108	56
1837	Studies of depressive symptoms in schizophrenia. <b>1981</b> , 139, 89-101	187
1836	Evaluation of data-base. <b>1981</b> , 64, 330-9	3
1835	Tables and References. <b>1981</b> , 64, 73-91	
1834	Cis(Z)-clopenthixol and clopenthixol in the treatment of acute psychoses and exacerbations of chronic psychoses  A DOUBLE-BLIND CLINICAL INVESTIGATION. <b>1981</b> , 64, 013-019	1
1833	Cis(Z)-clopenthixol and haloperidol in chronic schizophrenic patients - a double-blind clinical multicentre investigation. <b>1981</b> , 64, 030-038	11
1832	The Maine Scale of paranoid and nonparanoid schizophrenia: Reliability and validity.. <b>1981</b> , 49, 438-447	76
1831	Behavioral correlates for the MMPI standard F scale and for a modified F scale for Black and White psychiatric patients.. <b>1981</b> , 49, 455-459	7
1830	Propranolol in schizophrenia. II. Clinical and biochemical aspects of combining propranolol with chlorpromazine. <b>1981</b> , 139, 112-7	39
1829	A study of naloxone with schizophrenic and manic patients. <b>1981</b> , 138, 501-3	11
1828	Dissociation of smooth-pursuit and saccadic eye tracking in remitted schizophrenics. An ocular reaction time task that schizophrenic perform well. <b>1981</b> , 38, 991-6	117
1827	Single daily dose chlorpromazine therapy in psychosis. An evaluation. <b>1981</b> , 64, 158-66	2
1826	The post-acute functioning of the schizophrenic. <b>1981</b> , 37, 705-14	6
1825	Behavioral assessment of psychiatric inpatients and normal controls across different environmental contexts. <b>1981</b> , 3, 25-36	13
1824	Outcome evaluations in the mental health field. <b>1981</b> , 17, 132-42	15

1823	Mentally ill foragers and beggars in a peasant society: Their social networks and psychopathology. <b>1981</b> , 3, 295-309	
1822	[Building syndromes in the AMP-system (author's transl)]. <b>1981</b> , 231, 93-109	17
1821	Clozapine: plasma levels and prolactin response. <b>1981</b> , 73, 184-7	70
1820	Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients. <b>1981</b> , 73, 197-9	44
1819	A clinical and pharmacodynamic evaluation of sulpiride. <b>1981</b> , 73, 77-80	42
1818	Assessment of naltrexone in the treatment of schizophrenia. <b>1981</b> , 74, 51-3	27
1817	Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects. <b>1981</b> , 74, 306-9	43
1816	Monoamine oxidase activity and enzyme kinetics in three subpopulations of density-fractionated platelets in chronic paranoid schizophrenics. <b>1981</b> , 74, 344-8	10
1815	Vasopressin in anergic schizophrenia. A cross-over study with lysine-8-vasopressin and placebo. <b>1981</b> , 74, 379-82	27
1814	Short- and long-term effects of combining drug and family therapy. <b>1981</b> , 1981, 5-26	14
1813	Psychology versus anthropology in drug use studies: The representative case method. <b>1981</b> , 8, 167-177	1
1812	Part two: Lao folk diagnoses for mental disorder: Comparison with psychiatric diagnosis and assessment with psychiatric rating scales. <b>1981</b> , 5, 425-443	9
1811	Subjective response to antipsychotic drugs. <b>1981</b> , 38, 187-90	180
1810	Hamilton Depression Rating Scale. Extracted from Regular and Change Versions of the Schedule for Affective Disorders and Schizophrenia. <b>1981</b> , 38, 98-103	321
1809	DL-propranolol and chlorpromazine following admission for schizophrenia. A controlled comparison. <b>1981</b> , 63, 13-27	35
1808	Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol. Behavioral considerations. <b>1981</b> , 38, 195-9	110
1807	Borderline syndrome and incest in chronic pelvic pain patients. <b>1980</b> , 10, 79-96	91
1806	Halopemide, a New Psychotropic Drug. Clinical Effects in an Open Study. <b>1981</b> , 14, 21-26	5

1805	Propranolol in schizophrenia. I. Comparison of propranolol, chlorpromazine and placebo. <b>1981</b> , 139, 105-11	37
1804	Cerebral laterality and psychopathology: fact and fiction. <b>1981</b> , 11, 219-27	49
1803	Symptomatology differentials between urban and rural schizophrenics. <b>1982</b> , 28, 251-5	7
1802	Developing a Multidimensional Clinical Rating Scale: Evaluating Mental Health Services. <b>1982</b> , 6, 559-576	3
1801	Random number generation, psychopathology and therapeutic change. <b>1982</b> , 39, 680-3	41
1800	Phencyclidine intoxication: assessment of possible antidotes. <b>1982</b> , 19, 313-9	20
1799	Evaluating the long-term psychiatric patient: the Progress Review Index. <b>1982</b> , 4, 287-97	2
1798	Tool development for profiling the attitude of clients with schizophrenia toward their medication, using Fishbein's expectancy-value model. <b>1982</b> , 4, 343-57	4
1797	Parental representations of schizophrenics and their association with onset and course of schizophrenia. <b>1982</b> , 141, 573-81	106
1796	Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study. <b>1982</b> , 15, 70-4	37
1795	Research on the Psychiatric Evaluation of the Bilingual Patient: A Methodological Critique. <b>1982</b> , 4, 75-80	10
1794	Electrodermal activity and therapeutic response to neuroleptic treatment in chronic schizophrenic in-patients. <b>1982</b> , 12, 607-13	23
1793	Impact of treatment intervention on the relationship between dimensions of clinical psychopathology, social dysfunction and burden on the family of psychiatric patients. <b>1982</b> , 12, 651-8	79
1792	APPENDIX C: (REFERENCES). <b>1982</b> , 65, 82-88	1
1791	CSF monoamine metabolites in schizophrenic patients. <b>1982</b> , 66, 350-60	52
1790	Phenelzine and amitriptyline: effects on symptoms of neurotic depression. <b>1982</b> , 140, 475-83	86
1789	The effect of lithium on platelet monoamine oxidase activity in bipolar and schizoaffective disorders. <b>1982</b> , 140, 192-8	9
1788	Eye tracking in patients with unipolar and bipolar affective disorders in remission.. <b>1982</b> , 91, 35-44	92

1787	Nonverbal interaction of patients and therapists during psychiatric interviews.. <b>1982</b> , 91, 109-119	40
1786	Decision rules for phenomenological classification of psychiatric patients.. <b>1982</b> , 50, 535-545	13
1785	The rapid disability rating scale-2. <b>1982</b> , 30, 378-82	144
1784	Short-term naloxone administration in schizophrenic and manic patients. A World Health Organization Collaborative Study. <b>1982</b> , 39, 313-9	93
1783	Follow-up study of memory deficits after ECT. <b>1982</b> , 27, 325-9	28
1782	Patient assessment in clinical trials. <b>1982</b> , 6, 601-6	14
1781	Biofeedback treatment of narcotic addiction: a double-blind study. <b>1982</b> , 9, 111-7	7
1780	An analysis of the skin conductance orienting response in samples of American, British, and German schizophrenics. <b>1982</b> , 14, 155-211	179
1779	Naloxone in chronic schizophrenic patients: neuroendocrine and behavioral effects. <b>1982</b> , 7, 1-7	17
1778	Lithium and chlorpromazine in psychotic inpatients. <b>1982</b> , 7, 69-81	44
1777	The effect of methadone on the behavioral and neuroendocrine responses of manic patients. <b>1982</b> , 7, 163-70	14
1776	Altered platelet serotonin uptake kinetics in schizophrenia and depression. <b>1982</b> , 31, 583-8	69
1775	Low-dose apomorphine reduces serum homovanillic acid concentrations in schizophrenic patients. <b>1982</b> , 30, 753-6	46
1774	A Satisfaction with Mental Health Care Scale. <b>1982</b> , 23, 68-74	27
1773	Treatment of schizophrenic patients in their homes through a visiting nurse- some issues in the nurse's training. <b>1982</b> , 19, 167-72	13
1772	Studies of beta-endorphin in psychiatric patients. <b>1982</b> , 398, 448-59	6
1771	Clinical trial of des-tyrosyl-gamma-endorphin in mental illness. <b>1982</b> , 398, 470-7	2
1770	Predictive indices for chlorpromazine therapy in schizophrenics. <b>1982</b> , 14, 273-7	3

1769	Toxicity of lead additives. <b>1982</b> , 2, 333-4	4
1768	Cholecystokinin appears to have antipsychotic properties. <b>1982</b> , 6, 509-12	69
1767	Diazepam in high doses is effective in schizophrenia. <b>1982</b> , 6, 513-6	32
1766	Amoxapine: a review of its pharmacology and efficacy in depressed states. <b>1982</b> , 24, 1-23	119
1765	Influence of acetylator phenotype on antidepressant effects of phenelzine. <b>1982</b> , 141, 243-8	24
1764	Long-term pimozide pretreatment differentially affects behavioral responses to dextroamphetamine in schizophrenia. Further exploration of the dopamine hypothesis of schizophrenia. <b>1982</b> , 39, 275-81	20
1763	The syndrome of schizophrenia: relations between electrodermal response, lateral asymmetries and clinical ratings. <b>1982</b> , 141, 488-95	67
1762	Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics. <b>1982</b> , 39, 197-203	107
1761	The effect of tetrahydroisoxazopyridinol (THIP) in tardive dyskinesia: a new gamma-aminobutyric acid agonist. <b>1982</b> , 39, 1017-21	41
1760	Low serum neuroleptic levels predict relapse in schizophrenic patients. <b>1982</b> , 39, 998-1000	38
1759	Antipsychotic effects of caerulein, a decapeptide chemically related to cholecystokinin octapeptide, on schizophrenia. <b>1982</b> , 17, 255-73	43
1758	12-month study of haloperidol decanoate in chronic schizophrenic patients. <b>1982</b> , 17, 247-54	14
1757	Hla, and the response to treatment with gamma-type endorphins in schizophrenia. <b>1982</b> , 9, 381-8	18
1756	A double-blind dose-determination study with flutroline: A new neuroleptic. <b>1982</b> , 2, 357-362	1
1755	Prolactin stimulating effects of amoxapine and loxapine in psychiatric patients. <b>1982</b> , 78, 287-92	9
1754	Pimozide in the treatment of newly admitted schizophrenic patients. <b>1982</b> , 76, 13-9	36
1753	Dose dependent changes in propranolol half life when used as an adjunct to neuroleptic treatment. <b>1982</b> , 76, 62-5	3
1752	Dose-response relationships of perphenazine in the treatment of acute psychoses. <b>1982</b> , 78, 112-5	53

1751	Serum concentrations of cis(Z)-flupentixol and prolactin in chronic schizophrenic patients treated with flupentixol and cis(Z)-flupentixol decanoate. <b>1982</b> , 77, 58-65	29
1750	Glutamate in schizophrenics and healthy controls. <b>1982</b> , 231, 221-5	33
1749	Phenylethylamine and phenylacetic acid in CSF of schizophrenics and healthy controls. <b>1983</b> , 232, 463-71	24
1748	Effects of supidimide in schizophrenic inpatients undergoing neuroleptic maintenance therapy with haloperidol. <b>1982</b> , 22, 217-23	
1747	Habituation of the Blink reflex in normals and schizophrenic patients. <b>1982</b> , 19, 1-6	174
1746	Young psychophysiology award address, 1982. Psychophysiology and genetics: a key to psychopathology research. <b>1983</b> , 20, 371-83	26
1745	The effect of prolonged stimulus repetition on autonomic response and EEG activity in normal subjects, schizophrenic, and nonschizophrenic patients. <b>1983</b> , 20, 332-42	1
1744	Long-term outcome of hyperactive children. <b>1983</b> , 53, 532-41	49
1743	Phenylethylamine and monoamine metabolites in CSF of schizophrenics: effects of neuroleptic treatment. <b>1983</b> , 57, 103-10	21
1742	Enhancing the utilization of outpatient mental health services. <b>1983</b> , 19, 305-20	33
1741	A cross-cultural study of the reliability and factorial dimensions of the Brief Psychiatric Rating Scale (BPRS). <b>1983</b> , 80, 190-1	24
1740	Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment. <b>1983</b> , 81, 100-6	45
1739	Plasma levels of thiothixene by radioreceptor assay: clinical usefulness. <b>1983</b> , 79, 40-4	14
1738	Sulpiride trial in chronic schizophrenia with comparison of two dosage regimens. <b>1983</b> , 80, 259-62	1
1737	Effect of low-dose bromocriptine in treatment of psychosis: the dopamine autoreceptor-stimulation strategy. <b>1983</b> , 81, 37-41	42
1736	High doses of diazepam improve neuroleptic-resistant chronic schizophrenic patients. <b>1983</b> , 81, 42-7	27
1735	Convergent and discriminant validity of the WIST. <b>1983</b> , 39, 321-5	2
1734	Nine standardized scales for evaluating treatment outcome in a mental health clinic. <b>1983</b> , 39, 939-50	14

1733	The TSH-response to TRH: A possible predictor of outcome to antidepressant and neuroleptic treatment. <b>1983</b> , 7, 335-42	20
1732	Propranolol in schizophrenia. <b>1983</b> , 7, 89-99	3
1731	Apomorphine response and subtyping of schizophrenia. <b>1983</b> , 7, 83-8	17
1730	Assessment of patient satisfaction: development and refinement of a service evaluation questionnaire. <b>1983</b> , 6, 299-313	502
1729	Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. <b>1983</b> , 9, 271-83	48
1728	Platelet aggregation response in schizophrenia and prostaglandin E1. <b>1983</b> , 9, 309-18	18
1727	Dopamine and noradrenalin in the cerebrospinal fluid of schizophrenic patients. <b>1983</b> , 8, 243-50	46
1726	Effect of gamma-vinyl GABA in tardive dyskinesia. <b>1983</b> , 8, 261-9	32
1725	Family conflict, psychopathology, and dangerous behavior by schizophrenic inpatients. <b>1983</b> , 8, 271-80	25
1724	Plasma homovanillic acid and tardive dyskinesia during neuroleptic maintenance and withdrawal. <b>1983</b> , 9, 217-23	22
1723	The general adult inpatient psychiatric assessment scale (GAIPAS). <b>1983</b> , 10, 217-36	2
1722	Short-lived effect of (Des-Tyr)-gamma-endorphin in schizophrenia. <b>1983</b> , 10, 243-52	17
1721	Gamma-hydroxybutyrate in the treatment of schizophrenia. <b>1983</b> , 9, 1-8	13
1720	Lateral ventricular size and drug-induced Parkinsonism. <b>1983</b> , 9, 9-16	23
1719	Cerebrospinal fluid [Met5]enkephalin level in schizophrenics during treatment with naloxone. <b>1983</b> , 9, 77-81	14
1718	Met-enkephalin level in the cerebrospinal fluid of schizophrenic patients. <b>1983</b> , 128, 367-71	16
1717	Thought disorder and depression in psychiatric patients. <b>1983</b> , 24, 57-64	8
1716	Plasma cortisol concentrations in the functional psychoses and Alzheimer Type Dementia: A neuroendocrine day approach in drug-free patients. <b>1983</b> , 19, 247-250	7



1715	CSF monoamine metabolism in patients with tardive dyskinesia: effect of oxypertine and hydroxyzine pamoate. <b>1983</b> , 37, 129-35		
1714	Toward a concept of homelessness among aged men. <b>1983</b> , 38, 81-9		24
1713	Schizophrenia, conduct disorder and depressive disorder: neuropsychological, speech sample and EEG results. <b>1983</b> , 57, 427-44		5
1712	Clinical validity of the MMPI-168. <i>Psychological Reports</i> , <b>1983</b> , 53, 433-4	1.6	1
1711	High-dose haloperidol increases CSF opioid activity in patients with chronic schizophrenia. <b>1983</b> , 16, 9-12		9
1710	Thought-stopping for Delusions and Hallucinations: A Pilot Study. <b>1983</b> , 11, 177-184		19
1709	Early versus late lateral ventricular enlargement following closed head injury. <b>1983</b> , 46, 1092-7		35
1708	Clinical characteristics of akathisia. A systematic investigation of acute psychiatric inpatient admissions. <b>1983</b> , 143, 139-50		197
1707	Medical drug use by women: symptoms and change attributions. <b>1983</b> , 18, 45-51		1
1706	Psychiatric hospital versus community treatment: the results of a randomised trial. <b>1983</b> , 17, 160-7		213
1705	Cerebral laterality and psychopathology: a review of dichotic listening studies. <b>1983</b> , 9, 134-51		48
1704	Prediction of suicide in psychiatric patients. Report of a prospective study. <b>1983</b> , 40, 249-57		533
1703	Electrodermal activity in euthymic unipolar and bipolar affective disorders. A possible marker for depression. <b>1983</b> , 40, 557-65		88
1702	Social support and post hospital outcome for depressed women. <b>1983</b> , 28, 612-23		18
1701	Differences among clinicians in the decision to admit. <b>1983</b> , 40, 1133-7		31
1700	Evaluation of home care treatment for schizophrenic patients. <b>1983</b> , 67, 80-8		42
1699	A long term prospective study of electroencephalographic and neuropsychological correlates of tardive dyskinesia: initial findings at five year follow-up. <b>1983</b> , 14, 186-201		2
1698	Simulating normal MMPI profiles as a favourable prognostic sign in schizophrenia. <b>1983</b> , 35, 433-444		3

1697	Making cooperative living work for psychiatric outpatients. <b>1983</b> , 8, 271-82	3
1696	The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. <b>1983</b> , 67, 339-52	114
1695	Relapse in schizophrenia: a review of the concept and its definitions. <b>1983</b> , 13, 469-77	36
1694	Cognitive functions in tardive dyskinesia. <b>1983</b> , 13, 671-4	40
1693	The prolactin response to flutroline hydrochloride in schizophrenic patients. <b>1983</b> , 23, 505-16	
1692	Premorbid and symptomatic characteristics of schizophrenics from families with high and low levels of expressed emotion.. <b>1983</b> , 92, 359-367	97
1691	Hemodialysis in schizophrenics. A double-blind study. <b>1983</b> , 40, 211-4	6
1690	Low CSF concentrations of cyclic GMP in schizophrenia. <b>1983</b> , 142, 288-91	32
1689	Propranolol in schizophrenia: a double blind, placebo controlled trial of propranolol as an adjunct to neuroleptic medication. <b>1983</b> , 143, 151-5	29
1688	The withdrawal of benztropine mesylate in chronic schizophrenic patients. <b>1983</b> , 143, 584-90	54
1687	Alpha-2 adrenergic receptor sensitivity and the mechanism of action of antidepressant therapy. The effect of long-term amitriptyline treatment. <b>1983</b> , 142, 265-75	78
1686	Follow-up study of schizophrenic patients initially treated with home care. <b>1983</b> , 143, 447-50	24
1685	Assessment Scales for Depression: The Next 20 Years. <b>1983</b> , 68, 117-130	4
1684	Tactile-evoked potentials in schizophrenia. Interhemispheric transfer and drug effects. <b>1983</b> , 143, 156-64	26
1683	Validity of the AMP-System for its use in clinical psychopharmacology. <b>1983</b> , 20, 174-84	2
1682	Assessment of the Delineation of Psychopathology by Medical Students. <b>1983</b> , 7, 202-207	
1681	Economic losses associated with chronic mental disorder in a developing country. <b>1984</b> , 144, 475-81	5
1680	The Role of Social Networks in the Maintenance of Schizophrenic Patients. <b>1984</b> ,	

1679 V - Bibliografie. **1984**, 1, 425-439

1678 V ? Bibliographies. **1984**, 1, 425-439

1677 Behavioral Manifestations of Movement Disorders. **1984**, 2, 527-540 17

1676 Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients. **1984**, 225, 954-7 223

1675 The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: I. Factor structure on an inpatient unit. **1984**, 39, 187-93 146

1674 Treatment of schizoaffective disorders. **1984**, 10, 30-48 59

1673 The gerontology alcohol project: a behavioral treatment program for elderly alcohol abusers. **1984**, 24, 510-6 96

1672 Comparative validity of the MMPI and two short forms: psychiatric ratings. **1984**, 48, 265-70 1

1671 The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. **1984**, 10, 388-98 1330

1670 Brief psychotherapy of bereavement reactions. The relationship of process to outcome. **1984**, 41, 438-48 131

1669 Akathisia with haloperidol and thiothixene. **1984**, 41, 1036-9 112

1668 Can the client with chronic schizophrenia consent to nursing research?. **1984**, 9, 381-90 11

1667 Redundancy and complexity of information in cognitive performances of schizophrenic and normal individuals. **1984**, 40, 648-54 4

1666 Associative response bias and severity of thought disorder in schizophrenia and mania. **1984**, 40, 889-92 2

1665 Family affect and communication related to schizophrenia. **1984**, 1984, 47-62 2

1664 Haloperidol plasma levels and clinical response in paranoid schizophrenics. **1984**, 234, 231-6 41

1663 The dexamethasone suppression test and thyroid stimulating hormone response to TRH in RDC schizoaffective patients. **1984**, 234, 264-7 11

1662 An early phase II clinical trial of BW234U in the treatment of acute schizophrenia in newly admitted patients. **1984**, 84, 282-4 40

1661	High dose diazepam treatment and its effect on prolactin secretion in adolescent schizophrenic patients. <b>1984</b> , 82, 382-5	14
1660	Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients. <b>1984</b> , 82, 194-8	16
1659	Amoxapine and amitriptyline. I. Relative speed of antidepressant action. <b>1984</b> , 83, 129-33	6
1658	Fluperlapine in tardive dyskinesia and parkinsonism. <b>1984</b> , 84, 76-9	15
1657	Plasma haloperidol levels and therapeutic response in acute mania and schizophrenia. <b>1984</b> , 234, 1-4	11
1656	Serine metabolism and psychosis. <b>1984</b> , 12, 121-36	45
1655	Anxious depressions. Clinical, family history, and naturalistic outcome--comparisons with panic and major depressive disorders. <b>1984</b> , 6, 67-82	225
1654	Responses to phenelzine and amitriptyline absence of differential predictors by multiple regression analysis. <b>1984</b> , 6, 209-18	11
1653	A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients. <b>1984</b> , 7, 297-308	39
1652	Vasoactive intestinal polypeptide decreased in cerebrospinal fluid (CSF) in atypical depression. Vasoactive intestinal polypeptide, cholecystokinin and gastrin in CSF in psychiatric disorders. <b>1984</b> , 7, 325-37	31
1651	Clinical efficacy, extrapyramidal symptoms and serum levels: influence of administration schedules and concomitant drugs on serum bromperidol concentrations. <b>1984</b> , 38, 121-36	1
1650	Cholecystokinin-octapeptide in chronic schizophrenia: a double-blind placebo-controlled study. <b>1984</b> , 8, 711-4	12
1649	Biologic tests in depression. <b>1984</b> , 25, 443-7, 451	24
1648	Hyperactives as young adults: initial predictors of adult outcome. <b>1984</b> , 23, 250-60	96
1647	Positive and negative subtypes in acute schizophrenia. <b>1984</b> , 25, 455-64	51
1646	Community orientated treatment compared to psychiatric hospital orientated treatment. <b>1984</b> , 18, 1005-10	93
1645	Age-based transition periods and the outcome of mental health treatment. <b>1984</b> , 7, 237-44	6
1644	Clinical, biochemical, and hormonal aspects of treatment with Des-tyr <sup>1</sup> -gamma-endorphin in schizophrenia. <b>1984</b> , 11, 329-46	15

1643	Serum prolactin, psychopathology, and ventricular size in chronic schizophrenia. <b>1984</b> , 12, 149-53	11
1642	Phenylethylamine excretion in depression. <b>1984</b> , 13, 193-201	20
1641	Plasma and red cell levels of thioridazine and clinical response in schizophrenia. <b>1984</b> , 12, 287-96	17
1640	Repeated naloxone administration in schizophrenia. <b>1984</b> , 12, 297-312	18
1639	Biochemical markers in the study of clinical effects and extrapyramidal side effects of neuroleptics. <b>1984</b> , 13, 119-27	1
1638	Plasma L-tryptophan/neutral amino acid ratio and dexamethasone suppression in depression. <b>1984</b> , 11, 185-92	53
1637	Prazosin, a specific alpha 1-noradrenergic receptor antagonist, has no effect on symptoms but increases autonomic arousal in schizophrenic patients. <b>1984</b> , 11, 193-204	34
1636	The interpersonal impact approach to patient assessment: specific links between psychotics' symptoms and staff's feelings. <b>1984</b> , 11, 237-50	1
1635	Melatonin immunoreactivity in cerebrospinal fluid of schizophrenic patients and healthy controls. <b>1984</b> , 11, 107-10	18
1634	Information processing and neuroleptic response in acute and stabilized schizophrenic patients. <b>1984</b> , 13, 41-9	33
1633	The Genain Quadruplets 25 years later: a diagnostic and biochemical followup. <b>1984</b> , 13, 59-76	20
1632	Platelet alpha 2-adrenergic receptors in schizophrenic patients before and after phenothiazine treatment. <b>1984</b> , 12, 69-77	24
1631	TRH test abnormalities in psychiatric disorders. <b>1984</b> , 6, 273-81	21
1630	Investigation of the Karnofsky Performance Status as a measure of quality of life.. <b>1984</b> , 3, 129-142	126
1629	Tardive dyskinesia. A discontinuation study. <b>1984</b> , 41, 623-7	46
1628	Psychotropic Drug Effects on Smooth Pursuit Eye Movements: A Summary of Recent Findings. <b>1984</b> , 497-505	3
1627	Sexual offenders, violence and testosterone: a clinical study. <b>1984</b> , 29, 335-43	47
1626	Alternative drug therapies for mania: a literature review. <b>1984</b> , 18, 577-89	8

1625	A preliminary study on the use of calcitonin in clinical psychopathology. <b>1984</b> , 12, 23-9	2
1624	Comparison of haloperidol and chlorpromazine in the treatment of phencyclidine psychosis. <b>1984</b> , 24, 202-4	39
1623	Costs and benefits of two doses of fluphenazine. <b>1984</b> , 41, 1025-9	138
1622	Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses. <b>1984</b> , 41, 520-4	30
1621	The effects of ceruletide in schizophrenia. <b>1984</b> , 41, 617-9	76
1620	Reliability of clinical assessment of blunted affect. <b>1984</b> , 69, 242-9	5
1619	Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Relation to duration of illness and depressive symptoms. <b>1984</b> , 41, 512-9	91
1618	Electroencephalography of DSM-III borderline personality disorder. <b>1984</b> , 69, 129-34	45
1617	Factor analysis of a picture-preference test of personality. <b>1984</b> , 75, 469-480	1
1616	Sulpiride versus haloperidol, a clinical trial in schizophrenia. A preliminary report. <b>1984</b> , 311, 31-41	20
1615	Interactional correlates of expressed emotion in the families of schizophrenics. <b>1984</b> , 144, 482-7	172
1614	Schizophrenia. A comparative trial of community orientated and hospital orientated psychiatric care. <b>1984</b> , 69, 359-72	84
1613	Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. <b>1984</b> , 41, 165-70	118
1612	Statistical factor analysis and cluster analysis in the etiology of climacteric symptoms. <b>1984</b> , 143, 481-9	15
1611	Clinical and endocrinological features of statistical clusters of women with climacteric symptoms. <b>1985</b> , 146, 59-68	6
1610	Parental affective style and the treatment of schizophrenia. Predicting course of illness and social functioning. <b>1985</b> , 42, 34-42	100
1609	Scale for the assessment of reality testing: Reliability, validity, and factorial invariance.. <b>1985</b> , 53, 506-511	26
1608	Affective and behavioral features of DSM-III borderline personality disorder. Are they valid?. <b>1985</b> , 18, 3-10	3

1607	Demography of psychiatric patients with borderline personality traits. <b>1985</b> , 18, 38-49	20
1606	Music psychopathology. I. Musical tempo and psychiatric disease. <b>1985</b> , 18, 254-64	22
1605	[Clinical applications of data processing in psychiatry]. <b>1985</b> , 30, 513-20	0
1604	Speech and psychopathology. <b>1985</b> , 28 ( Pt 1), 57-79	5
1603	Psychiatric aftercare in a metropolitan setting. <b>1985</b> , 30, 329-36	13
1602	Comparing bilateral to unilateral electroconvulsive therapy in a randomized study with EEG monitoring. <b>1985</b> , 42, 1087-92	17
1601	An open clinical trial of carbamazepine in treatment-resistant bipolar and schizo-affective psychotics. <b>1985</b> , 147, 198-200	28
1600	Heterogeneity in dementia of the Alzheimer type: evidence of subgroups. <b>1985</b> , 35, 453-61	449
1599	Comparison of antimanic efficacy of clonidine and verapamil. <b>1985</b> , 25, 307-8	46
1598	An open multicentre study of the treatment of florid schizophrenia with remoxipride. <b>1985</b> , 72, 139-43	36
1597	Cholecystinin and other neuropeptides in the cerebrospinal fluid (CSF) in psychiatric disorders. <b>1985</b> , 39, 45-49	5
1596	Sulpiride and haloperidol in schizophrenia: a double-blind cross-over study of therapeutic effect, side effects and plasma concentrations. <b>1985</b> , 147, 283-8	63
1595	Changes in mental condition, hyperkinesias and biochemical parameters after withdrawal of chronic neuroleptic treatment. <b>1985</b> , 72, 430-5	10
1594	Efficacy of antipsychotics in the treatment of the behavioral complications of dementia: a review of the literature. <b>1985</b> , 33, 206-9	71
1593	Withdrawal of trihexyphenidyl. <b>1985</b> , 71, 297-303	20
1592	Characterizing anger in the DSM-III borderline personality disorder. <b>1985</b> , 72, 464-9	17
1591	Perphenazine Decanoate vs. Perphenazine Enanthate. <b>1985</b> , 72, 15-28	19
1590	A comparative validation of the Foulds and Bedford hierarchy of psychiatric symptomatology. <b>1985</b> , 146, 424-8	36

1589	Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems. <b>1985</b> , 42, 259-64	16
1588	[The Hamburg Rating Scale for psychiatric disorders following heart operations (HRPD)]. <b>1985</b> , 234, 308-18	8
1587	Social disability in schizophrenia: the controlled prospective Burghölzli study. I. Case-finding, research design, and characteristics of samples. <b>1985</b> , 234, 341-7	6
1586	Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. <b>1985</b> , 85, 329-32	118
1585	An open study of remoxipride, a benzamide derivative, in schizophrenia. <b>1985</b> , 86, 241-3	35
1584	Lithium attenuates the activation-euphoria but not the psychosis induced by d-amphetamine in schizophrenia. <b>1985</b> , 87, 111-5	31
1583	Efficacy of oral physostigmine in primary degenerative dementia. A double-blind study of response to different dose level. <b>1985</b> , 87, 147-51	94
1582	The treatment of tardive dyskinesia with baclofen. <b>1985</b> , 87, 480-3	25
1581	Positron emission tomography in schizophrenic patients with and without neuroleptic medication. <b>1985</b> , 5, 201-6	152
1580	Relation of neuroleptic dose and tardive dyskinesia to attention, information-processing, and psychophysiology in medicated schizophrenics. <b>1985</b> , 42, 849-59	44
1579	The effect of propranolol and thioridazine on positive and negative symptoms of schizophrenia. <b>1985</b> , 147, 623-30	26
1578	Regional cerebral blood flow in schizophrenic disorders. <b>1985</b> , 24, 176-81	56
1577	Neuroleptic serum levels measured by radioreceptor assay in patients receiving intramuscular depot neuroleptics. Some preliminary findings. <b>1985</b> , 146, 439-42	6
1576	Home care for chronic mental illness in Bangalore: an experiment in the prevention of repeated hospitalization. <b>1985</b> , 147, 175-9	20
1575	Effect of Neuroleptics on immunoglobulins in Schizophrenia. <b>1985</b> , 8, 43-46	
1574	Is There a Dementia Associated with the Major Psychoses?. <b>1985</b> , 20, 52-57	
1573	Cerebrospinal fluid vasopressin--changes in depression. <b>1985</b> , 147, 696-701	63
1572	Pharmacologic evidence for specificity of pursuit dysfunction to schizophrenia. Lithium carbonate associated with abnormal pursuit. <b>1985</b> , 42, 335-41	60



1571	Effect of the Neuroleptic EMD 30-533 on Schizophrenic Symptoms: An Open Study. <b>1985</b> , 18, 58-60	1
1570	Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. <b>1985</b> , 42, 977-83	378
1569	Family management in the prevention of morbidity of schizophrenia. Clinical outcome of a two-year longitudinal study. <b>1985</b> , 42, 887-96	430
1568	Guidelines for Drug Trials in the Treatment of Age-Associated Cognitive Decline and Alzheimer's Disease. <b>1985</b> , 19, 405-420	4
1567	Magnetic resonance imaging after 'diffuse' nonmissile head injury. A neurobehavioral study. <b>1985</b> , 42, 963-8	44
1566	Differences in psychopathology between black and white schizophrenics. <b>1985</b> , 31, 252-7	11
1565	A proposed method for measuring change beyond symptoms. <b>1985</b> , 42, 703-8	5
1564	Schizophrenia with good and poor outcome. III: Neurological 'soft' signs, cognitive impairment and their clinical significance. <b>1985</b> , 146, 348-57	150
1563	The Effect of Number of Rating Scale Categories on Levels of Interrater Reliability : A Monte Carlo Investigation. <b>1985</b> , 9, 31-36	167
1562	Irritability: definition, assessment and associated factors. <b>1985</b> , 147, 127-36	163
1561	Rating scales for measuring severity of schizophrenic states: An overview. <b>1985</b> , 39, 417-423	1
1560	Schizophrenia with good and poor outcome. I: Early clinical features, response to neuroleptics and signs of organic dysfunction. <b>1985</b> , 146, 229-39	171
1559	Vasopressin--oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls. <b>1985</b> , 10, 187-91	102
1558	Movement-related cerebral potentials in schizophrenics. <b>1985</b> , 39, 173-83	38
1557	The effects of cholecystokinin-like peptides in schizophrenics and normal human subjects. <b>1985</b> , 448, 542-52	12
1556	Pilot study on the effects of fenfluramine on negative symptoms in twelve schizophrenic inpatients. <b>1985</b> , 20, 1098-102	20
1555	Manic symptoms: an indication for bilateral ECT. <b>1985</b> , 20, 125-34	35
1554	Effect of valproic acid on behavior and plasma amino acid concentrations in chronic schizophrenic patients. <b>1985</b> , 20, 209-15	22

1553	Metabolism of an ingested serine load in psychotic and nonpsychotic subjects. <b>1985</b> , 20, 41-9	20
1552	Habituation and cortisol dysregulation in depression. <b>1985</b> , 20, 980-9	24
1551	Phenelzine-induced hypomania: effect of verapamil. <b>1985</b> , 20, 1009-14	27
1550	A treatment trial with an analog of thyrotropin-releasing hormone (DN-1417) in schizophrenia. <b>1985</b> , 20, 1030-5	7
1549	Gamma-vinyl-GABA treatment of tardive dyskinesia and other movement disorders. <b>1985</b> , 20, 888-93	34
1548	Neuropeptides in the cerebrospinal fluid (CSF) in psychiatric disorders. <b>1985</b> , 9, 533-8	14
1547	Case report of prolactin and bipolar illness: a longitudinal study. <b>1985</b> , 9, 451-7	5
1546	Remoxipride in schizophrenia: effects on plasma prolactin. <b>1985</b> , 9, 599-603	6
1545	Brain muscarinic receptors in senile dementia. <b>1985</b> , 336, 19-25	88
1544	Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients. <b>1985</b> , 16, 95-9	17
1543	Serotonin and schizophrenia: correlations between serotonergic activity and schizophrenic motor behavior. <b>1985</b> , 14, 235-40	30
1542	Lateral ventricular enlargement and clinical response in schizophrenia. <b>1985</b> , 14, 241-53	29
1541	A Negative Symptom Rating Scale. <b>1985</b> , 16, 27-36	105
1540	Binding of 3H-spiperone to human lymphocytes: a biological marker in schizophrenia?. <b>1985</b> , 15, 41-8	45
1539	Amphetamine response in borderline patients. <b>1985</b> , 15, 97-108	20
1538	Cerebrospinal fluid monoamine and monoamine metabolite concentrations in melancholia. <b>1985</b> , 15, 281-92	104
1537	Measuring thought disorder with clinical rating scales in schizophrenic and nonschizophrenic patients. <b>1985</b> , 15, 313-8	20
1536	Social skills training for patients with schizophrenia: a controlled clinical trial. <b>1985</b> , 15, 239-47	177

1535	Neuroleptic withdrawal in chronic schizophrenia: CT and endocrine variables relating to psychopathology. <b>1985</b> , 16, 207-19	30
1534	18Fluorodeoxyglucose PET in schizophrenia. <b>1985</b> , 16, 317-29	35
1533	Cognitive impairment in tardive dyskinesia. <b>1985</b> , 16, 331-7	40
1532	Message disruptions during syntactic processing in schizophrenia. <b>1985</b> , 18, 183-202	46
1531	Neurophysiological correlates of psychomotor activity in chronic schizophrenics. <b>1985</b> , 61, 218-28	67
1530	The signs and symptoms of schizophrenia. <b>1985</b> , 26, 103-12	50
1529	Negative and positive schizophrenic syndromes after the acute phase: a prospective follow-up. <b>1986</b> , 27, 276-86	63
1528	Two self-rating scales for depression in Hmong refugees: assessment in clinical and nonclinical samples. <b>1986</b> , 20, 103-13	22
1527	Central error-correcting behavior in schizophrenia and depression. <b>1986</b> , 21, 263-73	34
1526	Dexamethasone suppression test and noradrenergic function in affective and schizophrenic disorders. <b>1986</b> , 21, 621-31	22
1525	Tardive dyskinesia in schizophrenics under 60 years of age. <b>1986</b> , 21, 161-9	30
1524	Noradrenergic and neuroradiological abnormalities in tardive dyskinesia. <b>1986</b> , 21, 799-812	31
1523	Significance of positive and negative syndromes in chronic schizophrenia. <b>1986</b> , 149, 439-48	170
1522	Effects of bromocriptine on neuroleptic-induced amenorrhea, galactorrhea and impotence. <b>1986</b> , 40, 639-46	3
1521	Suicide and aggression in schizophrenia. Neurobiologic correlates. <b>1986</b> , 487, 189-96	30
1520	Effects of stimulus parameters on cognitive side effects. <b>1986</b> , 462, 315-25	183
1519	Preliminary study of carbamazepine in post-traumatic stress disorder. <b>1986</b> , 27, 849-54	157
1518	The TRH test during dopamine receptor blockade in depressed patients. <b>1986</b> , 11, 327-36	11

1517	Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. <b>1986</b> , 234, 1558-63	848
1516	Prolonged psychosis with first-rank symptoms following metrizamide myelography. <b>1986</b> , 27, 373-5	4
1515	Oestrogen-stimulated neurophysin and outcome after electroconvulsive therapy. <b>1986</b> , 1, 1411-4	30
1514	Membrane stabilising activity: a major cause of fatal poisoning. <b>1986</b> , 1, 1414-7	69
1513	Calcium antagonists in mania: a double-blind study of verapamil. <b>1986</b> , 18, 309-20	98
1512	Drug effects on serine metabolism in psychiatric patients. <b>1986</b> , 18, 119-26	21
1511	Effects of haloperidol on somatostatin-like immunoreactivity in the CSF of Schizophrenic patients. <b>1986</b> , 17, 1-6	22
1510	Neuroleptic bioavailability, psychosocial factors, and clinical status: a 1-year study of schizophrenic outpatients after dose reduction. <b>1986</b> , 19, 311-22	14
1509	Brain dopamine D-1 receptors in senile dementia. <b>1986</b> , 73, 219-30	19
1508	Reliability and validity of the symptoms of major depressive illness. <b>1986</b> , 43, 451-6	86
1507	Effects of intravenous and subcutaneous administration of apomorphine on the clinical symptoms of chronic schizophrenics. <b>1986</b> , 148, 204-8	7
1506	Raised plasma cortisol concentrations a feature of drug-free psychotics and not specific for depression. <b>1986</b> , 148, 58-65	68
1505	Gas-liquid chromatography of phencyclidine in serum, with nitrogen-phosphorus detection.. <b>1986</b> , 32, 1921-1924	3
1504	Radio receptor assay of serum neuroleptic levels in psychiatric patients. <b>1986</b> , 148, 187-93	27
1503	Orofacial dyskinesia, cognitive function and medication. <b>1986</b> , 149, 216-20	20
1502	Interactions between procyclidine and neuroleptic drugs. Some pharmacological and clinical aspects. <b>1986</b> , 149, 726-33	22
1501	Does propranolol have an antipsychotic effect? A placebo-controlled study in acute schizophrenia. <b>1986</b> , 148, 701-7	25
1500	Effects of six weeks' neuroleptic treatment on the pituitary-thyroid axis in schizophrenic patients. <b>1986</b> , 16, 72-7	14

1499	A comparative trial of depot pipothiazine. <b>1986</b> , 14, 72-7	8
1498	Stability of MMPI configurations for psychiatric inpatients.. <b>1986</b> , 54, 375-380	26
1497	Cognitive event-related potential correlates of schizophrenia.. <b>1986</b> , 100, 43-66	314
1496	Comparison of self-rated and observer-rated scales in DSM-III borderline personality disorder. <b>1986</b> , 31, 708-13	5
1495	Reduced sensitivity of red blood cell (Na <sup>+</sup> ,K <sup>+</sup> )-ATPase to ethanol in vitro in male alcoholic patients: relationship to clinical characteristics. <b>1986</b> , 10, 526-30	5
1494	Antipsychotic effect of remoxipride, a new substituted benzamide with selective antidopaminergic activity. <b>1986</b> , 73, 17-21	31
1493	Topography and possible physiological significance of EEG amplitude variability in psychosis. <b>1986</b> , 73, 665-75	12
1492	Positive and negative syndromes in schizophrenia as a function of chronicity. <b>1986</b> , 74, 507-18	78
1491	Characterizing somatization, hypochondriasis, and hysteria in the borderline personality disorder. <b>1986</b> , 73, 307-14	4
1490	Immunoglobulin and C3 abnormalities in acute psychiatric disorders. <b>1986</b> , 74, 542-7	8
1489	A comparative study on the antipsychotic properties of desenkephalin-gamma-endorphin and ceruletide in schizophrenic patients. <b>1986</b> , 73, 372-82	13
1488	Alternative paths to long-term care: nursing home, geriatric day hospital, senior center, and domiciliary care options. <b>1986</b> , 76, 38-44	22
1487	3H-spiperone binding in platelet membranes: a possible biological marker for schizophrenia. <b>1986</b> , 73, 186-90	4
1486	L-dopa in the treatment of negative schizophrenic symptoms: a single-subject experimental study. <b>1985</b> , 15, 293-8	20
1485	The Brief Psychiatric Rating Scale for Children: A Reliability Study. <b>1986</b> , 15, 341-345	15
1484	Comparison between the Brief Psychiatric Rating Scale and the Manchester Scale for the rating of schizophrenic symptoms. <b>1986</b> , 74, 563-8	20
1483	Absence of response to histamine <sub>1</sub> blockade in phencyclidine toxicity. <b>1986</b> , 26, 716-7	1
1482	Agitated behaviors in the elderly. I. A conceptual review. <b>1986</b> , 34, 711-21	491

1481	Characterizing paranoia in the DSM-III borderline personality disorder. <b>1986</b> , 73, 500-5	4
1480	Remoxipride in schizophrenia. A preliminary report. <b>1986</b> , 74, 409-14	14
1479	Selected behavioral features of patients with borderline personality traits. <b>1986</b> , 16, 28-39	10
1478	The effects of lateralized frontal lesions on mood regulation. <b>1986</b> , 109 ( Pt 6), 1127-48	171
1477	Correlates of early disability in Huntington's disease. <b>1986</b> , 20, 727-31	50
1476	The validity of MMPI subtle and obvious items in psychiatric patients. <b>1986</b> , 42, 100-8	4
1475	The Nurses Evaluation Rating Scale (NERS). <b>1986</b> , 42, 454-66	3
1474	A short form of the interpersonal style inventory (ISI). <b>1986</b> , 42, 466-469	13
1473	A scale for the assessment of object relations: reliability, validity, and factorial invariance. <b>1986</b> , 42, 733-41	109
1472	Plasma fluphenazine concentrations in outpatients receiving fluphenazine decanoate (Modecate). <b>1986</b> , 1, 89-92	1
1471	(Des-tyr <sup>1</sup> )-gamma-endorphin (DTE) in the treatment of depression: Double-blind placebo-controlled trial. <b>1986</b> , 1, 99-102	1
1470	Role of monoamine pathways in the control of attention: effects of droperidol and methylphenidate in normal adult humans. <b>1986</b> , 90, 28-34	27
1469	Symptoms of schizophrenia in Hispanic and Anglo veterans. <b>1986</b> , 10, 259-76	20
1468	Eye movement research with schizophrenic patients and normal controls using corneal reflection-pupil center measurement. <b>1986</b> , 235, 243-54	27
1467	An empirical typology of the chronically mentally ill. <b>1986</b> , 22, 3-26	11
1466	Cannabis psychosis in young psychiatric inpatients. <b>1986</b> , 81, 419-23	18
1465	Assessment in undergraduate psychiatric education. <b>1986</b> , 20, 117-22	17
1464	The Brief Psychiatric Rating Scale: Schizophrenia, Reliability and Validity Studies. <b>1986</b> , 40, 135-138	13

1463	The Emotionally Disturbed Military Criminal Offender: Identification, Background, and Institutional Adjustment. <b>1986</b> , 13, 261-285		8
1462	Relation of clinical symptoms to apomorphine-stimulated growth hormone release in mood-incongruent psychotic patients. <b>1986</b> , 43, 1162-7		20
1461	Borderline personality traits in psychiatric inpatients. <i>Psychological Reports</i> , <b>1986</b> , 58, 51-60	1.6	4
1460	Use of animals in the rehabilitation of psychiatric inpatients. <i>Psychological Reports</i> , <b>1986</b> , 58, 63-6	1.6	58
1459	Clinical Application of Neuropsychological Test Batteries. <b>1986</b> ,		8
1458	Symptom differences between urban and rural schizophrenics in Turkey. <b>1986</b> , 32, 65-71		
1457	Pharmacokinetics and therapeutic efficacy of haloperidol decanoate after loading dose administration. <b>1986</b> , 148, 560-6		28
1456	Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls. <b>1987</b> , 44, 211-8		682
1455	The efficacy of electroconvulsive therapy in the treatment of schizophrenia. A comparative study. <b>1987</b> , 151, 152-5		53
1454	Correlates of Institutional Adjustment in Two Groups of Emotionally Disturbed Offenders. <b>1987</b> , 31, 137-141		3
1453	The neurobehavioural rating scale: assessment of the behavioural sequelae of head injury by the clinician. <b>1987</b> , 50, 183-93		321
1452	Further evidence for dementia of the prefrontal type in schizophrenia? A controlled study of teaching the Wisconsin Card Sorting Test. <b>1987</b> , 44, 1008-14		379
1451	Changes in auditory P3 event-related potential in schizophrenia and depression. <b>1987</b> , 150, 154-60		291
1450	Neuropsychological test performance among major clinical subtypes of depression. <b>1987</b> , 2, 115-125		8
1449	Depot neuroleptic medication and serum levels by radioreceptor assay: prolactin concentration, electrocardiogram abnormalities and six-month outcome. <b>1987</b> , 21, 327-38		2
1448	Staff observation aggression scale, SOAS: presentation and evaluation. <b>1987</b> , 76, 657-63		231
1447	Anticholinergic-neuroleptic antagonism in terms of positive and negative symptoms of schizophrenia: implications for psychobiological subtyping. <b>1987</b> , 17, 39-48		46
1446	Hallucinations: Unintended or unexpected?. <b>1987</b> , 10, 532-533		47

1445	Are verbal hallucinations secondary to disordered thinking?. <b>1987</b> , 10, 534-534	1
1444	Cognitive models of verbal hallucinations in schizophrenia. <b>1987</b> , 10, 534-537	38
1443	Some information-processing models suggest possible connections between hallucinations and discourse failures. <b>1987</b> , 10, 532-532	40
1442	Multiple neuroendocrinological responses in borderline personality disorder patients. <b>1987</b> , 76, 593-7	22
1441	Tachistoscopic tests of colour naming and matching in schizophrenia: evidence for posterior callosum dysfunction?. <b>1987</b> , 17, 621-30	43
1440	Multiple nutrients in the treatment of Alzheimer's disease. <b>1987</b> , 35, 476-7	5
1439	Affective impairment in young acute schizophrenics: its structure, course and prognostic significance. <b>1987</b> , 75, 287-96	15
1438	The Present State Examination Change Rating Scale. <b>1987</b> , 150, 201-7	15
1437	Comparative effectiveness of psychotherapies for depressed elders.. <b>1987</b> , 55, 385-390	351
1436	L-deprenyl in Alzheimer's disease. Preliminary evidence for behavioral change with monoamine oxidase B inhibition. <b>1987</b> , 44, 427-33	169
1435	Violent and nonviolent schizophrenic patients clinical and developmental characteristics. <i>Psychological Reports</i> , <b>1987</b> , 61, 855-61	1.6 17
1434	Anxiogenic effects of generated ambient cations--a preliminary study. <b>1986</b> , 16, 243-8	2
1433	Age and duration of illness as predictors of ventricular brain ratio (VBR) size in chronic schizophrenic patients. A stepwise regression analysis study. <b>1987</b> , 76, 256-60	9
1432	Clonazepam/haloperidol combination therapy in schizophrenia: a double blind study. <b>1987</b> , 76, 702-6	24
1431	Observer rating scales of anxiety and depression with reference to DSM-III for clinical studies in psychosomatic medicine. <b>1987</b> , 17, 55-70	5
1430	Simple measures of progress and outcome in the evaluation of mental health services. <b>1987</b> , 10, 209-18	19
1429	Three subtypes of chronic schizophrenia identified using 11C-glucose positron emission tomography. <b>1987</b> , 21, 285-92	59
1428	Lack of effect of dopamine receptor blockade on the TSH response to TRH in borderline personality disorder. <b>1987</b> , 21, 307-11	8



1427	Effect of lithium in vitro and after chronic treatment on human platelet adenylate cyclase activity: postreceptor modification of second messenger signal amplification. <b>1987</b> , 21, 221-8	30
1426	Urinary trace amine excretion and platelet monoamine oxidase activity in schizophrenia. <b>1987</b> , 21, 229-36	25
1425	Cerebral glucose metabolic rates in normal human females versus normal males. <b>1987</b> , 21, 237-45	134
1424	Comparative study of schizophrenic patients relapsed on and off medication. <b>1987</b> , 22, 221-7	17
1423	Effects of ECT given two vs. three times weekly. <b>1987</b> , 21, 63-9	29
1422	Incorporation of <sup>14</sup> C-arachidonic acid into platelet phospholipids of untreated patients with schizophreniform or schizophrenic disorders. <b>1987</b> , 22, 275-82	24
1421	L-5-hydroxytryptophan attenuates positive psychotic symptoms induced by D-amphetamine. <b>1987</b> , 22, 283-9	6
1420	Carbamazepine as an adjunct of antipsychotic therapy. <b>1987</b> , 22, 303-10	66
1419	Deficit and nondeficit forms of schizophrenia: neuropsychological evaluation. <b>1987</b> , 22, 319-30	88
1418	Rating scales in research: the case of negative symptoms. <b>1987</b> , 20, 47-55	73
1417	Dextro-propranolol and depressive symptoms in a schizophrenic population. <b>1987</b> , 11, 625-32	2
1416	Sustained urinary norepinephrine and epinephrine elevation in post-traumatic stress disorder. <b>1987</b> , 12, 13-20	256
1415	Frontal spectral EEG findings in acutely ill schizophrenics. <b>1987</b> , 22, 1021-4	28
1414	Visuomotor performance of schizophrenic patients and normal controls in a picture viewing task. <b>1987</b> , 22, 1227-37	75
1413	Glutathione peroxidase and CT scan abnormalities in schizophrenia. <b>1987</b> , 22, 1349-56	62
1412	Elevated hematocrit in patients with schizophrenia. <b>1987</b> , 22, 907-10	4
1411	Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects: differences between normal controls and schizophrenic patients. <b>1987</b> , 22, 479-94	151
1410	Neurophysiological assessment of sensory gating in psychiatric inpatients: comparison between schizophrenia and other diagnoses. <b>1987</b> , 22, 603-17	109

1409	Dexamethasone suppression test in schizophrenic patients: report from India. <b>1987</b> , 22, 792-5	7
1408	Multivariate analyses of the EEG in normal adolescents. <b>1987</b> , 22, 199-204	2
1407	Failure to alleviate symptoms of schizophrenia with the novel use of an antiviral agent, acyclovir (Zovirax). <b>1987</b> , 22, 216-20	10
1406	Tritiated imipramine binding sites in affective disorders and schizophrenia. Influence of circannual variation. <b>1987</b> , 12, 193-8	9
1405	Fluphenazine decanoate in acute and maintenance therapy of schizophrenia. <b>1987</b> , 11, 613-23	6
1404	Verapamil in refractory schizophrenia: a case report. <b>1987</b> , 11, 185-8	5
1403	Neuropsychological test performance among major clinical subtypes of depression. <b>1987</b> , 2, 115-125	
1402	The effect of trihexphenidyl (Artane) on memory in schizophrenic patients. <b>1987</b> , 11, 71-8	5
1401	Severe puerperal mental illness and disturbances of maternal behaviour. <b>1987</b> , 7, 27-38	5
1400	Assessing Affect in the Elderly. <b>1987</b> , 3, 65-85	24
1399	Long-term replicability of EEG spectra and auditory evoked potentials in schizophrenic and normal subjects. <b>1987</b> , 18, 205-11	8
1398	The DSM-III concepts of schizophrenic disorder and schizophreniform disorder. A clinical and prognostic evaluation. <b>1987</b> , 151, 611-8	25
1397	Negative Symptomatology and Schizophrenia: A Conceptual and Empirical Review. <b>1987</b> , 16, 3-45	53
1396	Double-blind comparison of half-dose and standard-dose flupenthixol decanoate in the maintenance treatment of stabilised out-patients with schizophrenia. <b>1987</b> , 151, 634-8	96
1395	The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. <b>1987</b> , 91, 104-8	36
1394	Site of penetrating brain lesions causing chronic acquired stuttering. <b>1987</b> , 22, 60-6	95
1393	The Missouri Inpatient Behavior Scale. <b>1987</b> , 43, 100-10	8
1392	Effects of desipramine on irritable bowel syndrome compared with atropine and placebo. <b>1987</b> , 32, 257-66	175

1391	Cerebral complications of coronary by-pass surgery. A prospective study. <b>1988</b> , 77, 158-63	34
1390	Do object relations deficits distinguish BPD from other diagnostic groups?. <b>1988</b> , 44, 511-6	41
1389	Multidimensional assessment of combat-related PTSD: Phenomenological, psychometric, and psychophysiological considerations. <b>1988</b> , 1, 373-394	27
1388	Neuroleptics in the treatment of dementia. <b>1988</b> , 3, 79-88	47
1387	Psychiatric assessment in medical long-term care facilities: Reliability of commonly used rating scales. <b>1988</b> , 3, 229-233	32
1386	A comparison of brain choline acetyltransferase activity in Alzheimer's disease, multi-infarct dementia, and combined dementia. <b>1988</b> , 73, 121-8	8
1385	Effect of adjuvant reserpine treatment on catecholamine metabolism in schizophrenic patients under long-term neuroleptic treatment. <b>1988</b> , 71, 73-8	6
1384	Information disclosure, subject understanding, and informed consent in psychiatric research. <b>1988</b> , 12, 455-75	48
1383	An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET. <b>1988</b> , 94, 1-7	108
1382	Perception of emotion among schizophrenic patients. <b>1988</b> , 10, 319-332	34
1381	Intravenous nicotine in Alzheimer's disease: a pilot study. <b>1988</b> , 95, 171-5	229
1380	Prediction of neuroleptic on-drug response in schizophrenic in-patients by EEG. <b>1988</b> , 237, 144-55	12
1379	Clinical symptomatology and drug compliance in schizophrenic patients. <b>1988</b> , 77, 74-6	161
1378	Perseverative structuring of responses by schizophrenic and affective disorder patients. <b>1988</b> , 22, 261-77	18
1377	Violence and psychopathology: a longitudinal study. <b>1988</b> , 29, 174-81	24
1376	Methodological and strategical considerations in schizophrenia research. <b>1988</b> , 29, 337-54	14
1375	The development, use, and reliability of the brief psychiatric rating scale (nursing modification)--an assessment procedure for the nursing team in clinical and research settings. <b>1988</b> , 29, 575-87	57
1374	A critical appraisal of CSF monoamine metabolite studies in schizophrenia. <b>1988</b> , 537, 309-23	20

1373	Plasma homovanillic acid levels and subtyping of schizophrenia. <b>1988</b> , 23, 239-44	53
1372	Platelet alpha 2-adrenergic receptor function in psychiatric disorders. <b>1988</b> , 23, 11-22	18
1371	A symptom rating scale for delirium. <b>1988</b> , 23, 89-97	526
1370	Reliability and validity of the positive and negative syndrome scale for schizophrenics. <b>1988</b> , 23, 99-110	741
1369	Baclofen-induced growth hormone secretion is blunted in chronic schizophrenics: neuroendocrine evidence for a GABA disturbance in schizophrenia. <b>1988</b> , 26, 1-9	21
1368	High-dose naloxone in tardive dyskinesia. <b>1988</b> , 26, 19-28	24
1367	Luria-Nebraska performance and symptomatology in unmedicated schizophrenic patients. <b>1988</b> , 26, 29-34	14
1366	Plasma postdexamethasone cortisol levels in schizoaffective disorder. <b>1988</b> , 26, 35-42	4
1365	Plasma amine metabolites before and after withdrawal from neuroleptic treatment in chronic schizophrenic inpatients. <b>1988</b> , 25, 233-42	27
1364	The prediction of relapse of schizophrenic patients using emotional data obtained from their relatives. <b>1988</b> , 25, 261-76	25
1363	CT scans and neuroleptic response in schizophrenia: a multidimensional approach. <b>1988</b> , 26, 293-303	20
1362	Positron emission tomography and subcortical glucose metabolism in schizophrenia. <b>1988</b> , 24, 1-11	70
1361	Effects of ceruletide on clinical symptoms and EEGs in schizophrenia. <b>1988</b> , 12, 511-22	3
1360	Memory impairment in schizophrenic patients with tardive dyskinesia. <b>1988</b> , 23, 129-35	25
1359	Neurological soft signs in chronic schizophrenic patients: clinical correlates. <b>1988</b> , 24, 458-60	19
1358	Quantitative analyses of voluntary orofacial motor control in schizophrenia and tardive dyskinesia. <b>1988</b> , 24, 787-800	11
1357	Sleep EEG variables in young schizophrenic and depressive patients. <b>1988</b> , 24, 833-8	57
1356	Serum testosterone differences between patients with schizophrenia and those with affective disorder. <b>1988</b> , 23, 357-66	42

1355	Fluphenazine decanoate dose and severity of depression in patients with post-psychotic depression. <b>1988</b> , 1, 31-5	11
1354	Ongoing use of an affective rating scale in the treatment of a mentally retarded individual with a rapid-cycling bipolar affective disorder. <b>1988</b> , 9, 47-53	5
1353	An analysis of grammatical deviance occurring in spontaneous schizophrenic speech. <b>1988</b> , 3, 89-101	41
1352	Cortical atrophy in schizophrenia. Prevalence and associated features. <b>1988</b> , 1, 329-37	34
1351	Cerebellar vermal size predicts drug response in schizophrenic patients: a magnetic resonance imaging (MRI) study. <b>1988</b> , 12, 837-48	11
1350	Recurrent depression in adolescents: a follow-up study. <b>1988</b> , 27, 49-54	128
1349	Addition of reserpine to ongoing neuroleptic exposure in chronic schizophrenia. <b>1988</b> , 1, 307-8	2
1348	Outcome of schizophrenia in India using various diagnostic systems. <b>1988</b> , 1, 339-49	18
1347	Clinical correlations of one-carbon metabolism abnormalities. <b>1988</b> , 12, 491-502	6
1346	The assessment of mood and affect in developmentally disabled children and adolescents: the Emotional Disorders Rating Scale. <b>1988</b> , 9, 109-21	33
1345	Brain interactions in chronic schizophrenics under resting and activation conditions. <b>1988</b> , 1, 47-53	74
1344	Serum neuroleptic activities required to inhibit relapse in schizophrenic patients--a study by radioreceptor assay. <b>1988</b> , 12, 821-31	2
1343	Task-related EEG alpha asymmetry in schizophrenic patients prior to and after neuroleptic treatment. <b>1988</b> , 1, 283-93	10
1342	The Effectiveness of an Occupational Therapy Program in an Inpatient Geropsychiatric Setting. <b>1988</b> , 6, 63-74	1
1341	Overt psychopathology in systemic lupus erythematosus. <b>1988</b> , 17, 143-6	13
1340	Double-blind comparison of alprazolam, diazepam, and placebo for the treatment of negative schizophrenic symptoms. <b>1988</b> , 45, 655-9	50
1339	Topographical distribution of absolute alpha-power in the EEG and psychopathology in schizophrenic outpatients. <b>1988</b> , 77, 390-7	9
1338	Mechanisms of altered water metabolism in psychotic patients with polydipsia and hyponatremia. <b>1988</b> , 318, 397-403	244

1337	Electroencephalographic sleep in mania. <b>1988</b> , 45, 267-73	94
1336	The effects of acute scopolamine in geriatric depression. <b>1988</b> , 45, 906-12	52
1335	A community survey: Drug prescribing in dementia and in the normal elderly. <b>1988</b> , 3, 16-20	
1334	The role of serotonin in schizophrenia. <b>1988</b> , 14, 297-315	204
1333	Brain density in depression: methodological and psychopathological aspects. <b>1988</b> , 78, 610-2	1
1332	Brain computerized tomography in subtypes of severe chronic schizophrenia. <b>1988</b> , 18, 73-7	12
1331	High-dose naloxone in older normal subjects: implications for Alzheimer's disease. <b>1988</b> , 36, 681-6	9
1330	Depot neuroleptics in the treatment of behavioral disorders in patients with Alzheimer's disease. <b>1988</b> , 36, 619-21	17
1329	Psychiatric disability in female carriers of the fragile X chromosome. <b>1988</b> , 45, 25-30	104
1328	Paid friends for frequent recidivists: An evaluation of a multifaceted community aide program.. <b>1988</b> , 11, 29-39	6
1327	Another look at the nonspecific hypothesis of therapeutic effectiveness.. <b>1988</b> , 56, 48-55	108
1326	Supported work: An innovative approach to the vocational rehabilitation of persons who are psychiatrically disabled.. <b>1988</b> , 33, 27-36	4
1325	Supported work: An innovative approach to the vocational rehabilitation of persons who are psychiatrically disabled.. <b>1988</b> , 33, 27-36	25
1324	The significance of depression in the prediction of relapse in chronic schizophrenia. <b>1988</b> , 152, 320-3	86
1323	Multiple-dose arecoline infusions in Alzheimer's disease. <b>1988</b> , 45, 901-5	98
1322	Plasma 3-methoxy-4-hydroxyphenylglycol changes associated with clinical state and schizophrenic subtype. <b>1988</b> , 45, 842-6	31
1321	Glycosaminoglycan polysulfate in old-age dementias: a factor-analytic study of change in psychopathologic symptoms. <b>1988</b> , 19, 135-8	4
1320	Family attitudes and patient social adjustment in a longitudinal study of outpatient schizophrenics receiving low-dose neuroleptics: the family's view. <b>1988</b> , 51, 3-13	41

1319	A double blind comparative study of remoxipride and thioridazine in the acute phase of schizophrenia. <b>1988</b> , 78, 49-56	42
1318	Late-Onset Schizophrenia Studying Clinical Validity. <b>1988</b> , 11, 1-13	35
1317	Criteria for evaluating improvement in schizophrenia in psychopharmacological research (with special reference to gamma endorphin fragments). <b>1988</b> , 153, 354-8	9
1316	Methylphenidate-induced information processing dysfunction in nonschizophrenic patients. <b>1988</b> , 45, 827-32	12
1315	A clinical trial of the efficacy and acceptability of D-fenfluramine in the treatment of neuroleptic-induced obesity. <b>1988</b> , 153, 208-13	58
1314	Sydenham's chorea and psychopathology. <b>1988</b> , 19, 6-8	13
1313	Treatment of dopaminomimetic psychosis in Parkinson's disease with electroconvulsive therapy. <b>1988</b> , 15, 32-4	53
1312	Hormonal changes in major depressive disorder. <b>1989</b> , 38, 40-52	4
1311	Dopaminergic Balance and Subtypes of Schizophrenia. <b>1989</b> , 154, 57-60	5
1310	The Assessment of Negative and Positive Features in Schizophrenia. <b>1989</b> , 155, 41-44	61
1309	Schizophrenia and the perception of emotions. How accurately do schizophrenics judge the emotional states of others?. <b>1989</b> , 155, 225-8	45
1308	The Positive and Negative Syndrome Scale (PANSS): Rationale and Standardisation. <b>1989</b> , 155, 59-65	706
1307	Depression, Affect and Negative Symptoms in Schizophrenia. <b>1989</b> , 155, 108-114	26
1306	Assassination of Indira Gandhi: impact on psychiatric patients. <b>1989</b> , 43, 77-86	5
1305	Vocal Acoustic Correlates of Flat Affect in Schizophrenia: Similarity to Parkinson's Disease and Right Hemisphere Disease and Contrast with Depression. <b>1989</b> , 154, 51-56	38
1304	Patterns of Expressed Emotion and Patient Coping Styles that Characterise the Families of Recent Onset Schizophrenics. <b>1989</b> , 155, 107-111	29
1303	The Treatment of Basic Psychological Dysfunctions From a Systemic Point of View. <b>1989</b> , 155, 74-83	22
1302	Distractibility in Schizophrenia: State and Trait Aspects. <b>1989</b> , 155, 63-68	36

1301	Sex differences in schizophrenia. <b>1989</b> , 35, 237-44		8
1300	Letters to the Editor. <b>1989</b> , 23, 295-314		
1299	Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. A double-blind crossover comparison. <b>1989</b> , 46, 1088-92		301
1298	Psychiatric Epidemiology Across Cultures: Current Issues and Trends. <b>1989</b> , 26, 5-25		17
1297	Psykofarmakologisk behandling af Borderlinepatienten En oversigt. <b>1989</b> , 43, 159-164		1
1296	Studier av psykiatrisk vård, särskilt tvångsvård, i tvåvenska lä Den psykiatriska sjukdomsbilden hos tvångsvårdade. <b>1989</b> , 43, 125-129		2
1295	Development of a Management Information System for a Purchase of Service Setting. <b>1989</b> , 5, 71-82		6
1294	Origins and establishment of the schizophrenia research programme at Royal Park Psychiatric Hospital. <b>1989</b> , 23, 443-51		10
1293	Measuring cognitive and behavior changes in community dwelling Alzheimer's disease patients. <b>1989</b> , 4, 13-18		
1292	A Dictionary of Neuropsychology. <b>1989</b> ,		7
1291	3,5,3'-triiodothyroacetic acid therapy for thyroid hormone resistance. <b>1989</b> , 69, 461-6		52
1290	Validation of an MMPI short form with literate and illiterate patients. <i>Psychological Reports</i> , <b>1989</b> , 64, 327-36	1.6	1
1289	Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease. A controlled study. <b>1989</b> , 46, 542-9		77
1288	Cost-effectiveness index (CEI): a tool to help evaluate mental health programs. <b>1989</b> , 16, 97-110		1
1287	On characterizing new psychiatric long-stay patients. <b>1989</b> , 24, 88-95		13
1286	Saccadic reaction times in acute and remitted schizophrenics. <b>1989</b> , 239, 33-8		19
1285	Eye tracking, schizophrenic symptoms, and schizotypal personality disorder. <b>1989</b> , 239, 39-42		20
1284	Visual search, eeg, and psychopathology in schizophrenic patients. <b>1989</b> , 239, 49-57		10



1283	Elevated plasma prostaglandin E2 levels in schizophrenia. <b>1989</b> , 77, 39-46	52
1282	Case study evaluations of a bio-cognitive-behavioral approach for the treatment of borderline personality disorder. <b>1989</b> , 20, 477-489	20
1281	Seeking Person-Environment Fit in Community Care Placement. <b>1989</b> , 45, 49-64	26
1280	A factor analytic study of clinical competence in undergraduate psychiatry. <b>1989</b> , 23, 422-8	8
1279	Clinical assessment of psychiatric consultations in a medical long-term care facility: Interrater reliability for DSM-III diagnostic groups. <b>1989</b> , 4, 283-291	1
1278	Factor analytic study of depressive disorders. <b>1989</b> , 45, 369-73	4
1277	Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychotic patients. <b>1989</b> , 99, 445-9	111
1276	Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls. <b>1989</b> , 99, 129-33	31
1275	D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. <b>1989</b> , 99 Suppl, S28-31	252
1274	Effect of neuroleptics on positive and negative symptoms and the deficit state. <b>1989</b> , 99 Suppl, S41-6	61
1273	A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. <b>1989</b> , 99 Suppl, S68-72	193
1272	Tolerability of long term clozapine treatment. <b>1989</b> , 99 Suppl, S105-8	27
1271	Clozapine: new research on efficacy and mechanism of action. <b>1989</b> , 238, 332-9	78
1270	Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease. <b>1989</b> , 98, 403-7	63
1269	Is expressed emotion an index of a transactional process? I. Parents' affective style. <b>1989</b> , 28, 153-67	89
1268	The relationship of symptomatology and medication to electrodermal activity in schizophrenia. <b>1989</b> , 26, 148-57	56
1267	Effect of attention on frontal distribution of delta activity and cerebral metabolic rate in schizophrenia. <b>1989</b> , 2, 439-48	57
1266	Rehabilitation research methods for schizophrenia. <b>1989</b> , 2, 425-37	4

1265	The efficacy of the D2 and 5-HT2 antagonist risperidone (R 64,766) in the treatment of chronic psychosis. An open dose-finding study. <b>1989</b> , 2, 411-5	82
1264	Computed tomography in depression: association between ventricular size and psychopathology. <b>1989</b> , 29, 221-30	25
1263	Correlations between the MMPI and the Brief Psychiatric Rating Scale in schizophrenic and schizoaffective patients. <b>1989</b> , 28, 135-43	7
1262	Computerized tomography (CT) in affective disorders: relationship with psychopathology. <b>1989</b> , 29, 271-2	5
1261	Effects of brief naps on mood and sleep in sleep-deprived depressed patients. <b>1989</b> , 27, 253-65	41
1260	Clonidine treatment of schizophrenia: can we predict treatment response?. <b>1989</b> , 27, 297-311	29
1259	Laterality and frontality of cerebral blood flow and metabolism in schizophrenia: relationship to symptom specificity. <b>1989</b> , 27, 325-34	57
1258	Association between abnormal REM sleep and negative symptoms in schizophrenia. <b>1989</b> , 27, 359-61	38
1257	CSF phenylacetic acid and hostility in paranoid schizophrenia. <b>1989</b> , 30, 111-8	11
1256	Predictors of response to high dose antipsychotics in chronic schizophrenics. <b>1989</b> , 30, 1-9	17
1255	Midsagittal cortical pathomorphology of schizophrenia: a magnetic resonance imaging study. <b>1989</b> , 30, 11-20	57
1254	Haloperidol and reduced haloperidol plasma levels in Chinese vs. non-Chinese psychiatric patients. <b>1989</b> , 30, 45-52	39
1253	Bromocriptine and amantadine in cocaine detoxification. <b>1989</b> , 29, 11-6	57
1252	RBC and plasma choline in neuroleptic-treated schizophrenic patients. <b>1989</b> , 29, 45-53	3
1251	Changes in eye tracking during clinical stabilization in schizophrenia. <b>1989</b> , 28, 31-9	27
1250	Increased 3H-clonidine binding in the platelets of patients with depressive and schizophrenic disorders. <b>1989</b> , 28, 73-88	44
1249	Plasma and CSF HVA before and after pharmacological treatment. <b>1989</b> , 28, 97-104	50
1248	Limited eye movement patterns in chronic schizophrenic patients. <b>1989</b> , 28, 307-14	37

1247	Development of a graphic psychiatric self-rating scale. <b>1989</b> , 30, 189-94	6
1246	Why must some schizophrenic patients be involuntarily committed? The role of insight. <b>1989</b> , 30, 13-7	116
1245	Clinical, psychophysiological, and neurological characteristics of volunteers with impaired smooth pursuit eye movements. <b>1989</b> , 26, 35-51	30
1244	The effect of neuroleptic discontinuation on psychopathology, involuntary movements, and biochemical measures in patients with persistent tardive dyskinesia. <b>1989</b> , 26, 224-33	35
1243	Electroconvulsive therapy in neuroleptic-induced parkinsonism. <b>1989</b> , 26, 234-8	19
1242	Accumulation of diacylglycerol in platelet phosphoinositide turnover in schizophrenia: a biological marker of good prognosis?. <b>1989</b> , 26, 669-76	39
1241	Serum thyroxine change and clinical recovery in psychiatric inpatients. <b>1989</b> , 25, 67-74	17
1240	Alterations in sleep polygraphy after neuroleptic withdrawal: a putative supersensitive dopaminergic mechanism. <b>1989</b> , 25, 75-86	23
1239	Verapamil in affective disorders: a controlled, double-blind study. <b>1989</b> , 25, 128-40	75
1238	Amphetamine challenge test, response to treatment, and lateral ventricle size in schizophrenia. <b>1989</b> , 25, 207-14	18
1237	Acute and subchronic effects of low-dose bromocriptine in haloperidol-treated schizophrenics. <b>1989</b> , 25, 247-55	12
1236	DST in India. <b>1989</b> , 25, 363-5	6
1235	Cyclic-AMP production by polymorphonuclear leukocytes in psychiatric disorders. <b>1989</b> , 25, 413-20	13
1234	Repeated naloxone administration in schizophrenia: a phase II World Health Organization Study. <b>1989</b> , 25, 440-8	25
1233	Reaction time impairment in schizophrenia and affective illness: the role of attention. <b>1989</b> , 25, 540-8	82
1232	Serum homovanillic acid concentrations in carbamazepine-treated chronic schizophrenics. <b>1989</b> , 25, 639-41	5
1231	Effects of lithium on sleep in mania. <b>1989</b> , 25, 665-8	8
1230	Normal P300 in acute schizophrenics during a continuous performance test. <b>1989</b> , 25, 792-5	14

1229	Glycosaminoglycan polysulfate (Ateroid) in old-age dementias: effects upon depressive symptomatology in geriatric patients. <b>1989</b> , 13, 977-81	20
1228	Computer assisted psychological evaluations. <b>1989</b> , 9, 546-547	
1227	Social competence in schizoaffective disorder, bipolar disorder, and negative and non-negative schizophrenia. <b>1989</b> , 2, 391-401	37
1226	Computerized brain tomography measures compared with spontaneous and suppressed plasma cortisol levels in major depression. <b>1989</b> , 14, 209-16	20
1225	Somatization among refugees: an epidemiologic study. <b>1989</b> , 30, 34-43	59
1224	Determination of plasma haloperidol concentrations by radioreceptor assay in schizophrenia: clinical utility. <b>1989</b> , 13, 917-25	3
1223	Prevalence of Alzheimer's Disease in a Community Population of Older Persons. <b>1989</b> , 262, 2551	970
1222	The effect of pre-bed care on alcoholic patients' behavior during inpatient treatment. <b>1989</b> , 24, 707-14	6
1221	Clinical implications of determination of plasma haloperidol levels. <b>1989</b> , 79, 348-54	20
1220	The diagnostic dilemma of myxedema and madness, axis I and axis II: a longitudinal case report. <b>1988</b> , 18, 263-70	4
1219	[Saccadic reaction times and visuospatial disorders of attention in schizophrenic patients with negative symptoms]. <b>1989</b> , 57, 535-43	2
1218	Evaluation of the Brief Psychopathological Rating Scale in relation to aggressive behavior by acute involuntarily admitted patients. <b>1989</b> , 79, 313-6	27
1217	Towards selective and improved performance of the mental status examination. <b>1989</b> , 80, 207-15	
1216	Clonidine in the treatment of mixed bipolar disorder. <b>1989</b> , 79, 108-10	8
1215	Sulpiride and perphenazine in schizophrenia. A double-blind clinical trial. <b>1989</b> , 80, 92-6	17
1214	Negative and depressive symptoms in schizophrenia. <b>1989</b> , 154, 207-11	90
1213	Possible subtypes of affective disorder suggested by differences in cerebral laterality and testosterone. A preliminary report. <b>1989</b> , 46, 429-33	12
1212	Discriminant validity of the Psychopathy Checklist in a forensic psychiatric population.. <b>1989</b> , 1, 211-218	189

1211	A prospective study of stressful life events and schizophrenic relapse.. <b>1989</b> , 98, 407-411	147
1210	Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia.. <b>1989</b> , 98, 367-380	320
1209	Skin-conductance orienting response in chronic schizophrenics: The role of neuroleptics.. <b>1989</b> , 98, 478-486	27
1208	Pharmacotherapy of the borderline patient: a critical review and clinical guidelines. <b>1989</b> , 34, 347-53	5
1207	Social disability and clinical symptomatology in schizophrenia: their impact on compulsory admission. <b>1989</b> , 22, 177-81	1
1206	Relationship between Brain Imaging Findings in Schizophrenia and Psychopathology. <b>1990</b> , 24, 89-123	10
1205	Pediatric bone marrow transplants: psychological aspects. <b>1990</b> , 35, 769-75	27
1204	Methods for assessing positive and negative symptoms. <b>1990</b> , 24, 73-88	171
1203	[Who are the patients treated in an outpatient clinic with high dosage neuroleptics?]. <b>1990</b> , 35, 12-24	5
1202	Clinical profile of remoxipride--a combined analysis of a comparative double-blind multicentre trial programme. <b>1990</b> , 358, 92-8	115
1201	Experiences of long-term treatment with remoxipride: efficacy and tolerability. <b>1990</b> , 358, 158-63	23
1200	Psychopathology and limbic epilepsy: relationship to seizure variables and neuropsychological function. <b>1990</b> , 31, 275-80	18
1199	A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders. <b>1990</b> , 358, 138-41	15
1198	Psychometric properties of the Manchester Scale. <b>1990</b> , 81, 108-13	13
1197	Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide. <b>1990</b> , 81, 162-7	8
1196	Risk factors for aggressive behaviour are of limited value in predicting the violent behaviour of acute involuntarily admitted patients. <b>1990</b> , 81, 152-5	46
1195	A double-blind multicentre comparison of remoxipride, at two dose levels, and haloperidol. <b>1990</b> , 358, 78-82	15
1194	A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. <b>1990</b> , 47, 754-8	144

1193	An Evaluation of Family-based Intervention with Schizophrenia Using Single-system Research. <b>1990,</b>	
1192	Remoxipride versus thioridazine in elderly psychotic patients. <b>1990, 358, 181-5</b>	19
1191	Relationship of psychotic symptoms to haloperidol-stimulated prolactin release. <b>1990, 82, 271-4</b>	14
1190	A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation. <b>1990, 358, 111-9</b>	33
1189	Remoxipride and haloperidol in the acute phase of schizophrenia: a double-blind comparison. <b>1990, 358, 120-4</b>	10
1188	P300 and smooth eye pursuit: concordance of abnormalities and relation to clinical features in DSM-III schizophrenia. <b>1990, 82, 283-8</b>	24
1187	Handicraft or interactional groups: a comparative outcome study of neurotic inpatients. <b>1990, 82, 339-43</b>	5
1186	Computed tomography scans and negative symptoms in schizophrenia: chronic schizophrenics with negative symptoms and nonenlarged lateral ventricles. <b>1990, 81, 441-7</b>	4
1185	Quality of life in chronically mentally ill patients in day treatment. <b>1990, 20, 703-10</b>	57
1184	Distribution of remoxipride to the human brain and central D2-dopamine receptor binding examined in vivo by PET. <b>1990, 358, 67-71</b>	44
1183	Glucose metabolic rate in normals and schizophrenics during the Continuous Performance Test assessed by positron emission tomography. <b>1990, 156, 216-27</b>	269
1182	Biperiden and piroheptine do not affect the serum level of zotepine, a new antipsychotic drug. <b>1990, 157, 128-30</b>	12
1181	Patient psychopathology and expressed emotion in schizophrenia. <b>1990, 157, 877-80</b>	44
1180	Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. <b>1990, 157, 585-92</b>	86
1179	A prospective, multicenter study of patients' refusal of antipsychotic medication. <b>1990, 47, 949-56</b>	108
1178	Use of carbamazepine in psychosis after neuroleptic malignant syndrome. <b>1990, 156, 579-81</b>	21
1177	Positive and negative symptoms: historical and conceptual aspects. <b>1990, 24, 1-42</b>	35
1176	Effects of trihexyphenidyl on plasma chlorpromazine in young schizophrenics. <b>1990, 35, 604-7</b>	7

1175	Sample size and power in psychiatric research. <b>1990</b> , 35, 616-20	46
1174	Social skills and relapse history in outpatient schizophrenics. <b>1990</b> , 53, 340-5	40
1173	The Use of Psychoendocrine Strategies in Post-Traumatic Stress Disorder1. <b>1990</b> , 20, 1822-1846	28
1172	Event-related potential indices of selective attention and cortical lateralization in schizophrenia. <b>1990</b> , 27, 209-27	95
1171	Computer-based analysis of facial action in schizophrenic and depressed patients. <b>1990</b> , 240, 67-76	38
1170	On the validity of the German version of the Comprehensive Psychopathological Rating Scale. <b>1990</b> , 240, 48-53	3
1169	Double blind comparative study of remoxipride and haloperidol in acute schizophrenic patients. <b>1990</b> , 102, 76-84	22
1168	Reduced haloperidol plasma concentration and clinical response in acute exacerbations of schizophrenia. <b>1990</b> , 102, 514-20	15
1167	Integrating a research agenda into a new psychosocial rehabilitation program. <b>1990</b> , 1990, 91-102	2
1166	A controlled evaluation of inpatient crisis treatment for acute schizophrenic episodes. <b>1990</b> , 61, 143-54	5
1165	Clinicians' self-reported reactions to psychiatric emergency patients: effect on treatment decisions. <b>1990</b> , 61, 155-62	8
1164	Positive-negative symptom assessment in schizophrenia: psychometric issues and scale comparison. <b>1990</b> , 61, 163-78	95
1163	The Brief Psychiatric Rating Scale (BPRS) and the Nurses' Observation Scale for Inpatient Evaluation (NOSIE) in the evaluation of positive and negative symptoms. <b>1990</b> , 46, 168-74	17
1162	Ergot mesylates for alzheimer's disease: A year-long double-blind trial of 3 mg vs 12 mg daily. <b>1990</b> , 5, 375-380	3
1161	A double-blind comparative trial of remoxipride and haloperidol in the treatment of schizophrenia. <b>1990</b> , 5, 133-141	2
1160	Combined serotonin-5-HT <sub>2</sub> and dopamine-D <sub>2</sub> antagonism in schizophrenia: Clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R 64 766). <b>1990</b> , 5, 225-231	54
1159	Serum testosterone levels in post-traumatic stress disorder inpatients. <b>1990</b> , 3, 449-457	24
1158	Diagnostic and classification systems with special emphasis on the Minicompendium. <b>1990</b> , 2, 38-42	

1157	Depression Secondary to Anxiety: Findings from the McLean Hospital Depression Research Facility. <b>1990</b> , 13, 633-649	20
1156	References. <b>1990</b> , 249-264	
1155	Monitoring the Quality of Psychiatric Care. <b>1990</b> , 13, 73-88	13
1154	Discordance Between Self-Report and Observer-Rated Psychopathology in Borderline Patients. <b>1990</b> , 4, 381-390	10
1153	5-HIAA in cerebrospinal fluid and deficit schizophrenic characteristics. <b>1990</b> , 156, 501-7	20
1152	Intervenciones familiares en el tratamiento de los pacientes con esquizofrenia: aproximaciones recientes. <b>1990</b> , 11, 169-193	
1151	Using DSM-III criteria to diagnose delirium in elderly general medical patients. <b>1990</b> , 45, M113-9	68
1150	Outcome in manic disorders. A naturalistic follow-up study. <b>1990</b> , 47, 665-71	264
1149	Outcome in Mania. A 4-year prospective follow-up of 75 patients utilizing survival analysis. <b>1990</b> , 47, 1106-11	424
1148	Empirical clusters of disordered behavior among older psychiatric inpatients. <b>1990</b> , 45, P28-32	6
1147	Defining treatment refractoriness in schizophrenia. <b>1990</b> , 16, 551-61	192
1146	The Neurobehavioural Rating Scale: replication in an acute, inpatient rehabilitation setting. <b>1990</b> , 4, 215-22	19
1145	Coping styles to basic disorders among schizophrenics. <b>1990</b> , 82, 289-94	29
1144	An analysis of social competence in schizophrenia. <b>1990</b> , 156, 809-18	300
1143	Social Skills Training with Chronic Schizophrenic Patients Living in Community Settings. <b>1990</b> , 18, 49-64	6
1142	Pharmacokinetics and antipsychotic effect of remoxipride in chronic schizophrenic patients. <b>1990</b> , 4, 83-9	10
1141	The dexamethasone suppression test in dementia: a review of the literature. <b>1990</b> , 3, 124-38	6
1140	The effect of culture on the sex differences in schizophrenia. <b>1990</b> , 36, 272-9	8



1139	Perfenazin decanoat og flupentixol decanoat i langtidsbehandling Serumniveau ved laveste effektive dosis. <b>1990</b> , 44, 283-286		2
1138	Assessments on a geropsychiatry unit. <b>1990</b> , 3, 17-20		7
1137	Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. <b>1990</b> , 47, 761-8		75
1136	Thyroid hormone elevations during acute psychiatric illness: relationship to severity and distinction from hyperthyroidism. <b>1990</b> , 16, 415-47		55
1135	Physical features, physical attractiveness, and psychological adjustment among alcohol abuse inpatients. <b>1990</b> , 25, 931-46		
1134	Remoxiprid versus haloperidol i behandlingen af skizofreni En dobbelt-blind sammenlignende undersøgelse af remoxiprid og haloperidol i behandlingen af skizofreni. <b>1990</b> , 44, 287-289		
1133	Voluntary motor performance in psychotic disorders: a replication study. <i>Psychological Reports</i> , <b>1990</b> , 66, 1223-34	1.6	13
1132	Increased distractibility in schizophrenic patients. Electrophysiologic and behavioral evidence. <b>1990</b> , 47, 171-9		193
1131	Community-based rehabilitation of schizophrenia. <b>1990</b> , 44, 81-87		6
1130	The relationship of negative schizophrenia to parkinsonism. <b>1990</b> , 55, 1-59		19
1129	Insight and psychosis. <b>1990</b> , 156, 798-808		808
1128	Haloperidol decanoate in chronic schizophrenia: a study of 12 months with plasma levels. <b>1990</b> , 14, 25-35		15
1127	A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression. <b>1990</b> , 14, 929-39		28
1126	Neuroendocrine, physiologic, and behavioral responses following intravenous nicotine in nonsmoking healthy volunteers and in patients with Alzheimer's disease. <b>1990</b> , 15, 471-84		78
1125	A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. <b>1990</b> , 3, 315-20		15
1124	Effects of anticholinergic medication on memory in schizophrenia. <b>1990</b> , 3, 127-9		98
1123	Lymphocyte subsets in schizophrenic disorders. Relationship with clinical, neuromorphological and treatment variables. <b>1990</b> , 3, 269-75		44
1122	Hypofrontality and cognitive impairment in schizophrenia: dynamic single-photon tomography and neuropsychological assessment of schizophrenic brain function. <b>1990</b> , 27, 377-99		126

1121	Visual evoked potential correlates of positive/negative symptoms in schizophrenia. <b>1990</b> , 27, 400-10	10
1120	Prolactin response to low-dose haloperidol challenge in schizophrenic, non-schizophrenic psychotic, and control subjects. <b>1990</b> , 15, 225-31	9
1119	Dynorphin A and substance P in the cerebrospinal fluid of schizophrenic patients. <b>1990</b> , 34, 229-36	37
1118	Medication may be required for the development of automatic information processing in schizophrenia. <b>1990</b> , 32, 281-8	47
1117	Plasma HVA, tardive dyskinesia and psychotic symptoms in long-term drug-free inpatients with schizophrenia. <b>1990</b> , 33, 259-67	6
1116	Growth hormone response to growth hormone releasing hormone in depression and schizophrenia. <b>1990</b> , 33, 269-76	20
1115	Decreased somatostatin-like immunoreactivity in the cerebrospinal fluid of chronic schizophrenic patients with cognitive impairment. <b>1990</b> , 33, 307-12	19
1114	Skin conductance responding in schizophrenic patients with abnormal involuntary movements. <b>1990</b> , 34, 19-27	1
1113	Correlates of rapid neuroleptic response in male patients with schizophrenia. <b>1990</b> , 33, 171-7	16
1112	Attentional markers of vulnerability to schizophrenia: performance of medicated and unmedicated patients and normals. <b>1990</b> , 33, 179-88	52
1111	Effect of anticholinergic medication on positive and negative symptoms in medication-free schizophrenic patients. <b>1990</b> , 31, 235-41	46
1110	Distinguishing depression and negative symptoms in unmedicated patients with schizophrenia. <b>1990</b> , 31, 243-50	39
1109	Sensory physiology and catecholamines in schizophrenia and mania. <b>1990</b> , 31, 297-309	143
1108	Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. <b>1990</b> , 31, 1-14	59
1107	Pharmacological effects of methylphenidate on plasma homovanillic acid and growth hormone. <b>1990</b> , 32, 9-17	12
1106	Behavioral family treatment for patients with bipolar affective disorder. <b>1990</b> , 14, 457-89	106
1105	Schizophrene erkennen, verstehen, behandeln. <b>1990</b> ,	
1104	A pilot study of magnesium aspartate hydrochloride (Magnesiocard) as a mood stabilizer for rapid cycling bipolar affective disorder patients. <b>1990</b> , 14, 171-80	40

1103	The development and use of observational measurement scales. <b>1990</b> , 3, 73-7	8
1102	A semantic analysis of the various ways that the terms "affect," "emotion," and "mood" are used. <b>1990</b> , 23, 237-46	16
1101	The measurement of subjective experience in schizophrenia: the Subjective Deficit Syndrome Scale. <b>1990</b> , 31, 216-26	52
1100	Development of a scale for the measurement of symptom change in an outpatient clinic. <b>1990</b> , 31, 134-9	3
1099	A review of clozapine: an antipsychotic for treatment-resistant schizophrenia. <b>1990</b> , 31, 315-26	33
1098	Successful behavioral treatment of polydipsia in a schizophrenic patient. <b>1990</b> , 21, 53-61	11
1097	Nocturnal sleep in Huntington's disease. <b>1991</b> , 238, 203-8	141
1096	Supportive psycho-educational intervention for schizophrenics' families: influencing family dynamics. <b>1991</b> , 45, 601-15	
1095	Prevalence and stability of social skill deficits in schizophrenia. <b>1991</b> , 5, 167-76	137
1094	Two modes of central gaze fixation maintenance and oculomotor distractibility in schizophrenics. <b>1991</b> , 5, 145-52	23
1093	Effects of adjunctive verapamil administration in chronic schizophrenic patients. <b>1991</b> , 15, 343-9	16
1092	Plasma concentrations of remoxipride and haloperidol in relation to prolactin and short-term therapeutic outcome in schizophrenic patients. <b>1991</b> , 1, 535-40	4
1091	ROUNDS, a new time-sampling methodology for the quantitative behavioral assessment of schizophrenic withdrawal. Reliability and validity. <b>1991</b> , 5, 255-62	
1090	Wisconsin Card Sorting Test performance over time in schizophrenia. Preliminary evidence from clinical follow-up and neuroleptic reduction studies. <b>1991</b> , 5, 233-42	21
1089	Antidepressant for substance-abusing schizophrenic patients: a minireview. <b>1991</b> , 15, 1-13	14
1088	Glycosaminoglycan polysulfate in the treatment of old age dementias. <b>1991</b> , 15, 323-42	10
1087	Increased blink rates in schizophrenics. Influences of neuroleptics and psychopathology. <b>1991</b> , 4, 41-7	30
1086	Time course and clinical predictors of treatment response in schizophrenia. <b>1991</b> , 5, 161-6	17

1085	Diagnostic issues in chronic schizophrenia: kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms. <b>1991</b> , 4, 71-9	40
1084	Measurement of therapeutic response in schizophrenia. A critical survey. <b>1991</b> , 5, 249-53	52
1083	Prostaglandin E1 suppression of platelet aggregation response in schizophrenia. <b>1991</b> , 5, 67-80	14
1082	Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symptoms. <b>1991</b> , 4, 23-30	89
1081	Cerebrospinal fluid beta-endorphin-like immunoreactivity in patients with dementia associated with schizophrenia and chronic alcoholism. <b>1991</b> , 45, 309-311	
1080	Childhood and adolescent schizophrenic, bipolar, and schizoaffective disorders: a clinical and outcome study. <b>1991</b> , 30, 457-65	281
1079	Social skills training in adult psychiatric populations: a meta-analysis. <b>1991</b> , 22, 203-10	56
1078	"Panic-like" symptomatology in schizophrenic and schizoaffective patients with postpsychotic depression: observations and implications. <b>1991</b> , 32, 465-73	26
1077	Schizophrenic patients with depression: psychopathological profiles and relationship with negative symptoms. <b>1991</b> , 32, 528-33	32
1076	Stability of psychopathology dimensions in chronic schizophrenia: response to clozapine treatment. <b>1991</b> , 32, 28-35	7
1075	The N400 component of event-related potentials in schizophrenic patients: a preliminary study. <b>1991</b> , 78, 124-32	87
1074	Brief neuroleptic discontinuation and clinical symptoms in Kraepelinian and non-Kraepelinian chronic schizophrenic patients. <b>1991</b> , 38, 285-92	26
1073	Smooth pursuit and saccadic eye movements and neurological soft signs in obsessive-compulsive disorder. <b>1991</b> , 38, 173-85	30
1072	Relationship between membrane fluidity and adrenoceptor binding in depression. <b>1991</b> , 38, 1-12	11
1071	Conversation skills training of thought-disordered schizophrenic patients through attention focusing. <b>1991</b> , 38, 51-61	34
1070	Evaluation of the stability of neuropsychological functioning after acute episodes of schizophrenia: one-year followup study. <b>1991</b> , 38, 63-76	104
1069	Prediction of social skill acquisition in schizophrenic and major affective disorder patients from memory and symptomatology. <b>1991</b> , 37, 281-96	158
1068	Relationships between medication treatments and neuropsychological test performance in schizophrenia. <b>1991</b> , 37, 297-308	73

1067	Deficit syndrome in older schizophrenic patients. <b>1991</b> , 39, 285-92	25
1066	Electroencephalographic sleep and cerebral morphology in functional psychoses: a preliminary study with computed tomography. <b>1991</b> , 39, 293-301	15
1065	Thyrotropin and prolactin responses to ECT in schizophrenia and depression. <b>1991</b> , 37, 5-10	12
1064	Isometric force control in schizophrenic patients with tardive dyskinesia. <b>1991</b> , 37, 57-72	11
1063	Self-reports of childhood abuse in chronically psychotic patients. <b>1991</b> , 37, 73-80	83
1062	Relationship between the Brief Psychiatric Rating Scale and the Scale for the Assessment of Negative Symptoms: a study of their correlation and redundancy. <b>1991</b> , 36, 129-39	34
1061	Platelet autoantibodies in dementia and schizophrenia. Possible implication for mental disorders. <b>1991</b> , 621, 205-17	26
1060	Effect of neuroleptic treatment on polysomnographic measures in schizophrenia. <b>1991</b> , 30, 904-12	53
1059	Tardive dyskinesia: neuropsychological, computerized tomographic, and psychiatric symptom findings. <b>1991</b> , 30, 587-99	18
1058	Cerebral laterality, symptoms, and diagnosis in psychotic patients. <b>1991</b> , 29, 103-16	45
1057	The effects of physostigmine infusion on patients with panic disorder. <b>1991</b> , 29, 658-64	5
1056	A pilot placebo-controlled study of chronic m-CPP administration in Alzheimer's disease. <b>1991</b> , 30, 140-4	12
1055	Plasma phenylethylamine in schizophrenic patients. <b>1991</b> , 30, 145-50	28
1054	Measurement of tissue lithium concentration by lithium magnetic resonance spectroscopy in patients with bipolar disorder. <b>1991</b> , 29, 1161-70	54
1053	Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome. <b>1991</b> , 29, 953-64	147
1052	Effects of lithium treatment on eye movements. <b>1991</b> , 29, 1001-15	50
1051	Left turning (swivel) in medicated chronic schizophrenic patients. <b>1991</b> , 4, 53-8	18
1050	P300 in first degree relatives of schizophrenics. <b>1991</b> , 6, 9-13	62

1049	Effects of task relevance and attention on P3 in schizophrenic patients. <b>1991</b> , 4, 11-21	25
1048	Zuclopenthixol, a combined dopamine D1/D2 antagonist, versus haloperidol, a dopamine D2 antagonist, in tardive dyskinesia. <b>1991</b> , 1, 541-8	15
1047	Neurological soft signs in schizophrenia. <b>1991</b> , 6, 25-30	233
1046	Streßbewältigungsstrategien schizophrener Patienten: Eine Pilotstudie. <b>1991</b> , 1, 212-218	1
1045	Clinical target syndromes in psychiatry: latent structure analysis versus factor analysis. <b>1991</b> , 6, 301-306	3
1044	The use of benzodiazepines in schizophrenia: a review. <b>1991</b> , 6, 217-222	5
1043	Principal-component analysis of PANSS and SANS - SAPS global ratings in schizophrenic patients. <b>1991</b> , 6, 251-259	31
1042	The COSTAR programme. 1: Improving social networks of the long-term mentally ill. <b>1991</b> , 159, 245-9	40
1041	Vocational Outcomes Following Psychosocial Rehabilitation. <b>1991</b> , 1, 21-29	32
1040	Changes in patient coping style following individual and family treatment for schizophrenia. <b>1991</b> , 158, 642-7	20
1039	Negative symptoms in chronic schizophrenia. Relationship to duration of illness. <b>1991</b> , 159, 495-9	16
1038	Plasma levels of fluphenazine in patients receiving fluphenazine decanoate. Relationship to clinical response. <b>1991</b> , 158, 658-65	44
1037	Music psychopathology. IV. The course of musical expression during music therapy with psychiatric inpatients. <b>1991</b> , 24, 121-9	16
1036	A case of drug-drug interaction involving clozapine. <b>1991</b> , 36, 234-5	2
1035	Comparative neurobiological and neuropsychological deficits in adolescent and adult schizophrenic and nonschizophrenic patients. <b>1991</b> , 55, 32-41	3
1034	Stability of positive and negative symptom constructs during neuroleptic treatment in schizophrenia. <b>1991</b> , 24, 247-52	19
1033	Carbamazepine maintenance treatment in outpatient schizophrenics. <b>1991</b> , 48, 69-72	27
1032	The relationship of tardive dyskinesia to positive schizophrenia. <b>1991</b> , 56, 107-39	11

1031	Cerebrospinal fluid acetylcholinesterase in patients with dementia associated with schizophrenia or chronic alcoholism. <b>1991</b> , 83, 441-3	10
1030	Comparison of participants and nonparticipants in a neuroendocrine investigation of psychosis. <b>1991</b> , 83, 373-6	7
1029	The need for social support among out-patients suffering from functional psychosis. <b>1991</b> , 21, 209-17	8
1028	Delirium in the medically ill elderly: operationalizing the DSM-III criteria. <b>1991</b> , 3, 181-96	30
1027	Alzheimer disease: basic and clinical advances. <b>1991</b> , 39, 516-25	59
1026	A magnetic resonance imaging study of schizophrenia: brain structure and clinical symptoms. <b>1991</b> , 158, 158-64	106
1025	Reduction of perseverative error in patients with schizophrenia using monetary feedback.. <b>1991</b> , 100, 613-616	42
1024	Clinical, neuropsychological, and brain structural correlates of smooth-pursuit eye tracking performance in chronic schizophrenia.. <b>1991</b> , 100, 526-534	82
1023	Communication deviance in families of schizophrenic and manic patients.. <b>1991</b> , 100, 163-173	22
1022	Auditory selective attention and event-related potentials in schizophrenia. <b>1991</b> , 158, 534-9	78
1021	Symptom monitoring for relapse prevention in schizophrenia. <b>1991</b> , 5, 193-201	22
1020	A model for the provision of jail mental health services: an integrative, community-based approach. <b>1991</b> , 18, 209-22	21
1019	Uses of an empirically derived client typology based on level of functioning: twelve years of the CCAR. <b>1991</b> , 18, 88-100	42
1018	Negative symptoms and reaction time in schizophrenia. <b>1991</b> , 25, 131-40	30
1017	Comparison of three rating scales used with psychiatric patients. <b>1991</b> , 27, 19-25	4
1016	Neuropsychological, psychiatric, and physical manifestations in 149 members from 18 fragile X families. <b>1991</b> , 40, 234-43	34
1015	Mentally ill and non-mentally-ill patients' abilities to understand informed consent disclosures for medication: preliminary data. <b>1991</b> , 15, 377-88	69
1014	A comparison of demographic, behavioral, and ego function data in borderline and eating disorder patients. <b>1991</b> , 62, 19-33	8

1013	Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose. <b>1991</b> , 105, 42-8	30
1012	Brain morphology and sleep EEG in patients with Huntington's disease. <b>1991</b> , 240, 148-52	35
1011	Laterality in schizophrenia. A reaction time study. <b>1991</b> , 241, 126-30	5
1010	Acute drug-induced akathisia is not associated with low serum iron status. <b>1991</b> , 103, 138-9	26
1009	Effects of amperozide in schizophrenia. An open study of a potent 5-HT <sub>2</sub> receptor antagonist. <b>1991</b> , 104, 287-92	52
1008	Transfer between psychiatric hospitals: symptom, social function and patient attitude changes in long-term patients. <b>1991</b> , 26, 217-20	5
1007	The effects of electromyographic feedback training on suppression of the oral-lingual movements associated with tardive dyskinesia. <b>1991</b> , 16, 117-29	4
1006	Psychophysics of muscle tension in psychiatric inpatients. <b>1991</b> , 16, 131-41; discussion 143-6	1
1005	When symptoms persist: choosing among alternative somatic treatments for schizophrenia. <b>1991</b> , 17, 217-45	131
1004	The World Health Organization's cross-cultural study on neuropsychiatric aspects of infection with the human immunodeficiency virus 1 (HIV-1). Preparation and pilot phase. <b>1991</b> , 159, 351-6	39
1003	Valproate in the treatment of acute mania. A placebo-controlled study. <b>1991</b> , 48, 62-8	393
1002	Correlation between psychic and somatic symptoms and vision in aged patients before and after a cataract operation. <i>Psychological Reports</i> , <b>1991</b> , 69, 707-21	1.6 7
1001	Substance abuse, post-traumatic stress, and ethnicity. <b>1991</b> , 23, 83-4	7
1000	Psychometric evaluation of a standardized and expanded Brief Psychiatric Rating Scale. <b>1991</b> , 84, 294-300	51
999	The diagnosis of schizophrenia: a review of onset and duration issues. <b>1991</b> , 17, 51-67	45
998	Independent assessment of manic and depressive symptoms by self-rating. Scale characteristics and implications for the study of mania. <b>1991</b> , 48, 807-12	331
997	Instrumental evidence that age increases motor instability in neuroleptic-treated patients. <b>1991</b> , 46, B197-200	8
996	Environmental modifications in a specially designed unit for the care of patients with Alzheimer's disease: An overview and introduction: Article 1 in a series of 9. <b>1991</b> , 6, 3-9	6



995	Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naïve schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. <b>1991</b> , 48, 563-8	388
994	Delusions, hallucinations and depression in Alzheimer's disease: A biological perspective. <b>1991</b> , 6, 21-28	3
993	Experimental models of schizophrenia. <b>1991</b> , 58, 69-82	15
992	Contextual effects on choice reaction time and accuracy in acute and chronic schizophrenics. Impairment in selective attention or in the influence of prior learning?. <b>1991</b> , 159, 415-21	67
991	Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome. <b>1992</b> , 49, 522-30	439
990	Pineal calcification and its relationship to hallucinations in schizophrenia. <b>1992</b> , 64, 217-9	7
989	Hypofrontality in neuroleptic-naïve patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London. <b>1992</b> , 49, 943-58	709
988	Assessing the reliability of clinical scales when the data have both nominal and ordinal features: proposed guidelines for neuropsychological assessments. <b>1992</b> , 14, 673-86	32
987	The Structured Clinical Interview for DSM-III-R (SCID). I: History, rationale, and description. <b>1992</b> , 49, 624-9	3122
986	Symptomatic response to antipsychotics differs between recent onset and recurrent chronic schizophrenic patients. <b>1992</b> , 26, 417-22	4
985	Reconquest of the subjective. Against the waning of psychiatric diagnosing. <b>1992</b> , 160, 266-71	63
984	Whither cognitive-behavioral therapy for schizophrenia?. <b>1992</b> , 18, 27-35	48
983	Speaking in tongues: integrating economics and psychology into health and mental health services outcomes research. <b>1992</b> , 49, 191-231	7
982	Some reflections on the meaning of psychodiagnosis. 1971. <b>1992</b> , 59, 410-22; discussion 422-3	2
981	Estimating Individual Rater Reliabilities. <b>1992</b> , 16, 77-85	11
980	An open study of remoxipride in the long-term treatment of schizophrenia-. <b>1992</b> , 6, 519-25	3
979	Widespread cerebral gray matter volume deficits in schizophrenia. <b>1992</b> , 49, 195-205	326
978	Polysomnographic characteristics of young manic patients. Comparison with unipolar depressed patients and normal control subjects. <b>1992</b> , 49, 378-83	92

977	Reduction of dyskinesias and psychiatric disability with clozapine over different time courses. <b>1992</b> , 6, 514-8		5
976	Attributions of symptomatology: an exploration of family factors associated with expressed emotion. <b>1992</b> , 26, 408-16		29
975	Den kliniske betydning af negative og positive sympto-mer ved skizofreni. <b>1992</b> , 46, 23-27		
974	Mång af klinisk demens i relation til positive og negative symptomer ved skizofreni. <b>1992</b> , 46, 61-64		1
973	Sense of self in recovery from severe mental illness. <b>1992</b> , 65 ( Pt 2), 131-45		359
972	Performance of Snow Flakes, Suns, and Factorial Suns in the Graphical Representation of Multivariate Data. <b>1992</b> , 27, 43-55		11
971	Factors related to psychiatric hospitalisation for first contact patients. <b>1992</b> , 38, 293-303		4
970	Correlations of memory and learning with vision in aged patients before and after a cataract operation. <i>Psychological Reports</i> , <b>1992</b> , 71, 675-86	1.6	8
969	Evaluating the effects of drugs on behavior and quality of life: An alternative strategy for clinical trials.. <b>1992</b> , 60, 225-239		4
968	Discriminating variables among psychotherapy dropouts from a psychological training clinic.. <b>1992</b> , 23, 123-130		41
967	Concurrent and predictive electrodermal correlates of symptomatology in recent-onset schizophrenic patients.. <b>1992</b> , 101, 153-164		22
966	Music psychopathology. VI. The course objective instrumental performance characteristics with psychiatric inpatients. <b>1992</b> , 25, 273-82		4
965	On the distinctions between diagnosis, description and measurement of schizophrenia. <b>1992</b> , 25, 239-48		6
964	Pharmacologic Treatment of Alzheimer's Disease: A Methodologic Critique Based Upon Current Knowledge of Symptomatology and Relevance for Drug Trials. <b>1992</b> , 4, 9-42		23
963	The predictive value of thought disorder in manic psychosis. <b>1992</b> , 25, 161-5		5
962	Plasma free 3-methoxy-4-hydroxyphenylglycol in acute schizophrenics before and after treatment. <b>1992</b> , 25, 126-9		12
961	The assessment of insight in clinical psychiatry: a new scale. <b>1992</b> , 86, 159-64		107
960	Computerized psychiatric diagnoses based on euclidean distances: a Chinese example. <b>1992</b> , 85, 11-4		7

959	The ability of schizophrenics to perceive and cope with negative affect. <b>1992</b> , 160, 473-80	83
958	The Swedish version of the Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Construct validity and interrater reliability. <b>1992</b> , 86, 463-8	54
957	Measuring quality of life: The medical perspective. <b>1992</b> , 46, 85-89	12
956	Postimperative negative variation and skin conductance response in chronic DSM-III-R schizophrenia. <b>1992</b> , 86, 346-50	5
955	Community-based rehabilitation of schizophrenia. <b>1992</b> , 46, 121-127	4
954	Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures. <b>1992</b> , 22, 347-52	144
953	Social networks and support in long-term psychiatric patients. <b>1992</b> , 22, 1019-26	75
952	Beta-endorphin, vasoactive intestinal peptide and cholecystokinin in peripheral blood mononuclear cells from healthy subjects and from drug-free and haloperidol-treated schizophrenic patients. <b>1992</b> , 85, 207-10	21
951	Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation. <b>1992</b> , 85, 354-9	9
950	The course of alcohol amnestic disorder: a three-year follow-up study of clinical signs and social disabilities. <b>1992</b> , 86, 240-6	23
949	Quantitative electroencephalography. A new approach to the diagnosis of cerebral dysfunction in systemic lupus erythematosus. <b>1992</b> , 35, 1330-42	36
948	Timing of acute clinical response to fluphenazine. <b>1992</b> , 160, 365-71	17
947	Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. <b>1992</b> , 49, 966-74	144
946	Chromosome fragility and psychopathology in obligate female carriers of the fragile X chromosome. <b>1992</b> , 49, 54-60	57
945	Early serum levels of neuroleptics do not predict therapeutic response in schizophrenia. <b>1992</b> , 16, 891-900	3
944	Contribution of family, cognitive and clinical dimensions to long-term outcome in schizophrenia. <b>1992</b> , 6, 257-65	73
943	Pineal and habenula calcification in schizophrenia. <b>1992</b> , 67, 19-30	57
942	Left hypofrontality correlates with blunted affect in schizophrenia. <b>1992</b> , 46, 653-7	5

941	Seasonal variations of the dexamethasone suppression test in depression compared with schizophrenia: a gender effect. <b>1992</b> , 24, 87-91	13
940	Elevated IgG anti-histone antibodies in a subgroup of medicated schizophrenic patients. <b>1992</b> , 7, 49-54	18
939	IRAOS: an instrument for the assessment of onset and early course of schizophrenia. <b>1992</b> , 6, 209-23	454
938	Symptomatology and the prediction of social skills acquisition in schizophrenia. <b>1992</b> , 8, 59-68	17
937	The Kamin blocking effect, incidental learning and schizotypy (a reanalysis). <b>1992</b> , 13, 57-60	16
936	From The Lancet. <b>1992</b> , 340, 202	1
935	Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. <b>1992</b> , 340, 199-202	174
934	The effect of illness duration on perceptual asymmetry in schizophrenia. <b>1992</b> , 7, 211-6	7
933	The trained psychologist as expert witness. <b>1992</b> , 12, 451-467	14
932	Similar brain lesions in alcoholics and Korsakoff patients: MRI, psychometric and clinical findings. <b>1992</b> , 94, 197-203	28
931	Effects of mianserin in chronic schizophrenia. <b>1992</b> , 16, 517-28	10
930	Depressed nocturnal plasma melatonin levels in drug-free paranoid schizophrenics. <b>1992</b> , 7, 77-84	59
929	Gender differences in cognition in schizophrenia. <b>1992</b> , 8, 69-73	40
928	Increased motor activity and recurrent manic episodes: predictors of rapid relapse in remitted bipolar disorder patients after lithium discontinuation. <b>1992</b> , 31, 279-84	49
927	Loss of the Kamin blocking effect in acute but not chronic schizophrenics. <b>1992</b> , 32, 739-55	108
926	Platelet and whole blood serotonin content in depressed inpatients: correlations with acute and life-time psychopathology. <b>1992</b> , 32, 243-57	127
925	Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients. <b>1992</b> , 31, 968-70	33
924	Clinical predictors of relapse following neuroleptic withdrawal. <b>1992</b> , 32, 72-8	29

923	Psychotic symptoms resulting from intraventricular infusion of dopamine in Parkinson's disease. <b>1992</b> , 31, 1225-7	5
922	Effects of idebenone in elderly subjects with cognitive decline. Results of a multicentre clinical trial. <b>1992</b> , 15, 279-86	3
921	Evoked potential topography in major depression. II. Comparisons between subgroups. <b>1992</b> , 13, 255-61	8
920	Possible affective-state dependence of the Tridimensional Personality Questionnaire in first-episode psychosis. <b>1992</b> , 41, 215-26	51
919	Disorders of smooth pursuit eye movement and auditory N100 in schizophrenic patients. <b>1992</b> , 41, 227-35	21
918	Prodromal symptoms and signs of bipolar relapse: a report based on prospectively collected data. <b>1992</b> , 41, 1-8	27
917	Treatment of extrapyramidal side effects with terguride. <b>1992</b> , 41, 9-16	5
916	Dopamine uptake by platelets from subjects with schizophrenia: a correlation with the delusional state of the patient. <b>1992</b> , 41, 17-24	18
915	Effect of typical antipsychotic medications and clozapine on smooth pursuit performance in patients with schizophrenia. <b>1992</b> , 41, 25-36	40
914	A new scale for assessing behavioral agitation in dementia. <b>1992</b> , 41, 73-88	41
913	Visual information decoding deficits in schizophrenia. <b>1992</b> , 44, 203-16	14
912	Altered interleukin-2 production in schizophrenia: association between clinical state and autoantibody production. <b>1992</b> , 44, 113-23	67
911	Pupillary constriction during haloperidol treatment as a predictor of relapse following drug withdrawal in schizophrenic patients. <b>1992</b> , 43, 287-98	13
910	Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve. <b>1992</b> , 42, 129-44	27
909	Prolactin responses to domperidone in chronic schizophrenia. <b>1992</b> , 42, 159-69	6
908	Neuropsychological findings and psychiatric symptoms in HIV-1 infected and noninfected drug users. <b>1992</b> , 41, 163-77	35
907	Multivalent assessment of depression in schizophrenia. <b>1992</b> , 42, 199-207	12
906	Subsyndromes in chronic schizophrenia: do their psychopathological characteristics correspond to cerebral alterations?. <b>1992</b> , 42, 209-20	43

905	Serotonin function in schizophrenia: effects of meta-chlorophenylpiperazine in schizophrenic patients and healthy subjects. <b>1992</b> , 43, 1-12	44
904	Disengagement of attention in chronic schizophrenia. <b>1992</b> , 43, 87-92	34
903	The assessment of insight in psychosis. <b>1992</b> , 161, 599-602	308
902	Antecedents, Severity of Abuse, and Response to Treatment in Substance-Abusing Schizophrenic Individuals. <b>1992</b> , 1, 210-216	7
901	Neuropsychological test scores and clinical response to neuroleptic drugs in schizophrenic patients. <b>1992</b> , 33, 139-45	8
900	Crisis intervention response and long-term outcome: a pilot study. <b>1992</b> , 33, 388-96	8
899	Stimulant Drug Effects on Performance and Behavior After Prolonged Sleep Deprivation: A Comparison of Amphetamine, Nicotine, and Deprenyl. <b>1992</b> , 4, 207-233	25
898	Schizophrenics and social judgement. Why do schizophrenics get it wrong?. <b>1992</b> , 160, 481-7	35
897	Dimensions of Outcome with Clozapine. <b>1992</b> , 160, 46-53	187
896	Clinical Efficacy of Clozapine in Treatment-Refractory Schizophrenia: An Overview. <b>1992</b> , 160, 41-45	121
895	A Strategy of Combination Chemotherapy in Alzheimer's Disease: Rationale and Preliminary Results with Physostigmine plus Deprenyl. <b>1992</b> , 4, 291-309	15
894	Life events and schizophrenic relapse after withdrawal of medication. <b>1992</b> , 161, 615-20	43
893	The Pilot Project Boteria Berne Clinical Experiences and Results. <b>1992</b> , 161, 145-153	58
892	Efficacy of Tianeptine in Comparative Trials versus Reference Antidepressants An Overview. <b>1992</b> , 160, 72-75	29
891	Predictors of Outcome of Children with Attention-Deficit Hyperactivity Disorder. <b>1992</b> , 1, 567-578	4
890	Neuropsychiatry Sequelae of Head Injuries. <b>1992</b> , 15, 395-413	181
889	Extrapyramidal side-effects and clinical response during acute neuroleptic treatment of schizophrenia. <b>1992</b> , 7, 95-96	
888	Efficacy of clozapine in treatment-resistant psychosis and neuroleptic sensitivity: results of the Dutch open multi-center project. <b>1992</b> , 7, 77-84	8

887	Course of Illness and Predictors of Outcome in Chronic Schizophrenia: Implications for Pathophysiology. <b>1992</b> , 161, 38-43	21
886	Paths to Relapse: Possible Transactional Processes Connecting Patient Illness Onset, Expressed Emotion, and Psychotic Relapse. <b>1992</b> , 161, 88-96	54
885	Self- and interview-rated negative mood states in schizophrenia: Their convergence and prediction of thought disturbance. <b>1992</b> , 14, 277-291	4
884	Self-regulation of slow cortical potentials in psychiatric patients: schizophrenia. <b>1992</b> , 17, 277-92	43
883	Self-regulation of slow cortical potentials in psychiatric patients: depression. <b>1992</b> , 17, 203-14	25
882	Clinical issues in social network therapy for clients with schizophrenia. <b>1992</b> , 28, 427-40	14
881	DSM-III mental disorders in general medical sector: a follow-up and incidence study over a two-year period. <b>1992</b> , 27, 234-41	15
880	Expressed Emotion in families of chronic schizophrenics and its association with clinical measures. <b>1992</b> , 27, 4-9	24
879	Paranoid and nonparanoid schizophrenic processing of facially displayed affect. <b>1992</b> , 26, 169-82	79
878	Regional cerebral blood flow in patients with schizophrenia. A preliminary report. <b>1992</b> , 241, 195-200	56
877	Gestalt perception in schizophrenia. <b>1992</b> , 241, 215-21	58
876	Facial expression and emotional face recognition in schizophrenia and depression. <b>1992</b> , 242, 46-52	229
875	A placebo controlled trial of remoxipride in the prevention of relapse in chronic schizophrenia. <b>1992</b> , 107, 175-9	20
874	Acute nicotinic blockade produces cognitive impairment in normal humans. <b>1992</b> , 108, 480-4	125
873	Pharmacologic properties of (-)-3PPP (preclamol) in man. <b>1992</b> , 88, 165-75	35
872	Decision making in a schizophrenic population.. <b>1992</b> , 16, 651-662	11
871	Functional status outcomes of a nursing intervention in hospitalized elderly. <b>1992</b> , 24, 201-7	55
870	Elderly Chinese- and Caucasian-Americans compared on measures of psychic distress, somatic complaints and social competence. <b>1992</b> , 7, 191-198	13

869	Neuroleptic discontinuation in the very stable schizophrenic patient: Relapse rates and serum neuroleptic levels. <b>1992</b> , 7, 255-264	17
868	Rapid lithiumization in acute manic patients. <b>1992</b> , 7, 343-345	7
867	Clozapine prevents recurrence of psychosis in Parkinson's disease. <b>1992</b> , 7, 125-31	69
866	Object relations deficits in subtypes of schizophrenia. <b>1992</b> , 48, 433-44	18
865	Premutation for the Martin-Bell syndrome analyzed in a large Sardinian family: II. Neuropsychological and behavioral data. <b>1992</b> , 43, 103-10	7
864	Diagnostic utility of the MCMI-I and MCMI-II with psychiatric outpatients. <b>1993</b> , 49, 358-66	7
863	Correlates of the Woodcock-Johnson Reading Comprehension and Kaufman Brief Intelligence Test in a forensic psychiatric population. <b>1993</b> , 49, 593-8	9
862	An empirical typology of seriously and persistently mentally ill patients using symptom and social functioning factors. <b>1993</b> , 49, 622-37	8
861	Development of a structured interview scale for measuring quality of life of the severely mentally ill. <b>1993</b> , 49, 830-40	20
860	Influence of patient caregivers on course of patient illness: "expressed emotion" and alternative measures. <b>1993</b> , 49, 898-912	16
859	Prediction of first episode of clinical depression in patients newly admitted to a medical long-term care facility: Findings from a prospective study. <b>1993</b> , 8, 297-304	4
858	Tardive and chronically recurrent oculogyric crises. <b>1993</b> , 8, 93-7	51
857	Convergent validation of quality of life assessments for persons with severe mental illnesses. <b>1993</b> , 2, 327-33	118
856	A new patient focused index for measuring quality of life in persons with severe and persistent mental illness. <b>1993</b> , 2, 239-51	198
855	Symptom management: inpatient nursing care of persons with schizophrenia. <b>1993</b> , 1993, 23-31	4
854	Neuropsychiatric disturbance in cancer patients with epidural spinal cord compression receiving high dose corticosteroids: A prospective comparison study. <b>1993</b> , 2, 233-245	17
853	The Chinese General Health Questionnaire in a psychiatric setting: the development of the Chinese scaled version. <b>1993</b> , 28, 124-9	26
852	Differences between long-stay and short-stay inpatients and estimation of length of stay. A prospective study. <b>1993</b> , 28, 84-90	18



851	The Referral Decision Scale: A validation study.. <b>1993</b> , 17, 611-623	28
850	A follow-up study of early onset psychosis: comparison between outcome diagnoses of schizophrenia, mood disorders, and personality disorders. <b>1993</b> , 23, 243-62	101
849	Double-blind placebo crossover study of cyproterone acetate in the treatment of the paraphilias. <b>1993</b> , 22, 383-402	112
848	Relationship between crossover and modality shift effects in sequential reaction time performance of schizophrenic patients. <b>1993</b> , 243, 199-204	4
847	Addition of lithium to haloperidol in non-affective, antipsychotic non-responsive schizophrenia: a double blind, placebo controlled, parallel design clinical trial. <b>1993</b> , 111, 359-66	28
846	The cimetidine-induced increase in prolactin secretion in schizophrenia: effect of clozapine. <b>1993</b> , 112, 95-104	13
845	Different perspectives of short-term changes in the rehabilitation of schizophrenic patients. <b>1993</b> , 34, 352-9	5
844	Coercion in psychiatric care: Problems of medical ethics in a comprehensive empirical study. <b>1993</b> , 11, 323-334	28
843	A simple (or simplistic?) cognitive model for schizophrenia. <b>1993</b> , 31, 633-45	207
842	Treatment of primary degenerative dementia and multi-infarct dementia with glycosaminoglycan polysulfate: A comparison of two diagnoses and two doses. <b>1993</b> , 54, 44-64	5
841	Sex differences in schizophrenia: a demographic, symptomatic, life history and genetic study. <b>1993</b> , 47, 819-24	2
840	Three syndrome concept of schizophrenia. A factor analytic study. <b>1993</b> , 10, 143-50	112
839	Somatostatin in the cerebrospinal fluid of schizophrenic patients before and after neuroleptic drug treatment. <b>1993</b> , 8, 273-7	4
838	Pharmacokinetic optimisation of the treatment of psychosis. <b>1993</b> , 25, 217-36	24
837	Newer antipsychotic drugs. A review of their pharmacology and therapeutic potential. <b>1993</b> , 46, 585-93	36
836	Frontal intermittent delta activity in schizophrenic patients receiving antipsychotic drugs. <b>1993</b> , 24, 13-8	10
835	Altered fronto-central PINV topography and the primary negative syndrome in schizophrenia. <b>1993</b> , 8, 251-6	13
834	The clinical relevance of an auditory attention task (PAT) in a longitudinal study of chronic schizophrenia, with placebo substitution for chlorpromazine. <b>1993</b> , 10, 39-50	19

833	"Somatic Worry" and Medical Illness in Depressed Inpatients. <b>1993</b> , 1, 288-295	8
832	Elevated angiotensin-converting enzyme (kininase II) in the cerebrospinal fluid of neuroleptic-treated schizophrenic patients. <b>1993</b> , 9, 77-82	36
831	Early response to haloperidol treatment in chronic schizophrenia. <b>1993</b> , 10, 165-71	32
830	Effects of placebo, orphenadrine, and rising doses of chlorpromazine, on PAT performance in chronic schizophrenia. A two year longitudinal study. <b>1993</b> , 10, 51-9	9
829	Cholinergic hyperactivity and negative symptoms: behavioral effects of physostigmine in normal controls. <b>1993</b> , 9, 19-23	30
828	Behavioral response to buspirone in cocaine and phencyclidine withdrawal. <b>1993</b> , 10, 523-7	19
827	The relationship of clinical psychopathologic rating and cognitive factors to clinical dementia staging. <b>1993</b> , 17, 775-9	4
826	Differential effects of haloperidol on negative symptoms in drug-naive schizophrenic patients: effects on plasma homovanillic acid. <b>1993</b> , 9, 29-34	12
825	Psychological response to breast reconstruction. Expectations for and impact on postmastectomy functioning. <b>1993</b> , 34, 241-50	118
824	A Study of Elderly Suicide Attempters Admitted to an Inpatient Psychiatric Unit. <b>1993</b> , 1, 126-135	7
823	Assessing outcomes for sufferers of severe mental disorder: A conceptual framework and review. <b>1993</b> , 16, 347-363	93
822	Lateral asymmetries in auditory acuity distinguish hallucinating from nonhallucinating schizophrenic patients. <b>1993</b> , 46, 127-38	52
821	Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. <b>1993</b> , 46, 151-63	38
820	Erythrocyte membrane phospholipids in psychotic patients. <b>1993</b> , 49, 89-95	76
819	Serotonin2 receptor binding in blood platelets of schizophrenic patients. <b>1993</b> , 47, 111-9	32
818	Case identification and stability of the deficit syndrome of schizophrenia. <b>1993</b> , 47, 47-56	142
817	Dopamine D2 receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylspiperone. <b>1993</b> , 49, 219-37	106
816	The amphetamine challenge test correlates with affective lability in healthy volunteers. <b>1993</b> , 48, 219-28	14

815	Relations between attentional deficits and clinical symptoms in schizophrenic outpatients. <b>1993</b> , 47, 205-13	63
814	The Tridimensional Personality Questionnaire as a predictor of six-month outcome in first episode mania. <b>1993</b> , 48, 1-8	37
813	Abnormal processing of irrelevant information in schizophrenia: the role of illness subtype. <b>1993</b> , 48, 17-26	37
812	Platelet serotonin-2 receptors in schizophrenia: effects of illness and neuroleptic treatment. <b>1993</b> , 48, 57-68	25
811	CD5 positive B lymphocytes in schizophrenia: no alteration in numbers or percentage as compared with control subjects. <b>1993</b> , 48, 69-78	20
810	Growth hormone response to clonidine in neuroleptic-free patients with multidagnostically defined schizophrenia. <b>1993</b> , 48, 79-90	3
809	Electrodermal responsiveness, clinical variables, and brain imaging in male chronic schizophrenics. <b>1993</b> , 33, 786-93	26
808	Hypothalamic-pituitary-adrenal axis activity and 1-year outcome in depression. <b>1993</b> , 34, 392-400	32
807	Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication. <b>1993</b> , 34, 495-7	34
806	Clozapine treatment of borderline patients: a preliminary study. <b>1993</b> , 34, 402-5	93
805	Principal component analysis of the Swedish version of the Positive and Negative Syndrome Scale for schizophrenia. <b>1993</b> , 47, 257-263	36
804	Positive symptoms and chronicity of illness in schizophrenia. <b>1993</b> , 70, 65-7	1
803	Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study. <b>1993</b> , 23, 791-7	86
802	Clinical correlates of MMPI depression scales. <b>1993</b> , 60, 390-6	1
801	An assessment of gender as a factor among severely mentally disabled case management clients. <b>1993</b> , 19, 39-60	8
800	The prevalence of psychiatric disorder in a male remand population: A pilot study. <b>1993</b> , 4, 75-83	9
799	Aggressive behavior in schizophrenia: relationship to age of onset and cortical atrophy. <b>1993</b> , 68, 1-10	5
798	Initial validation of the MAC-P: A new clinician-rated scale for cognitive and affective changes in dementia. <b>1993</b> , 7, 420-429	2

797	Choroid plexus calcification as a possible marker of hallucinations in schizophrenia. <b>1993</b> , 71, 87-92		17
796	Extrapyramidal motor abnormalities associated with late-life psychosis. <b>1993</b> , 19, 747-54		15
795	m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia. <b>1993</b> , 50, 624-35		81
794	Sensory gating and inhibitory function in late-life schizophrenia. <b>1993</b> , 19, 733-46		74
793	Excitatory amino acid receptors in schizophrenia. <b>1993</b> , 19, 105-17		75
792	The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK. Clozapine Study Group. <b>1993</b> , 163, 150-4		40
791	Cyclic psychosis associated with the menstrual cycle. <b>1993</b> , 163, 824-8		21
790	Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. <b>1993</b> , 162, 38-42		93
789	Scale for the Prediction of Aggression and Dangerousness in Psychotic Patients, an introduction. <i>Psychological Reports</i> , <b>1993</b> , 73, 1363-77	1.6	28
788	Comparing the process in psychodynamic and cognitive-behavioral therapies.. <b>1993</b> , 61, 306-316		253
787	Evaluation of a diversion from custody scheme at magistrates' courts. <b>1993</b> , 4, 497-505		18
786	Biological determinants and risk factors for tardive dyskinesia in schizophrenia. <b>1993</b> , 69, 35-51		4
785	Methodological issues in evaluating the quality of life of long-stay psychiatric patients. <b>1993</b> , 2, 43-56		26
784	Once-daily controlled release remoxipride is equieffective with twice-daily immediate release remoxipride in the treatment of schizophrenia. <b>1993</b> , 7, 276-82		
783	The composition of the negative syndrome of chronic schizophrenia. <b>1993</b> , 162, 744-50		83
782	Effects of depot neuroleptics on driving performance in chronic schizophrenic patients. <b>1993</b> , 56, 910-3		16
781	Psychiatric disorder and disability in New Zealand long-stay psychiatric patients. <b>1993</b> , 27, 590-4		4
780	Neuropsychiatric Effects of Anabolic Steroids in Male Normal Volunteers. <b>1993</b> , 269, 2760		189

779	Sir Charles Bell 1774-1842. <b>1993</b> , 56, 913	5
778	The relationship of thought disorder to third ventricle width and calcification of the pineal gland in chronic schizophrenia. <b>1993</b> , 68, 53-9	13
777	Psychosocial functioning and subjective experience in schizophrenia. <b>1993</b> , 19, 599-608	120
776	Patients' perceptions of family emotional climate and outcome in schizophrenia. <b>1993</b> , 162, 751-4	44
775	Ritanserin, a selective 5-HT <sub>2</sub> /1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial. <b>1993</b> , 163, 451-5	136
774	Neuropsychological prediction of treatment efficacy and one-year outcome in schizophrenia. <b>1993</b> , 26, 122-6	39
773	[Effect of patient education on neuroleptic treatment of young psychotic patients]. <b>1993</b> , 38, 571-3	13
772	Counselor Knows Best? Clinician Assessments of In-Prison Substance Abuse Treatment Participants. <b>2017</b> , 44, 1462-1476	1
771	Sensorimotor cortex and supplementary motor area changes in schizophrenia. A study with functional magnetic resonance imaging. <b>1995</b> , 167, 197-201	147
770	Haematological monitoring for clozapine: do patients know why?. <b>1995</b> , 19, 536-537	6
769	Review of College guidelines on high-dose neuroleptic use in a psychiatric intensive care unit. <b>1998</b> , 22, 598-600	3
768	Acute Problems: A Survey of the Quality of Care in Acute Psychiatric Wards. By Sainsbury Centre for Mental Health. London: The Sainsbury Centre for Mental Health. 1998. 56 pp.. <b>1999</b> , 23, 637-637	0
767	Olanzapine in practice: a prospective naturalistic study. <b>1999</b> , 23, 178-180	1
766	Refusal of prescribed drugs in a psychiatric hospital. <b>1999</b> , 23, 346-348	1
765	Update on the use of new anticonvulsants as mood stabilisers. <b>1999</b> , 23, 554-558	1
764	Use of serotonin antagonists in the treatment of neuroleptic-induced akathisia. <b>2000</b> , 24, 348-351	1
763	Assessing risk and emotional disturbance using the COREDM and HoNOS outcome measures at the interface between primary and secondary mental healthcare. <b>2005</b> , 29, 419-422	14
762	Coping with Attentional Disorders as a Systemic Process in Schizophrenic Patients. <b>1989</b> , 155, 57-62	2

761	Psychosis. <b>2018</b> , 24, 845-860	6
760	Ruptured suprasellar dermoid cyst presenting olfactory delusion (Eigengeruchs erlebnis). <b>1993</b> , 33, 97-9	14
759	Case Report: Atypical psychotic onset of type I Arnold-Chiari malformation. 4, 915	1
758	Study on Effects of an Assertive Community Treatment in a Community Mental Health Center. <b>2012</b> , 21, 89	4
757	An event-related fMRI study of phonological verbal working memory in schizophrenia. <b>2010</b> , 5, e12068	14
756	The cognitive impact of the ANK3 risk variant for bipolar disorder: initial evidence of selectivity to signal detection during sustained attention. <b>2011</b> , 6, e16671	34
755	Perception of biological motion in schizophrenia and healthy individuals: a behavioral and fMRI study. <b>2011</b> , 6, e19971	68
754	Mismatch negativity/P3a complex in young people with psychiatric disorders: a cluster analysis. <b>2012</b> , 7, e51871	20
753	Are lay people good at recognising the symptoms of schizophrenia?. <b>2013</b> , 8, e52913	13
752	The roles of reward, default, and executive control networks in set-shifting impairments in schizophrenia. <b>2013</b> , 8, e57257	78
751	Abnormal contextual modulation of visual contour detection in patients with schizophrenia. <b>2013</b> , 8, e68090	24
750	Systematic review and meta-analysis of circulating S100B blood levels in schizophrenia. <b>2014</b> , 9, e106342	43
749	Childhood- versus adolescent-onset antisocial youth with conduct disorder: psychiatric illness, neuropsychological and psychosocial function. <b>2015</b> , 10, e0121627	11
748	Postural Stability of Patients with Schizophrenia during Challenging Sensory Conditions: Implication of Sensory Integration for Postural Control. <b>2016</b> , 11, e0158219	11
747	Use of Coercive Measures during Involuntary Psychiatric Admission and Treatment Outcomes: Data from a Prospective Study across 10 European Countries. <b>2016</b> , 11, e0168720	40
746	Monitoring risk assessment on an acute psychiatric ward: Effects on aggression, seclusion and nurse behaviour. <b>2020</b> , 15, e0240163	2
745	Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report. <b>2015</b> , 37, 13-20	236
744	Neuroimagem estrutural e psicopatologia: sintomas positivos e negativos e dilataç�o ventricular na esquizofrenia. <b>2001</b> , 23, 19-23	4

743	Method for evaluating subjective states of awareness that accompany recognition: adaptation for use in Portuguese-speaking patients with schizophrenia. <b>2005</b> , 27, 278-84	1
742	The effect of a multidisciplinary approach for smoking cessation in patients with Crohn's disease: Results from an observational cohort study. <b>2020</b> , 18, 29	1
741	DURATION OF UNTREATED PSYCHOSIS (DUP) AND PRE-MORBID FUNCTIONING, MAY PREDICT CLINICAL PRESENTATION IN FIRST EPISODE OF PSYCHOSIS (FEP): NORTH-EAST INDIAN STUDY. <b>2019</b> , 6, 1321-1328	1
740	Feasibility and Preliminary Effects of Implementing Acceptance and Commitment Therapy for Inpatients With Psychotic-Spectrum Disorders in a Clinical Psychiatric Intensive Care Setting. <b>2020</b> , 34, 80-96	3
739	Predictive Validity of the Brazilian Portuguese Version of the Family Questionnaire for Relapse in Patients With Schizophrenia. <b>2017</b> , 25, 559-572	3
738	A preliminary review of an outpatient dual diagnosis recovery group programme. <b>2011</b> , 21, 78-91	1
737	Increased serum interleukin-1beta and interleukin-6 in elderly, chronic schizophrenic patients on stable antipsychotic medication. <b>2005</b> , 1, 171-7	47
736	Quetiapine in the treatment of schizophrenia and related disorders. <b>2007</b> , 3, 219-35	45
735	The use of amisulpride in the treatment of acute psychosis. <b>2007</b> , 3, 3-11	13
734	Construction of a Neuro-Immune-Cognitive Pathway-Phenotype Underpinning the Phenome of Deficit Schizophrenia. <b>2020</b> , 20, 747-758	12
733	An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine. <b>2020</b> , 20, 554-584	17
732	Anti-purkinje cell and natural autoantibodies in a group of psychiatric patients. Evidences for a correlation with the psychopathological status. <b>2012</b> , 8, 81-90	4
731	Patients With First-Episode Psychosis are Not a Homogeneous Population: Implications for Treatment. <b>2013</b> , 10, 1-8	12
730	Sailing for rehabilitation of patients with severe mental disorders: results of a cross over randomized controlled trial. <b>2014</b> , 10, 73-9	8
729	A New Schizophrenia Model: Immune Activation is Associated with the Induction of Different Neurotoxic Products which Together Determine Memory Impairments and Schizophrenia Symptom Dimensions. <b>2019</b> , 18, 124-140	25
728	Mitochondrial Dysfunction in Blood Platelets of Patients with Manic Episode of Bipolar Disorder. <b>2019</b> , 18, 222-231	5
727	Predicting Early Warning Signs of Psychotic Relapse From Passive Sensing Data: An Approach Using Encoder-Decoder Neural Networks. <b>2020</b> , 8, e19962	18
726	Abnormal frontal activation during the perception of biological motion in patients with schizophrenia. <b>2014</b> , 26, 233-253	1

725	EYE-HAND PREFERENCE IN SCHIZOPHRENIA: SEX DIFFERENCES AND SIGNIFICANCE FOR HAND FUNCTION. <b>2004</b> , 98, 1225		2
724	CROSS-CULTURAL COMPARISON OF EXPLANATORY MODELS OF ILLNESS IN SCHIZOPHRENIC PATIENTS IN JORDAN AND GERMANY. <i>Psychological Reports</i> , <b>2007</b> , 101, 531	1.6	3
723	VOLUNTARY MOTOR PERFORMANCE IN PSYCHOTIC DISORDERS: A REPLICATION STUDY. <i>Psychological Reports</i> , <b>1990</b> , 66, 1223	1.6	3
722	PETS AND HEALTH. <i>Psychological Reports</i> , <b>1998</b> , 83, 1011	1.6	7
721	SUBJECTIVE AND OBJECTIVE MEASURES OF QUALITY OF LIFE HAVE DIFFERENT PREDICTORS FOR PEOPLE WITH SCHIZOPHRENIA. <i>Psychological Reports</i> , <b>2006</b> , 99, 477	1.6	4
720	The MAKE Biomarker Discovery for Enhancing anTidepressant Treatment Effect and Response (MAKE BETTER) Study: Design and Methodology. <b>2018</b> , 15, 538-545		22
719	Decreased IL-1ra and NCAM-1/CD56 Serum Levels in Unmedicated Patients with Schizophrenia Before and After Antipsychotic Treatment. <b>2018</b> , 15, 727-732		3
718	Physical Activity of Patients with Chronic Schizophrenia and Related Clinical Factors. <b>2018</b> , 15, 811-817		9
717	Association study of T102C 5-HT(2A) polymorphism in schizophrenic patients: diagnosis, psychopathology, and suicidal behavior. <b>2007</b> , 9, 97-101		11
716	Pharmacologic treatment of schizophrenia. <b>2010</b> , 12, 345-57		67
715	Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. <b>2011</b> , 13, 155-72		30
714	Randomised controlled trial of ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT study). <b>2017</b> , 4, 1-112		6
713	Health and social care services for older male adults in prison: the identification of current service provision and piloting of an assessment and care planning model. <b>2013</b> , 1, 1-138		22
712	Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. <b>2017</b> , 21, 1-192		19
711	Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia. <b>2017</b> , 21, 1-218		28
710	Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT. <b>2018</b> , 22, 1-160		24
709	Psychological approaches to understanding and promoting recovery in psychosis and bipolar disorder: a mixed-methods approach. <b>2016</b> , 4, 1-272		11
708	Crisis resolution teams for people experiencing mental health crises: the CORE mixed-methods research programme including two RCTs. <b>2019</b> , 7, 1-102		5



707	Supported accommodation for people with mental health problems: the QuEST research programme with feasibility RCT. <b>2019</b> , 7, 1-82	3
706	Cognitive Profile During Remission: Euthymic Bipolar Disorder Patients Compared to Schizophrenia Patients. <b>2007</b> , 1, 243-254	1
705	Treatment Discontinuation Following Randomization to Open-Label Olanzapine, Risperidone or Typical Antipsychotics During a One-Year Treatment for Schizophrenia. <b>2008</b> , 2, 226-234	3
704	Brain Natriuretic Peptide as a Biomarker of Asymptomatic Clozapine-Related Heart Dysfunction: A Criterion for a More Cautious Administration. <b>2019</b> , 12, 185-188	2
703	Recent Developments in the Treatment of Schizophrenia. <b>1976</b> , 6, 71-97	5
702	Behavioral Manifestations During the Early and Long-Term Stages of Recovery After Closed Head Injury. <b>1984</b> , 14, 540-546	14
701	Schizophrenia: A Multidimensional Disorder. <b>1994</b> , 24, 491-495	6
700	Insight and Psychiatric Disorders: A Review of the Literature, with a Focus on its Clinical Relevance for Bipolar Disorder. <b>1997</b> , 27, 782-790	13
699	Atypical Antipsychotic Drugs in Treatment-Refractory Schizophrenia. <b>1998</b> , 28, 618-626	6
698	Risperidone for Elderly Patients With Schizophrenia or Schizoaffective Disorder. <b>2000</b> , 30, 175-180	3
697	The Role of Insight in the Treatment and Outcome of Bipolar Disorder. <b>2000</b> , 30, 496-498	1
696	Soft Signs, Neuroleptic Side Effects, and Schizophrenia. <b>2003</b> , 33, 214-220	7
695	Measurement of inappropriate behavior associated with dementia. <b>1999</b> , 25, 42-51	56
694	Use of the Brief Psychiatric Rating Scale by Nurses. <b>1993</b> , 31, 9-9	7
693	PSYCHOSOCIAL ASSESSMENT for Treatment Planning and Evaluation. <b>1994</b> , 32, 31-42	11
692	LUNACY REVISITED. <b>2000</b> , 38, 28-35	22
691	A preliminary open trial of olanzapine in paediatric acute and transient psychotic disorders. <b>2006</b> , 48, 43-6	10
690	Self-medication hypothesis in substance-abusing psychotic patients: Can it help some subjects?. <b>2016</b> , 32, 325	1

689	Impact of neuropsychological rehabilitation on activities of daily living and community reintegration of patients with traumatic brain injury. <b>2018</b> , 60, 38-48	7
688	A cross-sectional comparative study on the assessment of quality of life in psychiatric patients under remission treated with monotherapy and polypharmacy. <b>2017</b> , 59, 333-340	3
687	Development and validation of Vellore Assessment of Social Performance among clients with chronic mental illness. <b>2020</b> , 62, 121-130	1
686	Clinical Practice Guidelines for Cognitive Behavioral Therapy for Psychotic Disorders. <b>2020</b> , 62, S251-S262	4
685	Bipolar I disorder and expressed emotion of families: A cohort study in Japan. <b>2012</b> , 02, 258-261	1
684	Obesity and Psychopathology of Inpatients with Schizophrenia. <b>2015</b> , 54, 172	0
683	Efficacy of Case Management for the Community Dwelling Schizophrenia Patients : A 36-Month Prospective Follow-Up Study. <b>2015</b> , 54, 578	2
682	Association between Antipsychotics-Induced Restless Legs Syndrome and Tyrosine Hydroxylase Gene Polymorphism. <b>2009</b> , 6, 211-5	13
681	MEIS1, a Promising Candidate Gene, Is Not Associated with the Core Symptoms of Antipsychotic-Induced Restless Legs Syndrome in Korean Schizophrenia Patients. <b>2015</b> , 12, 263-7	6
680	Distribution of Active and Resting Periods in the Motor Activity of Patients with Depression and Schizophrenia. <b>2016</b> , 13, 112-20	15
679	Chemokine and Chemokine Receptor Polymorphisms in Bipolar Disorder. <b>2016</b> , 13, 541-548	7
678	Validation of the Korean Version of the Clinical Assessment Interview for Negative Symptoms. <b>2017</b> , 14, 413-419	3
677	Level of function at discharge as a predictor of readmission among inpatients with schizophrenia. <b>2011</b> , 65, 314-9	8
676	Trihexyphenidyl (artane) abuse among Saudi psychiatric patients. <b>1992</b> , 12, 391-4	8
675	Trihexyphenidyl (Artane) dependence: A controlled investigation between users and abusers. <b>1997</b> , 17, 185-90	6
674	Prevalence of Restless Legs Syndrome Among Psychiatric Patients Who are Under Antidepressant or Antipsychotic Monotherapy. <b>2016</b> , 26, 161-168	4
673	A comparison of an acridan derivative (Smith Kline and French 14336) and trifluoperazine in the treatment of chronic schizophrenia. <b>1969</b> , 2, 550-3	2
672	Initial experiences with clozapine at Kenmore Psychiatric Hospital. <b>1994</b> , 161, 199-201	3

671	A study of cofactors implicated in response to electroconvulsive therapy in patients with psychotic disorders. <b>2013</b> , 34, 134	1
670	A cognitive behaviour an assertive outreach. <b>2000</b> , 3, 12-15	2
669	Perceived Coercion, Client-Centredness, and Positive and Negative Pressures in an Assertive Community Treatment Program: An Exploratory Study. <b>2010</b> , 29, 35-50	1
668	Gender Differences in the Clinical Characteristics of Psychotic Depression: Results from the CRESCEND Study. <b>2015</b> , 13, 256-62	2
667	Psychometric Properties of the Korean Version of the Clinical Language Disorder Rating Scale (CLANG). <b>2016</b> , 14, 49-56	4
666	Acceptance of the Deltoid Muscle Injection of Aripiprazole Long-acting Injectable in the Patients with Schizophrenia. <b>2020</b> , 18, 49-57	5
665	A Randomized Controlled Trial to Compare the Efficacy, Safety and Tolerability of Asenapine versus Olanzapine in Management of Schizophrenia. <b>2020</b> , 18, 587-598	1
664	The Therapeutic Threshold and the Point of Futility. <b>2021</b> , 34-59	
663	What Is an Adequate Antipsychotic Trial? Using Plasma Levels to Optimize Psychiatric Response and Tolerability. <b>2021</b> , 114-146	
662	Quality of life in first episode psychosis: a cluster analytic approach. <b>2021</b> , 1	0
661	Parenting interventions for people with schizophrenia or related serious mental illness. <b>2021</b> , 10, CD013536	3
660	Humour-based interventions for people with schizophrenia. <b>2021</b> , 10, CD013367	1
659	Recent Stressful Life Events and Suicidal Ideation in Schizophrenia: A 1-Year Follow-up Study. <b>2021</b> ,	
658	Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. <b>2021</b> , 21, 526	4
657	Neural Indicator of Altered Mismatch Detection Predicts Atypical Cognitive-Perceptual Experiences in Psychotic Psychopathology. <b>2021</b> ,	1
656	Adjunctive multi-session transcranial direct current stimulation for neurocognitive dysfunction in schizophrenia: A meta-analysis. <b>2021</b> , 66, 102887	2
655	Prevalence of Suicidal Ideation in Hospitalized Psychiatric Patients. <b>2021</b> , 12, 45-48	
654	Associations of Clozapine Use With Psychosocial Functioning and Quality of Life in Patients With Schizophrenia: A Community-Based Cross-Sectional Study. <b>2021</b> , 18, 968-976	

- 653 Validity and reliability of a Persian version of the self- evaluation of negative symptoms (SNS). **2021**, 21, 516 0
- 652 A comparison of stages of attention for social and nonsocial stimuli in schizophrenia: An ERP study. **2021**, 238, 128-136 2
- 651 Introduction to schizophrenia. **2000**, 3-17
- 650 Historical Perspectives. **2000**, 3-17 1
- 649 Frecuencia de la apolipoproteína E-e4, en la esquizofrenia de déficit. **2000**, 7, 41-44
- 648 Cualidades psicométricas de la versión francesa de la Escala de estimación de la calidad de vida de Heinrichs. **2000**, 7, 173-180
- 647 Factores cognitivos que discriminan entre pacientes esquizofrénicos con y sin respuesta al tratamiento. **2000**, 7, 257-268
- 646 Tratamiento combinado de clozapina y litio para la esquizofrenia y el trastorno esquizoafectivo. **2000**, 7, 310-313
- 645 Dementia: Trial Design and Experience with Large Multicentre Trials. **2001**, 183-198
- 644 RELATIONSHIPS BETWEEN HALLUCINATIONS AND DISORGANIZATION IN SCHIZOPHRENIC PATIENTS. *Psychological Reports*, **2001**, 89, 106 1.6 2
- 643 Evaluation of Psychiatric Treatments. **2001**, 563-577
- 642 Clozapin in der Kinder- und Jugendpsychiatrie Klinische Erfahrung und neue Befunde. **2001**, 1-12
- 641 Assessment Strategies. **2001**, 23-41 1
- 640 Evaluación del sistema supervisor en sujetos ancianos con y sin desinhibición. **2001**, 8, 27-37
- 639 Tratamiento a largo plazo de la esquizofrenia crónica con risperidona: un estudio con concentraciones plasmáticas. **2001**, 8, 155-162
- 638 El Estudio médico sobre pacientes esquizofrénicos que viven en la comunidad. Necesidades subjetivas y ayuda percibida. **2001**, 8, 462-470
- 637 Insight: Theory and Practice. **2002**, 114-122
- 636 An Integrated Approach to the Treatment and Rehabilitation of Persons with Schizophrenia. **2002**, 237-246

- 635 Neuropsychological Investigation of the Effects of Psychiatric Rehabilitation Strategies for Schizophrenia. **2002**, 20-27
- 634 Long-Term Olanzapine Treatment in Schizophrenic Outpatients: Its Effects on Their Quality of Life and Clinical Outcome. **2002**, 132-145
- 633 Subsyndrome der chronischen Schizophrenie. **2002**, 27-50
- 632 Clinicians' guide to reading psychiatric literature: therapeutic trials and systematic reviews. **2002**, 8, 73-80
- 631 Traumatic Brain Injury: Severity and Outcome. **2002**, 673-687
- 630 Principles and Results of Family Therapy in Schizophrenia. **2002**, 155-173
- 629 Traumatic Brain Injury: Severity and Outcome. **2002**, 673-687
- 628 Cognitive Deficits in Patients with First-Episode Psychosis as Identified by Exner's Schizophrenia Index in Finland and Spain. **2002**, 25, 175-194 2
- 627 Asociaci3n entre la gravedad de los s3ntomas esquizofrenicos y la retenci3n de orina. **2002**, 9, 193-196
- 626 Decreased Psychopathology & FAMILY BURDEN Associated With Clozapine Treatment of Patients with Refractory Schizophrenia. **2002**, 40, 34-39
- 625 Pertinencia cl3nica de la terapia electroconvulsiva (TEC) en adolescentes con trastorno grave del estado de 3nimo: datos de un estudio de seguimiento. **2002**, 9, 512-519
- 624 Consideration of Neuropsychological Factors in Interviewing. **2003**, 67-82 1
- 623 Schizophrenie. **2003**, 81-94
- 622 Service innovations: Home treatment for first-episode psychosis. **2003**, 27, 148-151 2
- 621 Psychological Assessment in Treatment. 119
- 620 La significaci3n del afrontamiento como variable terap3utica para el desenlace cl3nico de la terapia psicol3gica en la esquizofrenia. **2003**, 10, 421-427
- 619 ¿Se explican las relaciones terap3uticas en psiquiatr3a por los s3ntomas de los pacientes? Factores que influyen en las evaluaciones de los pacientes. **2003**, 10, 519-526
- 618 Supporting People and their Families During Psychopharmacotherapy. **2004**, 164-177

617 Defizitäres Fingertapping bei schizophrenen Patienten. **2004**, 147-174

2

616 Indikationsabhangige Durchfuhrung und Bewertung der Elektrokonvulsionstherapie. **2004**, 343-461

615 Psychosocial Interventions for People with Serious Mental Illness. **2004**, 273-289

614 Acute In-patient Setting. **2004**, 307-334

613 Zusammenhange zwischen Veranderungen in verschiedenen Funktionsbereichen von schizophren Erkrankten wahrend der Durchfuhrung sozialer Fertigkeitstrainings. **2004**, 33, 144-151

612 Similitudes y diferencias transversales entre esquizofrenia, trastorno esquizoafectivo y mana o mana mixta con rasgos psicoticos incongruentes con el estado de imo. **2004**, 11, 156-162

611 El sndrome deficitario en la esquizofrenia: implicaciones para el tratamiento de los sntomas negativos. **2004**, 11, 219-224

610 Calidad de vida en esquizofrnicos con y sin el sndrome de dficit. **2004**, 11, 374-377

609 Tranquilizacin rpida: nuevos enfoques en el tratamiento de urgencias de las perturbaciones del comportamiento. **2004**, 11, 477-484

608 Terapia combinada con el neuroleptico de baja potencia levomepromacina como auxiliar del haloperidol para pacientes agitados con exacerbacin aguda de esquizofrenia. **2005**, 12, 116-117

607 Procesamiento visual-espacial y dimensiones de la esquizofrenia: un estudio preliminar en 62 sujetos esquizofrnicos. **2005**, 12, 111-115

606 Experiencias del ingreso y el tratamiento psiquitrico de los pacientes ingresados voluntaria y no voluntariamente: una comparacin antes y despus del cambio de legislacin en Suecia. **2005**, 12, 139-144

605 Uso del tabaco en la esquizofrenia: un estudio de las concentraciones de cotinina en la saliva de pacientes y controles. **2005**, 12, 318-322

604 Ziprasidone alone or in combination for acute mania.

603 Kapitel 8 Literaturverzeichnis. **2007**, 167-196

602 Un ensayo comparativo doble ciego distribuido al azar de amisulprida frente a olanzapina durante 2 meses en el tratamiento de sujetos con esquizofrenia y depresion comorbida. **2007**, 14, 181-189

601 Diagnostic Rating Scales and Psychiatric Instruments. **2008**, 79-90

600 Can Psychological Testing Replace Psychiatric Evaluations in Patients with Epilepsy? Or Can Psychiatric Evaluations Replace Psychological Testing in Patients with Epilepsy?. **2008**, 211-219

599 Standardisierte psychiatrische Befunddiagnostik. **2008**, 455-481

598 Assessing Older People with Mental Health Issues. 95-111

597 Guides Case Exercise: Depression. **2009**, 14, 7-13

596 The Use of Rating Scales to Measure Outcomes in Child Psychiatry and Mental Health. **2009**, 175-194

595 Antipsychotic combinations for schizophrenia.

594 Critères d'Évaluation. **2010**, 48-82

593 Clinical Trials in Dementia. 1

592 A Geriatric Mobile Crisis Response Team: A Resilience-Promoting Program to Meet the Mental Health Needs of Community-Residing Older People. **2011**, 305-315

591 Ziprasidone alone or in combination for acute mania.

590 Traumatic Brain Injury. **2011**, 1133-1175

1

589 Negative Symptoms Across the Schizophrenia Spectrum: Phenomenological and Neurobiological Perspectives. **2011**, 1-32

588 Effect of initial ziprasidone dose on treatment outcome of Korean patients with acute manic or mixed episodes. **2011**, 8, 207-13

587 Toward a Multidimensional Continuum Model of Functional Psychoses for Research Purposes. **2011**, 85-113

2

586 Der Blick auf das Besondere: Störungsspezifische Diagnostik. **2011**, 99-126

585 Standardisierte psychiatrische Befunddiagnostik. **2011**, 545-568

584 Classical Somatic Treatments: Pharmacotherapy and ECT. **2012**, 331-347

583 Bibliographie. **2012**, 151-167

582 Service and Resource Management. **2012**, 533-542

- 581 The evaluation of physical treatments. **2012**, 1151-1158
- 580 Schizophrenia: a conceptual history. **2012**, 521-526
- 579 Virtual reality for treatment compliance for people with serious mental illness. 0
- 578 References. 185-195
- 577 Antipsychotic Polypharmacy and Associated Phenomena in Patients with Schizophrenia: Rational or Irrational?. **2013**, 61-80
- 576 Assessment of Insight and Overvalued Ideation: In ObsessiveCompulsive Disorder. **2013**, 217-230
- 575 Management of psychosis and dementia. **2013**, 192-224 0
- 574 Una psichiatria al di l dell'attuale paradigma. **2013**, 9-22 2
- 573 Health Conditions and Active Ageing. 73-119
- 572 Current Approaches to the Assessment of Depression. 397-412 1
- 571 The Development of a Mental Disorder Recovery Scale. **2013**, 11, 639-647
- 570 The Relationship between Impaired Methylnicotinate Response and Oxidative Stress in Schizophrenia. **2014**, 04, 141-146
- 569 Assessing for Schizophrenia in Asian Americans. **2014**, 305-326
- 568 Neurosurgery for obsessive-compulsive disorder, other anxiety disorders and depressive disorders.
- 567 Screening programmes for helping mental health professionals to detect violent victimisation in people with severe mental illness.
- 566 Response : Phenothiazine Dosage Levels and Auditory Signal Detection in Schizophrenia. **1973**, 179, 406-406
- 565 HYPOTHALAMIC RELEASING HORMONES AND CATECHOLAMINES: A NEW INTERFACE. **1973**, 1149-1155 1
- 564 Evoked Potentials in Psychopathology and Psychiatric Treatment. **1975**, 481-523 1



- 563 VALIDITY PROBLEMS IN PSYCHIATRIC RATING SCALES AS A FUNCTION OF THE SEVERITY OF DISTURBANCE. **1978**, 97-101
- 562 Assessment of Anti-Psychotic Drugs. **1981**, 113-124
- 561 The Clinical Assessment of Depression. **1981**, 79-88
- 560 Studies of ß-Endorphin in Patients with Mental Illness. **1981**, 293-310
- 559 HLA AND REVERSED CEREBRAL ASYMMETRIES: POSSIBLE MARKERS FOR A SUBGROUP OF SCHIZOPHRENICS. **1982**, 485-493
- 558 Research Methodology in Clinical Trials of Psychotropic Drugs. **1982**, 391-407 1
- 557 Effects of Opiate Antagonists and Agonists on Behavioral and Neuroendocrine Variables. **1982**, 271-289 0
- 556 Endorphins in Psychiatric Research and Treatment. **1982**, 213-229
- 555 Funktionelle Hemisphärenasymmetrien bei Schizophrenen. **1984**, 3-17 1
- 554 Der Gehalt von Leucinenkephalin und Methioninenkephalin im Lumballiquor von psychiatrischen und neurologischen Patienten. **1984**, 135-141
- 553 Evaluation of Treatment Results. **1984**, 121-137
- 552 Observer Ratings. **1984**, 97-131
- 551 Bibliography. **1984**, 453-456
- 550 Abnormal Behavior in Cultural Context. **1984**, 111-139
- 549 Die Bedeutung diagnostischer Kriterien für biologisch-psychiatrische Untersuchungen (Bericht über bisherige Ansätze). **1984**, 43-49 1
- 548 Hp-, SEP- und EsD-Phänotypen und Genfrequenzen bei schizophrenen Patienten. **1984**, 161-165
- 547 Neuroendocrine Changes during the Course of Neuroleptic Treatment of Schizophrenic Patients. **1984**, 583-597 1
- 546 Videotape in Psychiatric Education in Adelaide, South Australia. **1985**, 339-344

- 545 Problems in the Use of Global Scores of Rating Scales in Psychiatric Research. **1985**, 241-248
- 544 The Reliability and Validity of Diagnostic Categories. **1985**, 333-342
- 543 Neuroendocrine Involvement in Therapeutic Mechanisms of Neuroleptic and Antidepressant Drugs: Studies of Thyroid Axis. **1985**, 249-255
- 542 The Dysphoria Syndrome and its Relation to EPS. **1985**, 595-601 1
- 541 NB 106 1689 (FLUPERLAPINE) In 104 Schizophrenic Patients (Open Multicenter Trial). **1985**, 795-800
- 540 Antidepressive Efficacy of Pirlindole in Man. **1985**, 329-335 1
- 539 Gaba-Ergic Treatment of Tardive Dyskinesia. **1985**, 567-572
- 538 Guidelines to use of Plasma Levels From a Clinical Perspective. **1985**, 509-514
- 537 Carbamazepine in Excited Psychoses. **1985**, 485-489
- 536 Lateral Imbalance and Positive and Negative Symptoms. **1985**, 435-439
- 535 Dynamic Hemispheric Imbalance in Schizophrenia. **1985**, 313-319
- 534 AMDP-III in the Assessment of Depression. **1986**, 82-89 1
- 533 Schlaf und Schlafstörungen bei Depressionen im Alter. **1986**, 89-101
- 532 Clinical Heterogeneity in Patients with Dementia of the Alzheimer Type. **1986**, 129-134
- 531 Stimulation der Prostaglandinbildung in Blutplättchen von Patienten mit schizophrenen oder schizoaffektiven Psychosen. **1986**, 212-218
- 530 Sensitivity to Treatment Effects of Evaluation Instruments Completed by Psychiatrists, Psychologists, Nurses, and Patients. **1986**, 367-376 2
- 529 Clinical Interviewing of the Patient and History in Neuropsychological Assessment. **1986**, 45-73 1
- 528 Memory Assessment. **1986**, 41-65

527 Dopaminerge Supersensitivität als Sekundärsphänomen schizophrener Prozesse/psychosen. Zur pathophysiologischen Endstrecke schizophrener Syndrome. **1986**, 137-169

526 Biochemical alterations produced by neuroleptics in man: studies of plasma homovanillic acid in schizophrenic patients. **1987**, 3, 248-54

3

525 Literatur. **1987**, 116-128

524 Negative symptoms: a follow-up perspective. **1987**, 3-8

523 Outcome after 10 years of apomorphine-tested psychotic patients. **1987**, 159-167

522 Klinische Beurteilungsebenen hirnorganischer Psychosynndrome: Zum Problem einer differenzierten Befunderhebung. **1987**, 29-53

1

521 Neuroendokrinologische Untersuchungen bei schizophrenen Patienten nach Stimulation mit unterschiedlichen Dosierungen von Apomorphin. **1988**, 117-121

520 Carbamazepin als Adjuvans bei der Neuroleptikatherapie. **1988**, 379-381

519 Verlaufsuntersuchungen bei Neuroleptikatherapie. **1988**, 117-128

518 Elektroenzephalographische Indikatoren der neuroleptischen Akutresponse. **1988**, 303-306

4

517 Gibt es biologische Prädiktoren für den Verlauf endogener Psychosen? Untersuchungen zum Einbau von Arachidonsäure in Blutplättchenphospholipide. **1988**, 126-130

516 Systemtheoretische Aspekte bei der Pharmakotherapie schizophrener Erkrankungen. **1988**, 129-135

1

515 Individuelle und Familientherapie der Schizophrenie. **1988**, 190-218

2

514 Blickmotorische und psychopathologische Korrelate subjektiver Basisstörungen bei schizophrenen Kranken. **1988**, 157-161

513 Erhöhte Phospholipase-A2-Aktivität im Plasma schizophrener Patienten. **1988**, 213-217

512 Visuomotorisches Tracking bei Schizophrenen: Nachweis syndromspezifischer Aufmerksamkeitsdefizite. **1988**, 295-297

511 Une adaptation de l'échelle d'agressivité manifeste de Yudofsky sur une population de patients hospitalisés en unité de soins fermés. **1989**, 4, 227-233

1

510 Une voie de recherche en psychopathologie quantitative: présentation des travaux de P. Bech. **1989**, 4, 133-138

- 509 Antidepressants in Depressed Schizophrenics. **1989**, 215-232
- 508 The Development of Methods to Assess the Temporal Relationship of Depressive and Psychotic Symptoms in Schizophrenia. **1989**, 109-119
- 507 Literatur. **1989**, 155-162
- 506 The Neuroleptic Dysphoria Syndrome. **1989**, 233-243
- 505 Empirische Untersuchungen zur Konkordanz verschiedener Minussymptomatik-Skalen sowie zur Korrelation mit testpsychologischen Befunden. **1990**, 59-68 4
- 504 Antipsychotic Agents. **1990**, 443-453
- 503 PSE-standardisierte Verlaufsdaten zur Minussymptomatik. **1990**, 35-46 1
- 502 Positron Emission Tomography with [18F]Deoxyglucose and Topographic EEG in Schizophrenia. **1990**, 400-408
- 501 Einfluss der Antiparkinsonmedikation bei schizophrenen Patienten: eine klinische Langzeitprüfung von Fluphenazin- und Haloperidoldecanoat. **1990**, 75-90
- 500 Haldolmonitoring zur Optimierung der Therapie Schizophrener. **1990**, 93-104
- 499 Inhibiteurs calciques et troubles de l'humeur: une revue de la littérature. **1990**, 5, 103-111
- 498 Grundlagen und Probleme des Messens in der psychiatrischen Forschung. **1990**, 35-46 1
- 497 Alzheimer Disease and Other Dementias. **1990**, 353-388 1
- 496 Literatur. **1990**, 204-210
- 495 Zuclopenthixol [Klinische Erfahrungen bei agitierten und expansiven Psychosen. **1990**, 127-135
- 494 Measuring the efficacy of psychotropic drugs: clinical symptoms and rating scales. **1990**, 8, 105-20 2
- 493 Die Forschung über Familien- und Psychopharmakotherapie der Schizophrenie. **1990**, 111-130 3
- 492 Emotion and Attachment in Families of Schizophrenics: The Struggle for Recovery. **1991**, 213-241

491 Manual und Glossar. **1991**, 25-61

490 The Interaction of Drug and Family Therapy in the Prevention of Relapse in Schizophrenia. **1991**, 55-66

1

489 Molecular insights into schizophrenia. **1992**, 36, 23-40

5

488 Anxiety Disorders. **1992**, 215-261

487 Neuropsychiatric Assessment. **1992**, 603-641

486 Behandlungsergebnisse bei Patienten mit paranoiden Störungen. **1992**, 131-144

1

485 The Chronically Mentally Ill. **1992**, 445-460

484 Sind die Verlaufsprädiktoren für akut und chronisch Erkrankte gleich?. **1992**, 143-157

483 Psychometrie, Rating-Skalen, Evaluation. **1992**, 131-159

482 Operators and scales: diagnostic and rating issues in psychiatric PET research. **1992**, 19-25

481 Subjektive Bewertung psychiatrischer Behandlungen durch die Betroffenen. **1992**, 222-229

1

480 Psychophysiological contributions to clinical assessment and treatment. **1992**, 59-78

479 Responseprädiktoren einer neuroleptischen Akutbehandlung schizophrener Patienten – Ergebnisse mit dem Testdosismodell. **1993**, 183-190

478 Ventricle Size and P300 in Elderly Depressed Patients. **1993**, 43-46

477 Neuroleptische Behandlung und Voraussage des Ansprechens. **1993**, 128-136

476 Psychiatric Assessment and Diagnosis. **1993**, 73-97

475 Neurologische Soft Signs bei endogenen Psychosen. **1993**, 563-566

474 Simultaneous Electroencephalographic and Cerebral Metabolic Rate Measurement. **1993**, 313-324

- 473 Rating Scales for Psychopathological States. **1993**, 45-105
- 472 Residual and negative symptoms in treatment with neuroleptics. **1993**, 10, 131-7
- 471 Efficacy of Psychotherapy for Schizophrenia. **1993**, 325-354
- 470 Kortikale Aktivierungsmuster bei schizophran Erkrankten: eine faktorenanalytische Untersuchung. **1993**, 500-503
- 469 Neurologische Soft Signs: Gruppenunterschiede und klinische Korrelate. **1993**, 567-570
- 468 Die Behandlung des therapieresistenten schizophranen Patienten. **1993**, 82-96 1
- 467 STH- und PRL-Sekretion: Prädiktion des Therapieerfolges mit Neuroleptika?. **1993**, 69-74
- 466 The Regional Cerebral Blood Flow Landscape in Chronic Schizophrenia: An 18 Year Follow-up Study. **1993**, 81-85
- 465 Introduction: Rating Scales Versus DSM-III-R and ICD-10. **1993**, 1-43
- 464 Assessment Strategies. **1994**, 19-44
- 463 Borderline Disorder. **1994**, 305-322 1
- 462 Schizophrenia. **1994**, 15-32
- 461 Prediction of clinical response to neuroleptics and positron emission tomography in schizophrenia. **1994**, 123-133
- 460 Clozapin in der Kinder- und Jugendpsychiatrie. **1994**, 23-37 2
- 459 Quantitative Untersuchungen zur Informationsverarbeitung bei Patienten mit schizophrener Minussymptomatik. **1994**, 171-187
- 458 Schizophrenia. **1994**, 345-354
- 457 Suizidversuch, chirurgisch relevante Folgen. **1995**, 369-422
- 456 31P Magnetic Resonance Spectroscopy Study of Brain Metabolism in Schizophrenia. **1995**, 227-251 1

455 Reciprocity in Support Networks of Sheltered-Care Residents. **1995**, 73-86

454 Definition, Diagnostik und Therapie schizophrener Minussymptomatik. **1995**, 29-52

453 Measures of Global Functioning. **1995**, 453-467

452 The Psychopathology of the Sense of Music. **1995**, 153-162

451 EEG Mapping During Music Perception and MRI Data in Psychiatric Patients. **1995**, 257-266

450 Neurologische Soft Signs und Störungen im sensomotorischen Kortex bei schizophrenen Psychosen: Eine Studie mit der funktionellen Magnetresonanztomographie. **1996**, 681-684

449 EEG-Quellen im Frequenzbereich bei psychiatrischen Erkrankungen, der Demenz vom Alzheimer Typ und beim gesunden Altern, geschätzt mittels Frequenz-Quellen-Analysen des EEGs. **1996**, 625-637

448 Patterns of Clinical Efficacy for Antipsychotic Drugs. **1996**, 313-331

447 Using Information Systems to Improve Quality of Care. **1996**, 165-182

446 Schizophrenie. **1996**, 255-282

2

445 Biological Predictors of Antipsychotic Treatment Response. **1996**, 389-444

444 Quantitative Analyse von Störungen der zentralen Informationsverarbeitung bei postakut Schizophrenen. **1996**, 121-134

443 Immunological alterations and neuropsychiatry symptoms: antimicroglia antibodies and psychopathological subgroups in Alzheimer's Disease. **1997**, 85-92

442 Lebensqualität als Outcome-Kriterium. **1997**, 451-454

441 Adición de sulpirida a la clozapina en pacientes esquizofrénicos resistentes al tratamiento: un estudio preliminar de una serie clínica. **1997**, 4, 476-479

440 Predictors of length of stay in day hospital patients. **1997**, 21, 760-763

439 What Should Be Measured? Instruments. **1998**, 53-72

438 Bedeutung der primären Minussymptomatik bei der Therapie mit Neuroleptika. **1998**, 121-133

- 437 Mñchner 15-Jahres-Katamnese: Erste Ergebnisse einer Verlaufsuntersuchung an ersthospitalisierten Patienten mit schizophrenen, schizoaffektiven und affektiven Psychosen aus den Jahren 1980 bis 1982. **1998**, 61-73
- 436 Zur Beziehung von sozialer Anpassung und Lebensqualitñ bei schizophren Erkrankten. **1998**, 283-298 2
- 435 Practical Implementation Issues and Suggestions. **1998**, 93-109
- 434 Correlaciones Entre Potenciales Evocados Auditivos Estñdar y Síntomas en un Grupo de 50 Pacientes Esquizofrñicos. **1998**, 5, 309-318
- 433 Levels of Recovery From Psychotic Disorders Chart. **1998**, 36, 31-37 1
- 432 Network models and formal thought disorder: Associative processes in schizophrenic patients. **1999**, 259-279
- 431 Evaluation psychiatrischer Therapien. **1999**, 307-333
- 430 Efectividad de la clozapina en un servicio psiquiñtrico en Italia. **1999**, 6, 124-127
- 429 Estudio meta-analñtico de los beneficios y riesgos de tratar la esquizofrenia crñica con risperidona o neurofñticos convencionales. **1999**, 6, 100-105
- 428 Early experience of the use of olanzapine across three rehabilitation services. **1999**, 23, 480-483
- 427 Activaciñ frontal disminuida en esquizofrñicos durante la estimulaciñ con la prueba de ejecuciñ continua: un estudio de imñgenes de resonancia magnñtica funcionales. **1999**, 6, 509-518
- 426 Smoking and Persistent Mental Illness: An Exploratory Study. **1999**, 37, 26-34 17
- 425 Razonamiento en situaciñ de incertidumbre en pacientes esquizofrñicos delirantes: un estudio longitudinal. **1999**, 6, 498-505
- 424 A QUIT SMOKING GROUP: PILOT STUDY. **1999**, 37, 31-36 4
- 423 Schizophrenia. **2015**, 361-380
- 422 Structured and Semistructured Clinical Interviews Available for Use Among African American Clients: Cultural Considerations in the Diagnostic Interview Process. **2015**, 19-42 1
- 421 Clinical and Neuropsychological Characteristics of Adult Alcohol Use Disorder Patients with or without Attention-Deficit Hyperactivity Symptom. **2014**, 25, 209-216 2
- 420 Biomarker Symptom Profiles for Schizophrenia and Schizoaffective Psychosis. **2015**, 05, 78-112



419 Standardisierte Befunddiagnostik in der Psychiatrie. **2015**, 1-25

418 Psychopharmakotherapie [klinisch-empirische Grundlagen. **2015**, 1-48

417 [A double-blind randomized placebo-controlled study of the efficacy of the combined treatment with naltrexone and guanfacine for relapse prevention in opiate dependence]. **2015**, 115, 39-46

416 Factors Affecting Stigma Resistance in Patients with Bipolar Disorder. **2015**, 54, 309

415 Psychiatric Care, Economics of. **2015**, 295-300

414 References. **2015**, 165-183

413 An Investigation of the Secular Acceleration of Psychiatric Disorders. **2015**, 05, 121-127

412 Ripensare l'abuso nel Disturbo Borderline di Personalit  il caso dell'interazione verbale nell'arco di vita della persona. **2015**, 119-134

411 7 Schizofreniespectrum- en andere psychotische stoornissen. **2016**, 195-233

410 Changes in Interrelating over the Course of Psychotherapy. **2016**, 217-226

409 Yatarak Tedavi G en Bipolar Bozukluk Hastalarında Dissosiyatif Bozukluk Etkan  Olan ve Olmayan Hasta Gruplarında Karşılaştıran. **2016**, 1, 35-35

408 Clinical variables and factors affecting duration of hospitalization in a sample of patients with affective and nonaffective psychoses. **2017**, 38, 112

407 Chronic Mental Illness and the Changing Scope of Intervention Strategies, Diagnosis, and Treatment in Child and Adolescent Population. **2017**, 258-269

406 Psychopharmakotherapie [klinisch-empirische Grundlagen. **2017**, 795-842

405 Schizophrenie. **2017**, 7-37

404 Eye Movement Behavior Analyses for Studying Cognitive Performance and Conversion to Pathologies. **2017**, 281-292

403 Standardisierte Befunddiagnostik in der Psychiatrie. **2017**, 577-600

402 Brexpiprazole versus placebo for people with schizophrenia.

1

- 401 Conceptualization of the terms of self and the sense of identity and their disorders in the course of schizophrenia in the works of Polish authors. **2017**, 18, 201-216 1
- 400 Assessing and Treating Women Offenders. **2018**, 103-126 2
- 399 The Impact of Reward on Attention in Schizophrenia.
- 398 The Valuation of Social Rewards in Schizophrenia.
- 397 Supervised machine learning to decipher the complex associations between neuro-immune biomarkers and quality of life in schizophrenia.
- 396 Identifying the "Therapy Targets" for Treating the Negative Symptoms of Psychosis Using Cognitive Behavioral Therapy. **2018**, 32, 203-220 1
- 395 Psychotic Bipolar Disorder. **2019**, 59-72
- 394 Early-Onset Psychosis with Adolescence Onset. **2019**, 1-22
- 393 Atypically larger variability of resource allocation accounts for visual working memory deficits in schizophrenia. 0
- 392 Factors Affecting Admission Type in Patients with Schizophrenia Spectrum. **2019**, 58, 238
- 391 Chronic Mental Illness and the Changing Scope of Intervention Strategies, Diagnosis, and Treatment in Child and Adolescent Population. **2019**, 556-567
- 390 Effects of local guidelines on prescribing practice and treatment outcomes in a long-stay psychiatric facility. **2019**, 6, 756-764
- 389 Human and Animal Welfare Assessment During Animal Assisted Interventions (AAI): A Pilot Project in Progress. **2019**, 445-456 1
- 388 Step 3 of EBP: Part 2 Evaluating Research Methods. **2019**, 123-154
- 387 Social and clinical correlates of stimulant use disorder (mephedrone) in a tertiary mental health setting in Mumbai: A pilot exploratory study. **2019**, 24, 36
- 386 Therapeutic and prophylactic role of cognitive enhancers in electroconvulsive therapy-induced cognitive deficits. **2019**, 28, 286-293
- 385 Schizophrenia. **2019**, 261-292
- 384 Image analysis of the tree test using wavelet transform, singular value decomposition, and Fourier transform. **2019**, 90, 284-293

- 383 Cognitive Enhancement in Schizophrenia and Related Disorders. **2019**, 1
- 382 Influencia del sexo en el tratamiento con olanzapina: una revisión sistemática. **2019**, 26, 45-51
- 381 [The concept of narrative insight in schizophrenia: A systematic review]. **2019**, 45, 256-262 1
- 380 Patients and Carers Perspectives of Psychopharmacological Interventions Targeting Anorexia Nervosa Symptoms. 3
- 379 Reduced Influence of Perceptual Context in Schizophrenia: Behavioral and Neurophysiological Evidence.
- 378 Randomized Controlled Trials and the Efficacy of Psychotropic Medications. **2020**, 1-56
- 377 Diagnostic Assessment of Schizophrenia. **2020**, 101-113
- 376 Severe Psychopathology. **2020**, 239-249 1
- 375 G protein gene variants in schizophrenia. **2020**, 47, 31-34
- 374 Predicting Early Warning Signs of Psychotic Relapse From Passive Sensing Data: An Approach Using Encoder-Decoder Neural Networks (Preprint).
- 373 Factor structure of the Albanian version of the Clinical Assessment Interview for Negative Symptoms (CAINS): Associations with the Brief Symptoms Inventory (BSI). **2020**,
- 372 Using data from schizophrenia outcome study to estimate the time to treatment outcome and the early-response cut-off score that predicts outcome at week 16. **2020**, 47, 65-70 1
- 371 Characterization and Prediction of Clinical Pathways of Vulnerability to Psychosis through Graph Signal Processing.
- 370 Genome-Wide Association Identifies the First Risk Loci for Psychosis in Alzheimer Disease. 1
- 369 Refining the Empirical Constraints on Computational Models of Spatial Working Memory in Schizophrenia. **2020**, 5, 913-922 1
- 368 Effectiveness of Psychoeducation on Expressed Emotion of Family Members and as Perceived by the Patient with Schizophrenia. **2021**, 23, 21-26
- 367 Neuromelanin accumulation in patients with schizophrenia: A systematic review and meta-analysis. **2021**, 132, 1205-1205 0
- 366 Associations of serum cortisol levels, stress perception, and stressful events with suicidal behaviors in patients with depressive disorders. **2022**, 297, 602-609 0

- 365 Response : Phenothiazine Dosage Levels and Auditory Signal Detection in Schizophrenia. **1973**, 179, 406-406
- 364 PLASMA CORTISOL CONCENTRATIONS IN THE FUNCTIONAL PSYCHOSES AND ALZHEIMER TYPE DEMENTIA: A NEUROENDOCRINE DAY APPROACH IN DRUG-FREE PATIENTS. **1983**, 247-250
- 363 References. **1983**, 244-254
- 362 Neuroleptika: Grundlagen und Therapie. **1983**, 203-300 1
- 361 DC-MMS: Diagnostic Checklist of Major Depression, Mania and Schizophrenia. **2020**, 34, 853-867
- 360 Attenuated Psychosis Syndrome. **2020**, 159-176
- 359 Time-course of the Positive and Negative Affect Schedule (PANAS) during an episode of psychosis: a pilot study. **2020**, 61, 316-323
- 358 Is There Evidence That Stimulus Parameters and Electrode Placement Affect the Cognitive Side Effects of Electroconvulsive Therapy in Patients With Schizophrenia and Schizoaffective Disorder?: A Systematic Review. **2021**, 37, 133-139 2
- 357 Global DNA methylation in suicidal ideation and suicide attempt in schizophrenia. **2021**, 31, 65-71 0
- 356 Correlates of poor medication adherence in chronic psychotic disorders. **2021**, 7, 1 1
- 355 Mental and Behavioral Disorders. **2022**,
- 354 Encyclopedia of Autism Spectrum Disorders. **2020**, 1-4
- 353 Outcome Measurement in Schizophrenia: Challenges and Barriers. **2020**, 91-124 0
- 352 Gender and Outcome in Schizophrenia. **2020**, 15-25
- 351 The Treatment of the Dually Diagnosed: Intellectual Disability and Severe Psychopathology. **2020**, 475-504
- 350 Study protocol for a pilot high-intensity interval training intervention in inpatient mental health settings: a two-part study using a randomised controlled trial and naturalistic study design. **2021**, 7, 198 0
- 349 Atypically larger variability of resource allocation accounts for visual working memory deficits in schizophrenia. **2021**, 17, e1009544 0
- 348 Revisiting Drug Compliance: The Need for a Holistic Approach in the Treatment of Severe Mental Disorders. **2021**, 2, 17-25 0

347	Intimate Partner Violence Among Patients Diagnosed With Severe Mental Disorder. <b>2020</b> , 208, 749-754	1
346	Cis(Z)-clopenthixol and clopenthixol in the treatment of acute psychoses and exacerbations of chronic psychoses. A double-blind clinical investigation. <b>1981</b> , 294, 13-24	7
345	The Most Commonly Used Instruments in Research on Functioning in Schizophrenia. <b>2020</b> , 25, 283-292	2
344	The effect of psychomotor therapy on mental health in in-patient schizophrenia treatment: A randomized, double-blind intervention study. <b>2020</b> , 50, 83-88	
343	Antipsychotic drugs in community-based sheltered-care homes. <b>1980</b> , 14A, 589-96	2
342	Morita therapy for schizophrenia: An updated meta-analysis. <b>2020</b> , 53, 102169	2
341	What Does It Mean? A New Scale for Rating Patients' Behavior. <b>1989</b> , 27, 25-28	
340	High frequency of psychosis in late-stage Parkinson's disease.. <b>2021</b> , 5, 100119	0
339	Digital phenotyping. <b>2022</b> , 207-222	0
338	Momentary Manifestations of Negative Symptoms as Predictors of Clinical Outcomes in People at High Risk for Psychosis: Experience Sampling Study (Preprint).	
337	Electroconvulsive therapy in Huntington's disease. <b>2021</b> , 25, 33-38	
336	Diogenes Syndrome: Identification and Distinction from Hoarding Disorder. <b>2021</b> , 2021, 2810137	
335	The Course of Psychiatric Symptoms During Remand Imprisonment. <b>2021</b> , 306624X211058956	0
334	The Switch From Paliperidone Long-Acting Injectable 1- to 3-Monthly: Clinical Pharmacokinetic Evaluation in Patients With Schizophrenia (Preliminary Data). <b>2021</b> , 42,	1
333	The clinical and functional outcomes of a large naturalistic cohort of young people accessing national early psychosis services. <b>2021</b> , 48674211061285	1
332	Characterizing the sensorimotor domain in schizophrenia spectrum disorders. <b>2021</b> , 1	2
331	Brief mindfulness-oriented interventions (MOIs) to improve psychiatric symptoms in a psychiatric inpatient unit: a randomized controlled feasibility trial. 1-10	0
330	A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers.. <b>2021</b> , 12, 760671	1

329	Poor Separation of Clinical Symptom Profiles by DSM-5 Disorder Criteria.. <b>2021</b> , 12, 775762	2
328	Momentary Manifestations of Negative Symptoms as Predictors of Clinical Outcomes in People at High Risk for Psychosis: Experience Sampling Study. <b>2021</b> , 8, e30309	1
327	Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial. <b>2021</b> ,	0
326	Prediction of Suicidality According to Serum Folate Levels in Depressive Patients Receiving Stepwise Pharmacotherapy.. <b>2021</b> , 12, 747228	0
325	Schizophrenia and Related Psychoses. 1-224	
324	Association Between Failures in Perceptual Updating and the Severity of Psychosis in Schizophrenia. <b>2021</b> ,	1
323	Embedded figures in schizophrenia: A main deficit but no specificity.. <b>2022</b> , 28, 100227	
322	Models of Longitudinal CFA. <b>2021</b> , 111-190	
321	Lurasidone switching in patients with schizophrenia who showed suboptimal effect and/or intolerability to current antipsychotics: A multi-center, open-label, single-arm, flexible dose study. <b>2021</b> , 35, 132	
320	Network Analysis-Based Disentanglement of the Symptom Heterogeneity in Asian Patients with Schizophrenia: Findings from the Research on Asian Psychotropic Prescription Patterns for Antipsychotics.. <b>2022</b> , 12,	0
319	Volume deficits in hippocampal subfields in unaffected relatives of schizophrenia patients with high genetic loading but without any psychiatric symptoms.. <b>2022</b> , 240, 125-131	0
318	Long-term care utilization within older adults with schizophrenia: Associated factors in a multicenter study.. <b>2021</b> , 308, 114339	2
317	Inflammatory Subtypes in Antipsychotic-Naïve First-Episode Schizophrenia are Associated with Altered Brain Morphology and Topological Organization. <b>2021</b> , 100, 297-297	3
316	Open Dialogue compared to treatment as usual for adults experiencing a mental health crisis: Protocol for the ODDESSI multi-site cluster randomised controlled trial.. <b>2021</b> , 113, 106664	3
315	Serum glial cell derived neurotrophic factor (GDNF) as a predictor of response to HD-tDCS in bipolar affective disorder.. <b>2021</b> , 68, 102965	1
314	Randomised, placebo-controlled trial on topiramate add-on therapy for weight reduction and symptomatology in overweight/obese persons with schizophrenia.. <b>2021</b> , 68, 102963	0
313	Four-modality imaging of unmedicated subjects with schizophrenia: F-fluorodeoxyglucose and F-fallypride PET, diffusion tensor imaging, and MRI.. <b>2021</b> , 320, 111428	1
312	Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression.. <b>2021</b> , 115, 110507	1

311	Aggressive and violent behavior in a population of psychiatric inpatients. <b>1997</b> , 32, 428-34	29
310	Census tract predictors and the social integration of sheltered care residents. <b>1976</b> , 11, 153-161	25
309	The Quality of Internet Websites for People Experiencing Psychosis: Pilot Expert Assessment.. <b>2022</b> , 6, e28135	1
308	Early Schizophrenia and Bipolar Disorder Patients Display Reduced Neural Prepulse Inhibition.. <b>2022</b> , 12,	0
307	The relationship between clinical recovery and personal recovery among people living with schizophrenia: A serial mediation model and the role of disability and quality of life.. <b>2021</b> , 239, 168-175	2
306	Feasibility Analysis of Phenotype Quantification from Unstructured Clinical Interactions. <b>2022</b> , 6, 1	
305	Home practice in mindfulness-based interventions for psychosis groups: a systematic review and qualitative study.. <b>2022</b> , 10, 9	0
304	European Validation of the Self-Evaluation of Negative Symptoms (SNS): A Large Multinational and Multicenter Study.. <b>2022</b> , 13, 826465	3
303	Appetitive aggression is associated with lateralized activation in nucleus accumbens. <b>2021</b> , 319, 111425	
302	An interventional pilot of customized adherence enhancement combined with long-acting injectable antipsychotic medication (CAE-L) for poorly adherent patients with chronic psychotic disorder in Tanzania.. <b>2022</b> , 22, 62	0
301	Sexual dysfunction in people treated with long-acting injectable antipsychotics in monotherapy or polypharmacy: a naturalistic study.. <b>2022</b> ,	1
300	The magnitude of neurocognitive impairment is overestimated in depression: the role of motivation, debilitating momentary influences, and the overreliance on mean differences.. <b>2022</b> , 1-11	1
299	Efficacy and cost-effectiveness of task-shared care for people with severe mental disorders in Ethiopia (TaSCS): a single-blind, randomised, controlled, phase 3 non-inferiority trial.. <b>2022</b> , 9, 59-71	2
298	The psychopathological impact of the SARS-CoV-2 epidemic on subjects suffering from different mental disorders: An observational retrospective study.. <b>2021</b> , 307, 114334	2
297	A six-session group-based pilot intervention for alcohol and other drug use in hospitalised mentally ill young offenders.. <b>2022</b> , 10398562211065289	
296	Baseline data of a sequential multiple assignment randomized trial (STEP study).. <b>2022</b> ,	
295	Risks of Antidepressant induced psychotic events in patients with depression and psychosis.	
294	Factors Associated with Personal Recovery among Psychiatric Nursing Home Residents.. <b>2021</b> ,	

- 293 Treatment of co-occurring obsessive-compulsive and psychotic symptoms: A systematic review. **2022**, 32, 100704 1
- 292 The Expanded Endocannabinoid System Contributes to Metabolic and Body Mass Shifts in First-Episode Schizophrenia: A 5-Year Follow-Up Study.. **2022**, 10, 0
- 291 Premature commitment to uncertain decisions during human NMDA receptor hypofunction.. **2022**, 13, 338 0
- 290 Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial.. **2022**, 376, e067194 6
- 289 Peer support for discharge from inpatient mental health care versus care as usual in England (ENRICH): a parallel, two-group, individually randomised controlled trial.. **2022**, 9, 125-136 2
- 288 Long-term Safety and Efficacy of Esketamine Nasal Spray Plus an Oral Antidepressant in Patients with Treatment-resistant Depression- an Asian Sub-group Analysis from the SUSTAIN-2 Study.. **2022**, 20, 70-86 0
- 287 Cognitive rehabilitation outcomes in patients with Multiple sclerosis: Preliminary data about the potential role of personality traits.. **2022**, 58, 103533 0
- 286 Insula volumes in first-episode and chronic psychosis: A longitudinal MRI study.. **2022**, 241, 14-23 0
- 285 Validation of Beck Cognitive Insight Scale - Arabic version in a Tunisian sample.. **2022**, 0
- 284 Reconceptualizing schizophrenia in the Hierarchical Taxonomy Of Psychopathology (HiTOP).. **2022**, 1 1
- 283 Reduced paraoxonase 1 activities may explain the comorbidities between temporal lobe epilepsy and depression, anxiety and psychosis. **2022**, 12, 317-332 0
- 282 A novel pathway phenotype of temporal lobe epilepsy and comorbid psychiatric disorders: results of precision nomothetic medicine. 1 1
- 281 Assessment tools for screening and clinical evaluation of psychosocial aspects in addictive disorders. **2018**, 60, 444 1
- 280 Predicting Psychotic Relapse in Schizophrenia With Mobile Sensor Data: Routine Cluster Analysis.. **2022**, 10, e31006 0
- 279 Defining negative symptoms remission in schizophrenia using the Brief Negative Symptom Scale.. **2022**, 15, 3-13 0
- 278 Origin and Development of the Assessment of Clinician Subjective Experience (ACSE). **2022**, 95-114 0
- 277 Assessment of psychiatric disorders in consultation-liaison setting. **2022**, 64, 211 0
- 276 Prevalence and correlates of negative disposition to marital homogamy among a sample of psychiatric outpatients in Nigeria. **2022**, 36, 12 0



275	Prevalence of sexual dysfunction in women with schizophrenia: A prospective study. <b>2022,</b>	
274	Management of psychiatric disorders during the perinatal period. <b>2022, 64, 414</b>	1
273	Pharmacogenomics and antipsychotics: efficacy and adverse drug reactions. <b>2022, 161-188</b>	0
272	A pilot choral intervention in individuals with schizophrenia-spectrum conditions; Singing away loneliness.. <b>2022,</b>	0
271	Dissociative Model in Patients With Resistant Schizophrenia.. <b>2022, 13, 845493</b>	2
270	Safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease-Results of a multicenter open trial.. <b>2022,</b>	1
269	Reduced paraoxonase 1 activities may explain the comorbidities between temporal lobe epilepsy and depression, anxiety and psychosis.. <b>2022, 12, 308-322</b>	2
268	The Prediction and Influential Factors of Violence in Male Schizophrenia Patients With Machine Learning Algorithms.. <b>2022, 13, 799899</b>	0
267	Trajectories of response in schizophrenia-spectrum disorders: A one-year prospective cohort study of antipsychotic effectiveness.. <b>2022, 12, 521-532</b>	0
266	Deep learning model using retinal vascular images for classifying schizophrenia.. <b>2022, 241, 238-243</b>	1
265	High-risk sexual behaviours in young people experiencing a first episode of psychosis.. <b>2022,</b>	0
264	Machine learning based prediction and the influence of complement - coagulation pathway proteins on clinical outcome: results from the NEURAPRO trial.. <b>2022,</b>	
263	Psychological Interventions for Young People With Psychotic Disorders: A Systematic Review.. <b>2022, 13, 859042</b>	1
262	Anger rumination and imagined violence as related to violent behavior before and after psychiatric hospitalization.. <b>2022,</b>	
261	Clinical and Computational Speech Measures are Associated with Social Cognition in Schizophrenia Spectrum Disorders.	
260	Who Does What to Whom? Graph Representations of Action-Predication in Speech Relate to Psychopathological Dimensions of Psychosis.	0
259	The Impact of Mental Health Intensive Case Management on Functioning and Clinical Outcomes of Older Black and White Veterans With Serious Mental Illness.. <b>2022,</b>	0
258	Different patterns of white matter microstructural alterations between psychotic and non-psychotic bipolar disorder.. <b>2022, 17, e0265671</b>	

- 257 Early Markers in Resistant Schizophrenia: Effect of the First Antipsychotic Drug.. **2022**, 12, 0
- 256 Research on interpersonal violence in schizophrenia: based on different victim types.. **2022**, 22, 172
- 255 Endogenous oxytocin levels are associated with facial emotion recognition accuracy but not gaze behavior in individuals with schizophrenia.. **2022**, 1
- 254 [Characteristics of psychoses in adolescence-Longitudinal data of integrated care].. **2022**, 93, 331 1
- 253 Emotion regulation and social knowledge in youth at clinical high-risk for psychosis and outpatients with chronic schizophrenia: Associations with functional outcome and negative symptoms.. **2022**, 0
- 252 Adjunctive tDCS for treatment-refractory auditory hallucinations in schizophrenia: A meta-analysis of randomized, double-blinded, sham-controlled studies.. **2022**, 73, 103100 1
- 251 A case report of clozapine-treatment-resistant schizophrenia successfully managed with brexpiprazole combination therapy.. **2022**, 72, 103121 2
- 250 Movement markers of schizophrenia: a detailed analysis of patients' gait patterns.. **2022**, 1 0
- 249 The relationship between psychological characteristics of patients and their utilization of psychiatric inpatient treatment: A cross-sectional study, using machine learning.. **2022**, 17, e0266352
- 248 Metabolic Disturbances, Hemoglobin A1c, and Social Cognition Impairment in Schizophrenia Spectrum Disorders.
- 247 Thinking biases and their role in persecutory delusions: A systematic review.. **2022**,
- 246 Anti-aggressive effects of clozapine in involuntarily committed black patients with severe mental illness.. **2022**, 243, 163-169 0
- 245 Is there an association between inflammatory/anti-oxidant markers and the presence of psychotic symptoms or severity of illness in mood and psychotic disorders? A multi-centric study on a drug-free sample.. **2022**, 22, 100453 1
- 244 Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT).. **2021**, 3
- 243 Relationship Between Gender and Clinician's Subjective Experience during the Interaction with Psychiatric Patients.. **2021**, 17, 190-197
- 242 Efficacy of Cognitive Behavioral Therapy on Mood Disorders, Sleep, Fatigue, and Quality of Life in Parkinson's Disease: A Systematic Review and Meta-Analysis.. **2021**, 12, 793804 2
- 241 Mental Health Signs Relevant for an Assessment Tool Suitable for Student and Novice Nurses: A Document Analysis.. **2021**, 1-12 1
- 240 Investigating the Relationships of P3b with Negative Symptoms and Neurocognition in Subjects with Chronic Schizophrenia.. **2021**, 11, 2

239 Schizophrenia Patients Show Largely Similar Salience Signaling Compared to Healthy Controls in an Observational Task Environment.. **2021**, 11,

238 Separate Roles for State and Trait Anxiety in the Formation of SHU Syndrome: Testing a Moderated Mediation Hypothesis. **2022**, 102, 25-46 1

237 Correlation between Post-Acute Electroconvulsive Therapy Alpha-Band Spectrum Power Increase and Improvement of Psychiatric Symptoms.. **2021**, 11,

236 Predicting Non-Adherence With Very Low Nicotine Content Cigarettes Among Adults With Serious Mental Illness Who Smoke.. **2021**, 1

235 Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. **1999**, 156, 1336-41 233

234 Comparative Analysis of Lateral Preferences in Patients With Resistant Schizophrenia.. **2022**, 13, 868285 0

233 Scalability of the Positive and Negative Syndrome Scale in first-episode schizophrenia assessed by Rasch models.. **2022**, 0

232 Association of VEGF-A and KDR polymorphisms with the development of schizophrenia.. **2022**, 0

231 A Novel Pathway Phenotype of Temporal Lobe Epilepsy and Comorbid Psychiatric Disorders: Results of Precision Nomothetic Medicine. **2022**, 11, 803 0

230 Table\_1.DOCX. **2018**,

229 Table\_2.DOCX. **2018**,

228 Table\_3.DOCX. **2018**,

227 Table\_4.DOCX. **2018**,

226 Table\_5.DOCX. **2018**,

225 Table\_6.DOCX. **2018**,

224 Table\_7.DOCX. **2018**,

223 Table\_8.DOCX. **2018**,

222 Table\_9.DOCX. **2018**,

221	Table_1.doc. <b>2019</b> ,	
220	Data_Sheet_1.docx. <b>2020</b> ,	
219	DataSheet_1.pdf. <b>2020</b> ,	
218	DataSheet_1.xlsx. <b>2020</b> ,	
217	Interaction effect between childhood abuse and interleukin-1 $\beta$ levels on suicidality in depressed patients.. <b>2022</b> , 1	
216	Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response. <b>1999</b> , 156, 294-8	114
215	Multiple anxiety disorder comorbidity in patients with mood spectrum disorders with psychotic features. <b>1999</b> , 156, 474-6	62
214	Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. <b>1999</b> , 156, 610-6	99
213	Relationship of awareness of dyskinesia in schizophrenia to insight into mental illness. <b>1999</b> , 156, 1097-9	28
212	Prediction of neuropsychological performance by neurological signs in schizophrenia. <b>1999</b> , 156, 1349-57	71
211	Relationship between quality of life and clinical factors in inpatients with schizophrenia.. <b>2022</b> , 69, 80-85	
210	Increased psychomotor retardation and tension as short-term neuropsychiatric adverse events of immune checkpoint inhibitors: A prospective cohort study.. <b>2022</b> , 18, 140-146	
209	The Neutrophil-Lymphocyte Ratio Is Positively Correlated with Aggression in Schizophrenia.. <b>2022</b> , 2022, 4040974	2
208	Cognitive behavioural therapy plus standard care for first episode psychosis. <b>2022</b> , 2022,	
207	Deinstitutionalization from the perspective of community-dwelling adults with a severe mental illness in Amsterdam: a cohort study protocol.. <b>2022</b> , 22, 950	
206	Treatment of post-psychotic depression in first-episode psychosis. A systematic review.. <b>2022</b> , 1-9	
205	In schizophrenia, the effects of the IL-6/IL-23/Th17 axis on health-related quality of life and disabilities are partly mediated by generalized cognitive decline and the symptomatome.	0
204	Reappraising the variability of effects of antipsychotic medication in schizophrenia: a meta-analysis.. <b>2022</b> , 21, 287-294	0

203	Migration, Schizophrenia, and Crime: A Study From a Forensic Psychiatric Sample. <b>2022</b> , 13,	
202	The Arizona Sexual Experiences Scale-the Thai Translation (ASEX-Thai): Reliability and validity in Thai patients with mental disorders. 11, 503	
201	Prevalence of mental disorders in defendants at criminal court.. <b>2022</b> , 8, e92	1
200	Multiple serum biomarkers for predicting suicidal behaviours in depressive patients receiving pharmacotherapy.. <b>2022</b> , 1-10	0
199	A Pilot Remote Drama Therapy Program Using the Co-active Therapeutic Theater Model with People with Serious Mental Illness.. <b>2022</b> ,	1
198	Crisis-focused psychosocial interventions for borderline personality disorder: systematic review and narrative synthesis.. <b>2022</b> , 8, e94	1
197	Efficacy and Safety of Repeated Subcutaneous Ketamine Injections for Treatment Resistant Depression - The KADS Study: A Randomised, Double-Blind, Comparator-Controlled Trial.	
196	Advances in neuroRehabilitation of TREM2-related dementia. <b>2022</b> , 101, e29470	
195	NKCC1 to KCC2 mRNA Ratio in Schizophrenia and Its Psychopathology: a CaseControl Study.	
194	Utility and Validity of the Brief Psychiatric Rating Scale (BPRS) as a Transdiagnostic Scale. <b>2022</b> , 114659	0
193	Structural alterations of amygdala and hypothalamus contribute to catatonia. <b>2022</b> ,	0
192	The negative symptoms of schizophrenia: lessons from a precision nomothetic psychiatry approach.	
191	Theories and models of negative symptoms in schizophrenia and clinical implications.	1
190	Reduced contrast surround suppression associated with schizophrenia depends on visual acuity and scene context.	
189	Shared Transdiagnostic Neuroanatomical Signatures Across First-episode Patients with Major Psychiatric Diseases and Individuals at Familial Risk. <b>2022</b> , 103074	0
188	The pharmacotherapeutic management of comorbid bipolar disorder and alcohol use disorder. 1-13	
187	Prognostic accuracy and clinical utility of psychometric instruments for individuals at clinical high-risk of psychosis: a systematic review and meta-analysis.	0
186	Pretty patient - healthy patient? A study of physical attractiveness and psychopathology. <b>1977</b> , 33, 990-994	3

- 185 Metabolic disturbances, hemoglobin A1c, and social cognition impairment in Schizophrenia spectrum disorders. **2022**, 12,
- 184 Psychiatric and psychosocial rehabilitation path in a 44-year-old man with bipolar disorder and cluster B personality dysfunctional traits. **2022**, 63,
- 183 Sex differences in fronto-limbic white matter tracts in youth with mood disorders. 1
- 182 Immune-mediated inflammatory markers in acute and transient psychotic disorders—comparison with schizophrenia: An exploratory comparative study.
- 181 Detection of major depressive disorder, bipolar disorder, schizophrenia and generalized anxiety disorder using vocal acoustic analysis and machine learning: an exploratory study. 0
- 180 Evaluation of antipsychotic medication adherence and its relation to negative and positive psychiatric symptoms.
- 179 Psychiatric symptoms and mortality in older adults with major psychiatric disorders: results from a multicenter study.
- 178 Disrupted leptin-fatty acid biosynthesis is an early manifestation of metabolic abnormalities in schizophrenia. **2022**, 12, 827-842 0
- 177 Psychoeducation for the parents of people with severe mental illness. **2022**, 2022,
- 176 Quality of life after involuntary psychiatric admission. **2022**, 83, 101810
- 175 Historical Perspectives on the History of Measurement in Psychiatry. **2022**, 1-20
- 174 Using mHealth to improve adherence and reduce blood pressure in individuals with hypertension and bipolar disorder (iTAB-CV): study protocol for a 2-stage randomized clinical trial. **2022**, 23, 1
- 173 Metacognitive mastery moderates the relationship between positive symptoms and distress in adults with serious mental illness. 1-8
- 172 Who does what to whom? graph representations of action-predication in speech relate to psychopathological dimensions of psychosis. **2022**, 8, 0
- 171 The clinical relevance of serum versus CSF NMDAR autoantibodies associated exclusively with psychiatric features: a systematic review and meta-analysis of individual patient data. 0
- 170 Gender Differences in the Psychopharmacological Treatment of Forensic In-Patients With Schizophrenia. 13,
- 169 Demographic and clinical characteristics of lithium-treated older adults with bipolar disorder. 0
- 168 A Randomized Control Trial of Cognitive Compensatory Training (CCT) and Computerized Interactive Remediation of Cognition-Training for Schizophrenia (CIRCuiTS). 13,

- 167 Is clinical insight a determinant factor of subjective recovery in persons living with schizophrenia or schizoaffective disorders?. **2022**, 114726
- 166 Clinical and computational speech measures are associated with social cognition in schizophrenia spectrum disorders. **2022**, ○
- 165 Cluster analysis of negative symptoms identifies distinct negative symptom subgroups. **2022**, 246, 207-215 ○
- 164 Cognitive behavioural therapy without medication for schizophrenia. **2022**, 2022,
- 163 Cognitive behavioural therapy (group) for schizophrenia. **2022**, 2022, 1
- 162 Play Badminton Forever: A Systematic Review of Health Benefits. **2022**, 19, 9077 2
- 161 Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms. **2022**, 2022,
- 160 Intramuscular ketamine vs. escitalopram and aripiprazole in acute and maintenance treatment of patients with treatment-resistant depression: A randomized double-blind clinical trial. 13,
- 159 The Reliability of symptom assessment by telepsychiatry compared with Face to Face Psychiatric Interviews. **2022**, 114728
- 158 Risk of Developing Non-Cancerous Central Nervous System Diseases Due to Ionizing Radiation Exposure during Adulthood: Systematic Review and Meta-Analyses. **2022**, 12, 984 1
- 157 Aberrant brain dynamics in major depressive disorder with suicidal ideation. **2022**, 314, 263-270 ○
- 156 Implicit cognitive effort monitoring impairments are associated with expressive negative symptoms in schizophrenia. **2022**, 248, 14-20
- 155 The aggressive tendencies in HIV-positive persons with concomitant mental disorders. **2022**, 56, 67-77
- 154 Aripiprazole vs risperidone head-to-head effectiveness in first-episode-non- affective-psychosis: A 3-month randomized, flexible-dose, open-label clinical trial.
- 153 Disentangling dyskinesia from parkinsonism in motor structures of patients with schizophrenia. **2022**, 4, ○
- 152 The more things change? Stability of delusional themes across 12 years of presentations to an early intervention service for psychosis. ○
- 151 Factor structure and item response of psychosis symptoms among Kenyan adults. **2022**,
- 150 The relationship between cognitive clusters and telomere length in bipolar-schizophrenia spectrum disorders. 1-8 ○

- 149 A randomized controlled trial of customized adherence enhancement (CAE-E): study protocol for a hybrid effectiveness-implementation project. **2022**, 23,
- 148 In Schizophrenia, Chronic Fatigue Syndrome- and Fibromyalgia-Like Symptoms are Driven by Breakdown of the Paracellular Pathway with Increased Zonulin and Immune Activation-Associated Neurotoxicity.. **2022**, 21, 1
- 147 Clinical efficacy and neurobiological correlates of electroconvulsive therapy in patients with clozapine-resistant/intolerant schizophrenia: study protocol of multi-site parallel arm double-blind randomized sham-controlled study. 7, 212
- 146 Behavioural family interventions versus structural family interventions for people with schizophrenia. **2022**, 2022,
- 145 Integrity of cerebellar tracts associated with the risk of bipolar disorder. **2022**, 12,
- 144 Gender-associated role in patients with schizophrenia. Is there a connection with the resistance?. 13, 0
- 143 Complementary and integrative medicines for behavioral and psychological symptoms of dementia: Overview of systematic reviews. **2022**, 0
- 142 Metabolic monitoring of the patients with serious mental illness (SMI) in a community mental health center (CMHC) during the COVID-19 pandemic. **2022**, 13,
- 141 Methodological Considerations in Evaluating Antianxiety Drugs. **1970**, 10, 12-18 0
- 140 Blunted pupil light reflex is associated with negative symptoms and working memory in individuals with schizophrenia. **2022**, 248, 254-262 0
- 139 The flickering spotlight of visual attention: Characterizing abnormal object-based attention in schizophrenia. **2022**, 248, 151-157 0
- 138 El consumo de cannabis como factor desencadenante de primeros episodios psicóticos. **2022**, 48, 101823 0
- 137 Embodiment of emotion in schizophrenia in the context of culture. **2022**, 2, 100072 0
- 136 Long-acting paliperidone in Ekbom's syndrome in Lewy body dementia: A case report. **2022**, 13, 201-210 0
- 135 Measuring Psychotropic Drug Effects and Side Effects. **2022**, 505-533 0
- 134 Non-SARS Coronaviruses in Individuals with Psychiatric Disorders. **2022**, 0
- 133 A Case of Poststroke Psychosis in a Patient With Moyamoya Disease. **2022**, 61, 237 0
- 132 Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies. **2022**, 65, 0



131	Effects of missed dose and delayed dose quetiapine on its pharmacokinetics and pharmacodynamics. <b>2022,</b>	0
130	Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia. <b>2022, 2022,</b>	1
129	Patterns of antipsychotic prescription and accelerometer-based physical activity levels in people with schizophrenia spectrum disorders: a multicenter, prospective study. Publish Ahead of Print,	0
128	Factors associated with medication non-adherence among patients with severe mental disorder - A cross sectional study in a tertiary care centre. <b>2022, 7, 100178</b>	0
127	Health-related quality of life in severe psychotic disorders during integrated care: 5-year course, prediction and treatment implications (ACCESS II). <b>2022, 20,</b>	0
126	Autobiographical memory impairment in chronic schizophrenia: Significance and clinical correlates.	0
125	Effects of adjunctive brexpiprazole on sleep-wake and circadian parameters in youth with depressive disorders: study protocol for a clinical trial. <b>2022, 12, e056298</b>	0
124	Building a neurocognitive profile of suicidal risk in severe mental disorders. <b>2022, 22,</b>	1
123	The impact of familial involvement on dropout in a culturally informed group therapy for people diagnosed with 'Schizophrenia'1-13	0
122	Positive and negative syndrome scale in forensic patients with schizophrenia spectrum disorders: a systematic review and meta-analysis. <b>2022, 21,</b>	1
121	Effects of omega-3 polyunsaturated fatty acid supplementation on cognitive functioning in youth at ultra-high risk for psychosis: secondary analysis of the NEURAPRO randomised controlled trial. <b>2022, 8,</b>	0
120	Emergence of Language Related to Self-experience and Agency in Autobiographical Narratives of Individuals With Schizophrenia.	0
119	Nabilone Impairs Spatial and Verbal Working Memory in Healthy Volunteers.	0
118	Clinical efficacy and neurobiological correlates of electroconvulsive therapy in patients with clozapine-resistant/intolerant schizophrenia: study protocol of multi-site parallel arm double-blind randomized sham-controlled study. <b>7, 212</b>	0
117	The Arizona Sexual Experiences Scale-the Thai Translation (ASEX-Thai): Reliability and validity in Thai patients with mental disorders. <b>11, 503</b>	0
116	Pharmacological interventions for prevention of weight gain in people with schizophrenia. <b>2022, 2022,</b>	0
115	Trial protocol of an open label pilot study of lisdexamfetamine for the treatment of acute methamphetamine withdrawal. <b>2022, 17, e0275371</b>	0
114	Hearing voices in the head: Two meta-analyses on structural correlates of auditory hallucinations in schizophrenia. <b>2022, 36, 103241</b>	0

- 113 Schizophrenia Spectrum and Other Psychotic Disorders: Third Wave Case Conceptualization. **2022**, 505-524 ○
- 112 Creating Value: Resource and Quality Management. **2022**, 737-751 ○
- 111 Electroconvulsive Therapy Practice in Thailand: A Nationwide Survey. Volume 18, 2477-2484 ○
- 110 A Marked Low-Grade Inflammation and a Significant Deterioration in Metabolic Status in First-Episode Schizophrenia: A Five-Year Follow-Up Study. **2022**, 12, 983 ○
- 109 A five-year follow-up of the verbal memory performance of individuals with bipolar disorder and schizophrenia: evidence of unchanging deficits under treatment. 1-17 ○
- 108 Dorsal striatal hypoconnectivity predicts antipsychotic medication treatment response in first-episode psychosis and unmedicated patients with schizophrenia. ○
- 107 Prediction of 12-Week Remission by Psychopharmacological Treatment Step in Patients With Depressive Disorders. **2022**, 19, 866-871 ○
- 106 Predictors of anxiety in Parkinson's disease: results from a 3-year longitudinal cohort study. ○
- 105 Increased lipid peroxidation and lowered antioxidant defenses predict methamphetamine induced psychosis. ○
- 104 The Effect of Agomelatine in Behavioral and Psychological Symptoms of Dementia. **2022**, 20, 701-714 ○
- 103 Randomized Controlled Trials and the Efficacy of Psychotropic Medications. **2022**, 305-359 ○
- 102 A single-blind, randomised controlled trial of a physical health nurse intervention to prevent weight gain and metabolic complications in first-episode psychosis: the Physical Health Assistance in Early Psychosis (PHAsTER) study. **2022**, 8, ○
- 101 Pharmacological interventions for people with borderline personality disorder. **2022**, 2022, 1
- 100 Mediators of quality of life change in people with severe psychotic disorders treated in integrated care (ACCESS II study). 1-24 ○
- 99 Heterogeneity of quality of life in the later stages of first-episode psychosis recovery. ○
- 98 Heterogeneity of quality of life in the later stages of first-episode psychosis recovery. ○
- 97 Major neurocognitive psychosis: a novel schizophrenia endophenotype class that is based on machine learning and resembles Kraepelin's and Bleuler's conceptions. 1-47 ○
- 96 Cannabidiol for people with schizophrenia. **2022**, 2022, ○

95	Abnormal resting-state functional connectome in methamphetamine-dependent patients and its application in machine-learning-based classification. 16,	0
94	Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot feasibility and safety trial. <b>2022</b> , 241, 109692	0
93	Lurasidone in adolescents and adults with schizophrenia: from clinical trials to real-world clinical practice. <b>2022</b> , 23, 1801-1818	0
92	Treatment of schizophrenia with catatonic symptoms: A narrative review. <b>2022</b> ,	0
91	The prognosis of schizophrenia: A systematic review and meta-analysis with meta-regression of 20-year follow-up studies. <b>2022</b> , 250, 152-163	0
90	Mental and Behavioral Disorders. <b>2023</b> ,	0
89	Cross-sectional and longitudinal assessment of the association between DDR1 variants and processing speed in patients with early psychosis and healthy controls. <b>2023</b> , 158, 49-55	0
88	THE CULTURAL ADAPTATION, RELIABILITY AND VALIDITY OF THE TURKISH VERSION OF THE SIMPLE PHYSICAL ACTIVITY QUESTIONNAIRE IN COMMON MENTAL DISORDERS.	0
87	In Schizophrenia, the Effects of the IL-6/IL-23/Th17 Axis on Health-Related Quality of Life and Disabilities Are Partly Mediated by Generalized Cognitive Decline and the Symptomatome. <b>2022</b> , 19, 15281	0
86	The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial. <b>2022</b> , 22,	0
85	Antipsychotic dose reduction compared to dose continuation for people with schizophrenia. <b>2022</b> , 2022,	0
84	Comparing the functional neuroanatomy of proactive and reactive control between patients with schizophrenia and healthy controls.	0
83	Increased Lipid Peroxidation and Lowered Antioxidant Defenses Predict Methamphetamine Induced Psychosis. <b>2022</b> , 11, 3694	0
82	Increased blood neutrophil extracellular traps (NETs) associated with early life stress: translational findings in recent-onset schizophrenia and rodent model. <b>2022</b> , 12,	0
81	Schizophrenie. <b>2023</b> , 9-57	0
80	Effectiveness and safety of Baduanjin for schizophrenia: A protocol for systematic review and meta-analysis. <b>2022</b> , 101, e32007	0
79	Suicide Risk in Post-COVID-19 Syndrome. <b>2022</b> , 12, 2019	1
78	Pimozide in Chronic Schizophrenic Patients. <b>1971</b> , 11, 304-309	1

- 77 Predictors of engagement with peer support: analysis of data from a randomised controlled trial of one-to-one peer support for discharge from inpatient psychiatric care. 002076402211480 ○
- 76 Placebo versus no treatment for people with schizophrenia. **2023**, 2023, ○
- 75 A randomized pilot study of the prophylactic effect of ketamine on laboratory-induced stress in healthy adults. **2023**, 22, 100505 1
- 74 Acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans: A TD-fNIRS neuroimaging study. ○
- 73 Hope and resilience among patients affected by unipolar and bipolar depression. 002076402211471 ○
- 72 The mediating role of alexithymia in the relationship between affective temperament and craving: Cross-sectional study conducted in a sample of bipolar and alcohol use disorder patients. **2023**, 325, 110-118 ○
- 71 Validation of the Bipolar Prodrome Symptom Interview and Scale-Abbreviated Prospective (BPSS-AP) in a clinical sample and healthy controls. **2023**, 324, 463-468 ○
- 70 Clinical Psychiatry in the Nursing Home. **2022**, ○
- 69 A Data-Driven Approach for the Analysis of Behavioral Disorders With a Focus on Classification and Severity Estimation. **2022**, ○
- 68 Mediating effect of genome-wide DNA methylation on suicidal ideation induced by stressful events. **2023**, 33, 26-33 ○
- 67 Onset of Action of Selected Second-Generation Antipsychotics (Pines)A Systematic Review and Meta-Analyses. **2023**, 11, 82 ○
- 66 Comparison of Psychiatric and Clinical Profiles Between People Who Use Synthetic Cathinones and Methamphetamine. Publish Ahead of Print, ○
- 65 Safety and Tolerability of the Acute Ketamine Treatment in Treatment-Resistant Depression: Focus on Comorbidities Interplay with Dissociation and Psychomimetic Symptoms. **2023**, 16, 173 ○
- 64 Sexuality and Quality of Life in Eastern Taiwan People With Schizophrenia. **2023**, 20, 1-8 ○
- 63 Ribosomal DNA gene copies are increased in blood and brain of Japanese schizophrenia patients. **2023**, 18, e0280694 ○
- 62 Serum cortisol and insulin-like growth factor 1 levels in major depressive disorder and schizophrenia. **2023**, 13, ○
- 61 Behavioural activation for depressive symptoms in young people with emerging or early psychosis: A pilot study protocol. **2023**, 18, e0280559 ○
- 60 Psychometric properties of measures designed to assess common mental health problems and wellbeing in adults with intellectual disabilities: a systematic review. **2023**, 67, 397-414 ○

- 59 Is there Any Relevance for the Use of Cyamemazine in the Treatment of Schizophrenia?. **2023**, 17, 14-19 ○
- 58 Obsessive-compulsive symptoms in patient with schizophrenia: The influence of disorganized symptoms, duration of schizophrenia, and drug resistance. 14, ○
- 57 Validation of the Social Effort and Conscientious Scale (SEACS) in Schizophrenia. ○
- 56 Gender impact on the outcome of rehabilitation programs in psychiatry: Brief report from a metropolitan residential rehabilitative service. 14, ○
- 55 Shared and distinct abnormalities in sleep-wake patterns and their relationship with the negative symptoms of Schizophrenia Spectrum Disorder patients. ○
- 54 Emotion regulation relates to clinical characteristics and quality of life but not daily functioning in psychosis spectrum outpatients. **2023**, 161, 289-297 ○
- 53 ETSNet: A deep neural network for EEG-based temporal-spatial pattern recognition in psychiatric disorder and emotional distress classification. **2023**, 158, 106857 ○
- 52 Structural connectivity of an interoception network in schizophrenia. **2023**, 331, 111636 ○
- 51 Discrimination of auditory verbal hallucination in schizophrenia based on EEG brain networks. **2023**, 331, 111632 ○
- 50 Eveningness chronotype and depressive affective temperament associated with higher high-sensitivity C-reactive protein in unipolar and bipolar depression. **2023**, 332, 210-220 ○
- 49 Pentylentetrazol in the Treatment of Geriatric Patients with Disturbed Memory Function. **1971**, 11, 301-303 ○
- 48 A Double-Blind Comparison of Molindone and Trifluoperazine in the Treatment of Acute Schizophrenia. **1971**, 11, 227-236 ○
- 47 Troxonium Tosylate in Drug-Induced Parkinsonism: a Controlled Comparative Study. **1971**, 11, 367-370 ○
- 46 A Clinical Trial of an Antiserotonin Compound, Cinanserin, in Chronic Schizophrenia. **1971**, 11, 220-226 ○
- 45 The Antidepressant Properties of IN 1060: A Preliminary Report. **1966**, 6, 278-283 ○
- 44 Factor Analysis of Outpatient Clinical Data. **1969**, 9, 195-199 ○
- 43 Early Clinical Trials in Clinical Psychopharmacology: Basic Clinical Controls. **1966**, 6, 133-136 1
- 42 Controlled Comparison of SK&F 14336 and Chlorpromazine in Newly Admitted Schizophrenics. **1969**, 9, 328-338 ○

- 41 Two Pilot Studies of AHR-1680 in Chronic Schizophrenic Patients. **1969**, 9, 183-186 ○
- 40 Mesoridazine (TPS-23), A New Antipsychotic Drug. **1966**, 6, 182-188 1
- 39 A New Rating Scale for Evaluating Clinical Response in Psychoneurotic Outpatients. **1969**, 9, 187-194 ○
- 38 A Comparison of Mesoridazine and Chlorpromazine in Chronic Psychiatric Patients. **1969**, 9, 176-182 ○
- 37 First episode psychosis during the Covid-19 pandemic in Milan, Italy: Diagnostic outcomes at 1-year follow-up. **2023**, 321, 115068 ○
- 36 Psychoses after an antiepileptic drug administration: Frequency, timing, and duration. **2023**, 140, 109087 ○
- 35 Relation of ATPase6 Mutations and Telomere Length in Schizophrenia Patients. **2023**, 21, 162-170 ○
- 34 Weakened untuned gain control is associated with schizophrenia while atypical orientation-tuned suppression depends on visual acuity. **2023**, 23, 2 ○
- 33 Time perspective affects daily time use and daily functioning in individuals with Schizophrenia Spectrum Disorders: Results from the multicentric DiAPAson study. **2023**, 160, 93-100 ○
- 32 Tic Reduction Following Heat-Induced Dehydration in Gilles de la Tourette Syndrome (TS). ○
- 31 A computational neuroimaging study of reinforcement learning and goal-directed exploration in schizophrenia spectrum disorders. 1-11 ○
- 30 Hippocampal Hyperconnectivity to the Visual Cortex Predicts Treatment Response. ○
- 29 Associations Between Cognitive and Physical EffortBased Decision Making in People With Schizophrenia and Healthy Control Subjects. **2023**, ○
- 28 Faster bi-stable visual switching in psychosis. ○
- 27 Dexamphetamine influences funneling illusion based on psychometric score. **2023**, 38, ○
- 26 Aripiprazole versus brexpiprazole for people with schizophrenia. **2023**, 2023, ○
- 25 Double-blind, randomised placebo-controlled clinical trial of metformin as an adjunct to a sleepwake, activity and metabolically focused behavioural intervention to improve cardiometabolic outcomes and mood symptoms in youth with major mood syndromes: study protocol. **2023**, 13, e064682 ○
- 24 Efficacy of clozapine compared with other second-generation antipsychotic drugs in patients with treatment-resistant schizophrenia: protocol for a systematic review and individual patient data meta-analysis of randomised controlled trials. **2023**, 13, e064504 ○

- 23 **μ**Opioid Receptor Plasma Levels Are Associated With Sex and Diagnosis of Major Depressive Disorder But Not Response to Ketamine. **2023**, 43, 89-96 ○
- 22 A controlled open clinical trial of the positive effect of a physical intervention on quality of life in schizophrenia. 14, ○
- 21 Successful high dose antipsychotic treatment with cariprazine in patients on the schizophrenia spectrum: Real-world evidence from a Spanish hospital setting. 14, ○
- 20 Perimenopausal Effects of Estradiol on Anhedonia and Psychosis Study (PEEPs): study protocol for a neural and molecular mechanistic clinical trial. **2023**, 24, ○
- 19 Evaluating STC-1 and STC-2 mRNA expressions in Schizophrenia patients with increased oxidative stress. **2023**, ○
- 18 Multivariate Associations Among White Matter, Neurocognition, and Social Cognition Across Individuals With Schizophrenia Spectrum Disorders and Healthy Controls. ○
- 17 Symptoms and functioning: a content analysis of the PANSS under the ICF framework. 1-8 ○
- 16 Uric acid is negatively associated with cognition in the first- episode of schizophrenia. **2023**, ○
- 15 Impact of lithium on mortality among older adults with major psychiatric disorders: A 5-year prospective multicenter study. 1-10 ○
- 14 Meta-cognitive training for schizophrenia. **2023**, 2023, ○
- 13 Feasibility of an Open Dialogue-Inspired Approach for Young Adults with Psychosis in a Public Hospital System. ○
- 12 Effects of cognitive stimulus therapy on middle-aged and elderly institutionalized patients with chronic schizophrenia with declined cognition. **2023**, ○
- 11 Long-Term Outcome of Clozapine in Treatment-Resistant Schizophrenia. Publish Ahead of Print, ○
- 10 Qualitatively different delay-dependent working memory distortions in people with schizophrenia and healthy control subjects. ○
- 9 Needs for care of residents with schizophrenia spectrum disorders and association with daily activities and mood monitored with experience sampling method: the DIAPASON study. **2023**, 32, ○
- 8 A Comparative Double-blind Trial of Fluspirilene and Fluphenazine Decanoate in the Treatment of Chronic Schizophrenia. **1973**, 27, 377-380 ○
- 7 Post-incident debriefing for people with schizophrenia after coercive measures. **2023**, 2023, ○
- 6 An open-label study of oral acetazolamide for the prevention of antipsychotic associated weight gain. **2023**, 32, 150 ○

- 5 Dissociation of Cognitive Effort-Based Decision Making and its Associations with Symptoms, Cognition, and Everyday Life Function Across Schizophrenia, Bipolar Disorder, and Depression. **2023**, ○
- 4 Difference between Ultra-High Risk of Psychosis and Above-Threshold Psychosis: A Natural Language Processing Analysis (Preprint). ○
- 3 Evidence of Neurovascular Water Exchange and Endothelial Vascular Dysfunction in Schizophrenia: An Exploratory Study. ○
- 2 Mixed Depression in the Post-COVID-19 Syndrome: Correlation between Excitatory Symptoms in Depression and Physical Burden after COVID-19. **2023**, 13, 688 ○
- 1 Predictors of cognitive changes in patients with schizophrenia undergoing electroconvulsive therapy. **2023**, 18, e0284579 ○